U.S. patent application number 16/532834 was filed with the patent office on 2019-11-28 for indolizine compounds, a process for their preparation and pharmaceutical compositions containing them.
The applicant listed for this patent is LES LABORATOIRES SERVIER, VERNALIS (R&D) LTD. Invention is credited to I-Jen CHEN, James Edward Paul DAVIDSON, Guillaume DE NANTEUIL, Olivier GENESTE, Jean-Michel HENLIN, Thierry LE DIGUARHER, Arnaud LE TIRAN, James Brooke MURRAY, Jerome-Beno t STARCK.
Application Number | 20190359595 16/532834 |
Document ID | / |
Family ID | 50023640 |
Filed Date | 2019-11-28 |
![](/patent/app/20190359595/US20190359595A1-20191128-C00001.png)
![](/patent/app/20190359595/US20190359595A1-20191128-C00002.png)
![](/patent/app/20190359595/US20190359595A1-20191128-C00003.png)
![](/patent/app/20190359595/US20190359595A1-20191128-C00004.png)
![](/patent/app/20190359595/US20190359595A1-20191128-C00005.png)
![](/patent/app/20190359595/US20190359595A1-20191128-C00006.png)
![](/patent/app/20190359595/US20190359595A1-20191128-C00007.png)
![](/patent/app/20190359595/US20190359595A1-20191128-C00008.png)
![](/patent/app/20190359595/US20190359595A1-20191128-C00009.png)
![](/patent/app/20190359595/US20190359595A1-20191128-C00010.png)
![](/patent/app/20190359595/US20190359595A1-20191128-C00011.png)
View All Diagrams
United States Patent
Application |
20190359595 |
Kind Code |
A1 |
LE TIRAN; Arnaud ; et
al. |
November 28, 2019 |
INDOLIZINE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND
PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
Abstract
Compounds of formula (I) wherein Ra, Rb, Rc, Rd, T, R3, R4, R5,
X, Y and Het are as defined in the description. ##STR00001##
Medicinal products containing the same which are useful in treating
pathologies involving a deficit in apoptosis, such as cancer,
auto-immune diseases, and diseases of the immune system.
Inventors: |
LE TIRAN; Arnaud; (Croissy
sur Seine, FR) ; LE DIGUARHER; Thierry; (Saint Denis
de l'Hotel, FR) ; STARCK; Jerome-Beno t;
(Rueil-Malmaison, FR) ; HENLIN; Jean-Michel;
(Suresnes, FR) ; DE NANTEUIL; Guillaume;
(SURESNES, FR) ; GENESTE; Olivier;
(Rueil-Malmaison, FR) ; DAVIDSON; James Edward Paul;
(Great Shelford, GB) ; MURRAY; James Brooke;
(Linton, GB) ; CHEN; I-Jen; (Cambridge,
GB) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
LES LABORATOIRES SERVIER
VERNALIS (R&D) LTD |
SURESNES CEDEX
Winnersh |
|
FR
GB |
|
|
Family ID: |
50023640 |
Appl. No.: |
16/532834 |
Filed: |
August 6, 2019 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
15906389 |
Feb 27, 2018 |
10414754 |
|
|
16532834 |
|
|
|
|
14906330 |
Jan 20, 2016 |
9944620 |
|
|
PCT/FR2014/051885 |
Jul 22, 2014 |
|
|
|
15906389 |
|
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A61K 31/4985 20130101;
A61K 9/2059 20130101; A61P 13/10 20180101; A61P 1/04 20180101; A61K
31/5377 20130101; A61N 5/10 20130101; A61P 37/06 20180101; A61K
9/2018 20130101; C07D 401/14 20130101; A61K 31/4725 20130101; A61K
9/2054 20130101; A61K 45/06 20130101; A61P 25/00 20180101; A61P
37/02 20180101; A61P 13/08 20180101; A61P 19/00 20180101; A61P
43/00 20180101; A61P 1/16 20180101; C07D 471/04 20130101; A61P
35/00 20180101; A61P 35/02 20180101; A61P 17/00 20180101; A61P
37/00 20180101; A61K 31/475 20130101; A61P 15/00 20180101; C07D
487/04 20130101; A61K 31/4709 20130101; C07D 519/00 20130101; A61K
31/4725 20130101; A61K 2300/00 20130101; A61K 31/475 20130101; A61K
2300/00 20130101; A61K 31/5377 20130101; A61K 2300/00 20130101;
A61K 31/4985 20130101; A61K 2300/00 20130101 |
International
Class: |
C07D 401/14 20060101
C07D401/14; A61N 5/10 20060101 A61N005/10; A61K 9/20 20060101
A61K009/20; A61K 31/5377 20060101 A61K031/5377; A61K 31/475
20060101 A61K031/475; A61K 31/4709 20060101 A61K031/4709; A61K
45/06 20060101 A61K045/06; C07D 519/00 20060101 C07D519/00; C07D
487/04 20060101 C07D487/04; C07D 471/04 20060101 C07D471/04; A61K
31/4985 20060101 A61K031/4985; A61K 31/4725 20060101
A61K031/4725 |
Foreign Application Data
Date |
Code |
Application Number |
Jul 23, 2013 |
FR |
13/57265 |
Claims
1. A method of treating a condition selected from auto-immune
diseases and diseases of the immune system in a subject in need
thereof, comprising administration of a compound of formula (I):
##STR00012## wherein: X and Y represent a carbon atom or a nitrogen
atom, it being understood that they may not simultaneously
represent two carbons atoms or two nitrogen atoms; the Het moiety
of the group ##STR00013## represents an optionally substituted,
aromatic or non-aromatic ring composed of 5, 6 or 7 ring members,
which may have, in addition to the nitrogen represented by X or by
Y, from one to 3 hetero atoms selected independently from oxygen,
sulphur and nitrogen, it being understood that the nitrogen in
question may be substituted by a group representing a hydrogen
atom, a linear or branched (C.sub.1-C.sub.6)alkyl group or a
--C(O)--O-Alk group wherein Alk is a linear or branched
(C.sub.1-C.sub.6)alkyl group; T represents a hydrogen atom, a
linear or branched (C.sub.1-C.sub.6)alkyl group optionally
substituted by from one to three halogen atoms, a
(C.sub.2-C.sub.4)alkyl-NR.sub.1R.sub.2 group, or a
(C.sub.1-C.sub.4)alkyl-OR.sub.6 group; R.sub.1 and R.sub.2
independently of one another represent a hydrogen atom or a linear
or branched (C.sub.1-C.sub.6)alkyl group, or R.sub.1 and R.sub.2,
together with the nitrogen atom carrying them, form a
heterocycloalkyl; R.sub.3 represents a linear or branched
(C.sub.1-C.sub.6)alkyl group, a linear or branched
(C.sub.2-C.sub.6)alkenyl group, a linear or branched
(C.sub.2-C.sub.6)alkynyl group, a cycloalkyl group, a
(C.sub.3-C.sub.10)cycloalkyl-(C.sub.1-C.sub.6)alkyl group wherein
the alkyl moiety is linear or branched, a heterocycloalkyl group,
an aryl group or a heteroaryl group, it being understood that one
or more of the carbon atoms of the preceding groups, or of their
possible substituents, may be deuterated; R.sub.4 represents an
aryl group, a heteroaryl group, a cycloalkyl group or a linear or
branched (C.sub.1-C.sub.6)alkyl group, it being understood that one
or more of the carbon atoms of the preceding groups, or of their
possible substituents, may be deuterated; R.sub.5 represents a
hydrogen or halogen atom, a linear or branched
(C.sub.1-C.sub.6)alkyl group, or a linear or branched
(C.sub.1-C.sub.6)alkoxy group; R.sub.6 represents a hydrogen atom
or a linear or branched (C.sub.1-C.sub.6)alkyl group; R.sub.a,
R.sub.b, R.sub.c and R.sub.d, each independently of the others,
represent a hydrogen atom, a linear or branched
(C.sub.1-C.sub.6)alkyl group, a linear or branched
(C.sub.2-C.sub.6)alkenyl group, a linear or branched
(C.sub.2-C.sub.6)alkynyl group, an aryl group or a heteroaryl
group, a halogen atom, a linear or branched (C.sub.1-C.sub.6)alkoxy
group, a hydroxy group, a linear or branched
(C.sub.1-C.sub.6)polyhaloalkyl group, a trifluoromethoxy group,
--NR.sub.7R.sub.7', nitro, R.sub.7--CO--(C.sub.0-C.sub.6)alkyl-,
R.sub.7--CO--NH--(C.sub.0-C.sub.6)alkyl-,
NR.sub.7R.sub.7'--CO--(C.sub.0-C.sub.6)alkyl-,
NR.sub.7R.sub.7'--CO--(C.sub.0-C.sub.6)alkyl-O--,
R.sub.7--SO.sub.2--NH--(C.sub.0-C.sub.6)alkyl-,
R.sub.7--NH--CO--NH--(C.sub.0-C.sub.6)alkyl-,
R.sub.7--O--CO--NH--(C.sub.0-C.sub.6)alkyl-, a heterocycloalkyl
group, or the substituents of one of the pairs (R.sub.a,R.sub.b),
(R.sub.b,R.sub.c) or (R.sub.c,R.sub.d), together with the carbon
atoms carrying them, form a ring composed of from 5 to 7 ring
members, which may have from one to 2 hetero atoms selected from
oxygen and sulphur, it being understood that one or more carbon
atoms of the ring defined hereinbefore may be deuterated or
substituted by from one to 3 groups selected from halogen and
linear or branched (C.sub.1-C.sub.6)alkyl; R.sub.7 and R.sub.7',
each independently of the other, represent a hydrogen, a linear or
branched (C.sub.1-C.sub.6)alkyl, a linear or branched
(C.sub.2-C.sub.6)alkenyl, a linear or branched
(C.sub.2-C.sub.6)alkynyl, an aryl or a heteroaryl, or R.sub.7 and
R.sub.7', together with the nitrogen atom carrying them, form a
heterocycle composed of from 5 to 7 ring members; wherein the aryl,
heteroaryl, cycloalkyl and heterocycloalkyl groups so defined and
the groups alkyl, alkenyl, alkynyl and alkoxy may be optionally
substituted by from 1 to 3 groups selected from optionally
substituted, linear or branched (C.sub.1-C.sub.6)alkyl,
(C.sub.3-C.sub.6)spiro, optionally substituted, linear or branched
(C.sub.1-C.sub.6)alkoxy, (C.sub.1-C.sub.6)alkyl-S--, hydroxy, oxo
(or N-oxide where appropriate), nitro, cyano, --COOR', --OCOR',
NR'R'', linear or branched (C.sub.1-C.sub.6)polyhaloalkyl,
trifluoromethoxy, (C.sub.1-C.sub.6)alkylsulphonyl, halogen,
optionally substituted aryl, heteroaryl, aryloxy, arylthio,
cycloalkyl, heterocycloalkyl optionally substituted by one or more
halogen atoms or alkyl groups, it being understood that R' and R'',
each independently of the other, represent a hydrogen atom or an
optionally substituted, linear or branched (C.sub.1-C.sub.6)alkyl
group, and wherein the Het moiety of the group ##STR00014## defined
in formula (I) may be optionally substituted by from one to three
groups selected from linear or branched (C.sub.1-C.sub.6)alkyl,
hydroxy, linear or branched (C.sub.1-C.sub.6)alkoxy,
NR.sub.1'R.sub.1'' and halogen, wherein R.sub.1' and R.sub.1'',
each independently of the other, represent a hydrogen atom or an
optionally substituted, linear or branched (C.sub.1-C.sub.6)alkyl
group, it being understood that: "aryl" means a phenyl, naphthyl,
biphenyl or indenyl group, "heteroaryl" means any mono- or
bi-cyclic group composed of from 5 to 10 ring members, having at
least one aromatic moiety and containing from 1 to 4 hetero atoms
selected from oxygen, sulphur and nitrogen (including quaternary
nitrogens), "cycloalkyl" means any mono- or bi-cyclic,
non-aromatic, carbocyclic group containing from 3 to 10 ring
members, "heterocycloalkyl" means any mono- or bi-cyclic,
non-aromatic, condensed or spiro group containing from 3 to 10 ring
members and containing from 1 to 3 hetero atoms selected from
oxygen, sulphur, SO, SO.sub.2 and nitrogen, its enantiomers and
diastereoisomers, and addition salts thereof with a
pharmaceutically acceptable acid or base, wherein the compound of
formula (I) is administered alone or in combination with one or
more pharmaceutically acceptable excipients.
2. The method according to claim 1, wherein the group ##STR00015##
represents: 5,6,7,8-tetrahydroindolizine optionally substituted by
an amino group; indolizine;
1,2,3,4-tetrahydropyrrolo[1,2-a[pyrazine optionally substituted by
a methyl; or pyrrolo [1,2-a[pyrimidine.
3. The method according to claim 1, wherein T represents hydrogen,
methyl, 2-(morpholin-4-yl)ethyl, 3-(morpholin-4-yl)propyl,
--CH.sub.2--OH, 2-aminoethyl, 2-(3,3-difluoropiperidin-1-yl)ethyl,
2-[(2,2-difluoroethyl)amino]ethyl or
2-(3-methoxyazetidin-1-yl)ethyl.
4. The method according to claim 1, wherein R.sub.a and R.sub.d
each represent a hydrogen atom and (R.sub.b,R.sub.c), together with
the carbon atoms carrying them, form a 1,3-dioxolane group or a
1,4-dioxane group; or R.sub.a, R.sub.c and R.sub.d each represent a
hydrogen atom and R.sub.b represents a hydrogen, a halogen, a
methyl or a methoxy; or R.sub.a, R.sub.b and R.sub.d each represent
a hydrogen atom and R, represents a hydroxy or methoxy group.
5. The method according to claim 1, wherein R.sub.4 represents a
4-hydroxyphenyl group.
6. The method according to claim 1, wherein R.sub.3 represents a
linear (C.sub.1-C.sub.6)alkyl, aryl or heteroaryl group, wherein
the latter two groups may be optionally substituted by from one to
three groups selected from halogen, linear or branched
(C.sub.1-C.sub.6)alkyl, linear or branched (C.sub.1-C.sub.6)alkoxy
and cyano.
7. The method according to claim 1, wherein R.sub.3 represents a
heteroaryl group selected from: 1H-indole, 2,3-dihydro-1H-indole,
1H-indazole, pyridine, 1H-pyrrolo[2,3-b]pyridine, 1H-pyrazole,
imidazo[1,2-a[pyridine, pyrazolo[1,5-a[pyrimidine,
[1,2,4[triazolo[1,5-a[pyrimidine, and 1H-pyrazolo[3,4-b]pyridine,
all of which may be optionally substituted by a linear or branched
(C.sub.1-C.sub.6)alkyl group.
8. The method according to claim 1, wherein the compound of formula
(I) is selected from:
N-(4-hydroxyphenyl)-3-(6-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]-
-carbonyl}-1,3-benzodioxol-5-yl)-N-{1-[2-(morpholin-4-yl)ethyl]-1H-indol-5-
-yl}-5,6,7,8-tetrahydroindolizine-1-carboxamide,
N-(4-hydroxyphenyl)-3-(6-{[(3S)-3-[2-(morpholin-4-yl)ethyl]-3,4-dihydrois-
o-quinolin-2(1H)-yl]carbonyl}-1,3-benzodioxol-5-yl)-N-phenyl-5,6,7,8-tetra-
hydro-indolizine-1-carboxamide,
N-{3-fluoro-4-[2-(morpholin-4-yl)ethoxy]phenyl}-N-(4-hydroxyphenyl)-3-(6--
{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}-1,3-benzodioxol--
5-yl)indolizine-1-carboxamide,
N-(4-hydroxyphenyl)-3-(6-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]-
carbonyl}-1,3-benzodioxol-5-yl)-N-(pyridin-4-yl)indolizine-1-carboxamide,
N-(4-hydroxyphenyl)-3-(6-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]-
-carbonyl}-1,3-benzodioxol-5-yl)-N-(2-methylpyridin-4-yl)indolizine-1-carb-
oxamide,
N-(4-hydroxyphenyl)-3-(6-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2-
(1H)-yl]-carbonyl}-1,3-benzodioxol-5-yl)-N-(1-methyl-1H-pyrrolo[2,3-b]pyri-
din-5-yl)-indolizine-1-carboxamide,
N-(4-hydroxyphenyl)-3-(6-{[(3R)-3-[3-(morpholin-4-yl)propyl]-3,4-dihydro--
isoquinolin-2(1H)-yl]carbonyl}-1,3-benzodioxol-5-yl)-N-phenyl-5,6,7,8-tetr-
ahydroindolizine-1-carboxamide,
N-(2,6-dimethylpyridin-4-yl)-N-(4-hydroxyphenyl)-3-(6-{[(3R)-3-methyl-3,4-
-dihydroisoquinolin-2(1H)-yl]carbonyl}-1,3-benzodioxol-5-yl)indolizine-1-c-
arboxamide,
N-(4-hydroxyphenyl)-3-(6-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]-
-carbonyl}-1,3-benzodioxol-5-yl)-N-(pyridin-4-yl)-5,6,7,8-tetrahydroindoli-
zine-1-carboxamide,
3-(5-chloro-2-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}ph-
enyl)-N-(4-hydroxyphenyl)-N-(1-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)indoli-
zine-1-carboxamide,
N-(4-hydroxyphenyl)-N-(2-methoxypyridin-4-yl)-3-(6-{[(3R)-3-methyl-3,4-di-
hydroisoquinolin-2(1H)-yl]carbonyl}-1,3-benzodioxol-5-yl)indolizine-1-carb-
oxamide, and their enantiomers and diastereoisomers, and addition
salts thereof with a pharmaceutically acceptable acid or base.
Description
[0001] The present invention relates to new indolizine compounds,
to a process for their preparation and to pharmaceutical
compositions containing them.
[0002] The compounds of the present invention are new and have very
valuable pharmacological characteristics in the field of apoptosis
and cancerology.
[0003] Apoptosis, or programmed cell death, is a physiological
process that is crucial for embryonic development and maintenance
of tissue homeostasis.
[0004] Apoptotic-type cell death involves morphological changes
such as condensation of the nucleus, DNA fragmentation and also
biochemical phenomena such as the activation of caspases which
cause damage to key structural components of the cell, so inducing
its disassembly and death. Regulation of the process of apoptosis
is complex and involves the activation or repression of several
intracellular signalling pathways (Cory S. et al., Nature Review
Cancer, 2002, 2, 647-656).
[0005] Deregulation of apoptosis is involved in certain
pathologies. Increased apoptosis is associated with
neurodegenerative diseases such as Parkinson's disease, Alzheimer's
disease and ischaemia. Conversely, deficits in the implementation
of apoptosis play a significant role in the development of cancers
and their chemoresistance, in auto-immune diseases, inflammatory
diseases and viral infections. Accordingly, absence of apoptosis is
one of the phenotypic signatures of cancer (Hanahan D. et al., Cell
2000, 100, 57-70).
[0006] The anti-apoptotic proteins of the Bcl-2 family are
associated with numerous pathologies. The involvement of proteins
of the Bcl-2 family is described in numerous types of cancer, such
as colorectal cancer, breast cancer, small-cell lung cancer,
non-small-cell lung cancer, bladder cancer, ovarian cancer,
prostate cancer, chronic lymphoid leukaemia, follicular lymphoma,
myeloma, prostate cancer, etc. Overexpression of the anti-apoptotic
proteins of the Bcl-2 family is involved in tumorigenesis, in
resistance to chemotherapy and in the clinical prognosis of
patients affected by cancer. There is, therefore, a therapeutic
need for compounds that inhibit the anti-apoptotic activity of the
proteins of the Bcl-2 family.
[0007] In addition to being new, the compounds of the present
invention have pro-apoptotic properties making it possible to use
them in pathologies involving a defect in apoptosis, such as, for
example, in the treatment of cancer, auto-immune diseases and
diseases of the immune system.
[0008] The present invention relates more especially to compounds
of formula (I):
##STR00002##
[0009] wherein: [0010] X and Y represent a carbon atom or a
nitrogen atom, it being understood that they may not simultaneously
represent two carbons atoms or two nitrogen atoms, [0011] the Het
moiety of the group
##STR00003##
[0011] represents an optionally substituted, aromatic or
non-aromatic ring composed of 5, 6 or 7 ring members, which may
contain, in addition to the nitrogen represented by X or by Y, from
one to 3 hetero atoms selected independently from oxygen, sulphur
and nitrogen, it being understood that the nitrogen in question may
be substituted by a group representing a hydrogen atom, a linear or
branched (C.sub.1-C.sub.6)alkyl group or a group --C(O)--O-Alk
wherein Alk is a linear or branched (C.sub.1-C.sub.6)alkyl group,
[0012] T represents a hydrogen atom, a linear or branched
(C.sub.1-C.sub.6)alkyl group optionally substituted by from one to
three halogen atoms, a group
(C.sub.2-C.sub.4)alkyl-NR.sub.1R.sub.2, or a group
(C.sub.1-C.sub.4)alkyl-OR.sub.6, [0013] R.sub.1 and R.sub.2
independently of one another represent a hydrogen atom or a linear
or branched (C.sub.1-C.sub.6)alkyl group, [0014] or R.sub.1 and
R.sub.2 form with the nitrogen atom carrying them a
heterocycloalkyl, [0015] R.sub.3 represents a linear or branched
(C.sub.1-C.sub.6)alkyl group, a linear or branched
(C.sub.2-C.sub.6)alkenyl group, a linear or branched
(C.sub.2-C.sub.6)alkynyl group, a cycloalkyl group, a
(C.sub.3-C.sub.10)cycloalkyl-(C.sub.1-C.sub.6)alkyl group wherein
the alkyl moiety is linear or branched, a heterocycloalkyl group,
an aryl group or a heteroaryl group, it being understood that one
or more of the carbon atoms of the preceding groups, or of their
possible substituents, may be deuterated, [0016] R.sub.4 represents
an aryl group, a heteroaryl group, a cycloalkyl group or a linear
or branched (C.sub.1-C.sub.6)alkyl group, it being understood that
one or more of the carbon atoms of the preceding groups, or of
their possible substituents, may be deuterated, [0017] R.sub.5
represents a hydrogen or halogen atom, a linear or branched
(C.sub.1-C.sub.6)alkyl group, or a linear or branched
(C.sub.1-C.sub.6)alkoxy group, [0018] R.sub.6 represents a hydrogen
atom or a linear or branched (C.sub.1-C.sub.6)alkyl group, [0019]
R.sub.a, R.sub.b, R.sub.c and R.sub.d, each independently of the
others, represent R.sub.7, a halogen atom, a linear or branched
(C.sub.1-C.sub.6)alkoxy group, a hydroxy group, a linear or
branched (C.sub.1-C.sub.6)polyhaloalkyl group, a trifluoromethoxy
group, --NR.sub.7R.sub.7', nitro,
R.sub.7--CO--(C.sub.0-C.sub.6)alkyl-,
R.sub.7--CO--NH--(C.sub.0-C.sub.6)alkyl-,
NR.sub.7R.sub.7'--CO--(C.sub.0-C.sub.6)alkyl-,
NR.sub.7R.sub.7'--CO--(C.sub.0-C.sub.6)alkyl-O--,
R.sub.7--SO.sub.2--NH--(C.sub.0-C.sub.6)alkyl-,
R.sub.7--NH--CO--NH--(C.sub.0-C.sub.6)alkyl-,
R.sub.7--O--CO--NH--(C.sub.0-C.sub.6)alkyl-, a heterocycloalkyl
group, or the substituents of one of the pairs (R.sub.a,R.sub.b),
(R.sub.b,R.sub.c) or (R.sub.c,R.sub.d) form together with the
carbon atoms carrying them a ring composed of from 5 to 7 ring
members, which may contain from one to 2 hetero atoms selected from
oxygen and sulphur, it also being understood that one or more
carbon atoms of the ring defined hereinbefore may be deuterated or
substituted by from one to 3 groups selected from halogen and
linear or branched (C.sub.1-C.sub.6)alkyl, [0020] R.sub.7 and
R.sub.7', each independently of the other, represent a hydrogen, a
linear or branched (C.sub.1-C.sub.6)alkyl, a linear or branched
(C.sub.2-C.sub.6)alkenyl, a linear or branched
(C.sub.2-C.sub.6)alkynyl, an aryl or a heteroaryl, or R.sub.7 and
R.sub.7', together with the nitrogen atom carrying them, form a
heterocycle composed of from 5 to 7 ring members,
[0021] it being understood that: [0022] "aryl" means a phenyl,
naphthyl, biphenyl or indenyl group, [0023] "heteroaryl" means any
mono- or bi-cyclic group composed of from 5 to 10 ring members,
having at least one aromatic moiety and containing from 1 to 4
hetero atoms selected from oxygen, sulphur and nitrogen (including
quaternary nitrogens), [0024] "cycloalkyl" means any mono- or
bi-cyclic, non-aromatic, carbocyclic group containing from 3 to 10
ring members, [0025] "heterocycloalkyl" means any mono- or
bi-cyclic, non-aromatic, condensed or spiro group containing from 3
to 10 ring members and containing from 1 to 3 hetero atoms selected
from oxygen, sulphur, SO, SO.sub.2 and nitrogen,
[0026] it being possible for the aryl, heteroaryl, cycloalkyl and
heterocycloalkyl groups so defined and the groups alkyl, alkenyl,
alkynyl and alkoxy to be substituted by from 1 to 3 groups selected
from optionally substituted, linear or branched
(C.sub.1-C.sub.6)alkyl, (C.sub.3-C.sub.6)spiro, optionally
substituted, linear or branched (C.sub.1-C.sub.6)alkoxy,
(C.sub.1-C.sub.6)alkyl-S--, hydroxy, oxo (or N-oxide where
appropriate), nitro, cyano, --COOR', --OCOR', NR'R'', linear or
branched (C.sub.1-C.sub.6)polyhalo alkyl, trifluoromethoxy,
(C.sub.1-C.sub.6)alkylsulphonyl, halogen, optionally substituted
aryl, heteroaryl, aryloxy, arylthio, cycloalkyl, heterocycloalkyl
optionally substituted by one or more halogen atoms or alkyl
groups, it being understood that R' and R'', each independently of
the other, represent a hydrogen atom or an optionally substituted,
linear or branched (C.sub.1-C.sub.6)alkyl group,
[0027] it being possible for the Het moiety of the group
##STR00004##
defined in formula (I) to be substituted by from one to three
groups selected from linear or branched (C.sub.1-C.sub.6)alkyl,
hydroxy, linear or branched (C.sub.1-C.sub.6)alkoxy,
NR.sub.1'R.sub.1'' and halogen, it being understood that R.sub.1'
and R.sub.1'' are as defined for the groups R' and R'' mentioned
hereinbefore,
[0028] to their enantiomers and diastereoisomers, and to addition
salts thereof with a pharmaceutically acceptable acid or base.
[0029] Among the pharmaceutically acceptable acids there may be
mentioned, without implying any limitation, hydrochloric acid,
hydrobromic acid, sulphuric acid, phosphonic acid, acetic acid,
trifluoroacetic acid, lactic acid, pyruvic acid, malonic acid,
succinic acid, glutaric acid, fumaric acid, tartaric acid, maleic
acid, citric acid, ascorbic acid, oxalic acid, methanesulphonic
acid, camphoric acid etc.
[0030] Among the pharmaceutically acceptable bases there may be
mentioned, without implying any limitation, sodium hydroxide,
potassium hydroxide, triethylamine, tert-butylamine etc.
[0031] Advantageously, the group:
##STR00005##
[0032] represents one of the following groups:
5,6,7,8-tetrahydroindolizine optionally substituted by an amino
group; indolizine; 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine
optionally substituted by a methyl; pyrrolo[1,2-a[pyrimidine. The
groups 5,6,7,8-tetrahydroindolizine and indolizine are more
especially preferred.
[0033] In preferred compounds of the invention, T represents a
hydrogen atom, a methyl group (and more especially an (R)-methyl),
a group 2-(morpholin-4-yl)ethyl, 3-(morpholin-4-yl)propyl,
--CH.sub.2--OH, 2-aminoethyl, 2-(3,3-difluoropiperidin-1-yl)ethyl,
2-[(2,2-difluoroethyl)amino]ethyl or
2-(3-methoxyazetidin-1-yl)ethyl.
[0034] Preferably, R.sub.a and R.sub.d each represent a hydrogen
atom and (R.sub.b,R.sub.c), together with the carbon atoms carrying
them, form a 1,3-dioxolane group or a 1,4-dioxane group; or
R.sub.a, R.sub.c and R.sub.d each represent a hydrogen atom and
R.sub.b represents a hydrogen, a halogen, a methyl or a methoxy; or
R.sub.a, R.sub.b and R.sub.d each represent a hydrogen atom and
R.sub.c represents a hydroxy or methoxy group. Even more
preferably, R.sub.a and R.sub.d each represent a hydrogen atom and
(R.sub.b,R.sub.c), together with the carbon atoms carrying them,
form a 1,3-dioxolane group; or R.sub.a, R.sub.c and R.sub.d each
represent a hydrogen atom and R.sub.b represents a halogen.
[0035] Preference is given to the R.sub.4 group being a
4-hydroxyphenyl.
[0036] In preferred compounds of the invention, R.sub.3 represents
a linear (C.sub.1-C.sub.6)alkyl, aryl or heteroaryl group, it being
possible for the latter two groups to be substituted by from one to
three groups selected from halogen, linear or branched
(C.sub.1-C.sub.6)alkyl, linear or branched (C.sub.1-C.sub.6)alkoxy,
cyano and heterocycloalkyl-(C.sub.1-C.sub.6)alkyl wherein the alkyl
moiety is linear or branched. Even more preferably, R.sub.3
represents a heteroaryl group selected from the following group:
1H-indole, 2,3-dihydro-1H-indole, 1H-indazole, pyridine, 1H
-pyrrolo[2,3-b]pyridine, 1H-pyrazole, imidazo[1,2-c]pyridine,
pyrazolo[1,5-c]pyrimidine, [1,2,4]triazolo[1,5-c]pyrimidine, and
1H-pyrazolo[3,4-b]pyridine, all of which may be substituted by a
linear or branched (C.sub.1-C.sub.6)alkyl group.
[0037] Preferred compounds according to the invention are included
in the following group: [0038]
N-(4-hydroxyphenyl)-3-(6-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]-
carbonyl}-1,3-benzodioxol-5-yl)-N-{1-[2-(morpholin-4-yl)ethyl]-1H-indol-5--
yl}-5,6,7,8-tetrahydroindolizine-1-carboxamide, [0039]
N-(4-hydroxyphenyl)-3-(6-{[(3S)-3-[2-(morpholin-4-yl)ethyl]-3,4-dihydrois-
oquinolin-2(1H)-yl]carbonyl}-1,3-benzodioxol-5-yl)-N-phenyl-5,6,7,8-tetrah-
ydroindolizine-1-carboxamide, [0040] N
-{3-fluoro-4-[2-(morpholin-4-yl)ethoxy]phenyl}-N-(4-hydroxyphenyl)-3-(6-{-
[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}-1,3-benzodioxol-5-
-yl)indolizine-1-carboxamide, [0041]
N-(4-hydroxyphenyl)-3-(6-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]-
carbonyl}-1,3-benzodioxol-5-yl)-N-(pyridin-4-yl)indolizine-1-carboxamide,
[0042]
N-(4-hydroxyphenyl)-3-(6-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(-
1H)-yl]carbonyl}-1,3-benzodioxol-5-yl)-N-(2-methylpyridin-4-yl)indolizine--
1-carboxamide, [0043]
N-(4-hydroxyphenyl)-3-(6-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]-
carbonyl}-1,3-benzodioxol-5-yl)-N-(1-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-
indolizine-1-carboxamide, [0044]
N-(4-hydroxyphenyl)-3-(6-{[(3R)-3-[3-(morpholin-4-yl)propyl]-3,4-dihydroi-
soquinolin-2(1H)-yl]carbonyl}-1,3-benzodioxol-5-yl)-N-phenyl-5,6,7,8-tetra-
hydroindolizine-1-carboxamide, [0045]
N-(2,6-dimethylpyridin-4-yl)-N-(4-hydroxyphenyl)-3-(6-{[(3R)-3-methyl-3,4-
-dihydroisoquinolin-2(1H)-yl]carbonyl}-1,3-benzodioxol-5-yl)indolizine-1-c-
arboxamide, [0046]
N-(4-hydroxyphenyl)-3-(6-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]-
carbonyl}-1,3-benzodioxol-5-yl)-N-(pyridin-4-yl)-5,6,7,8-tetrahydroindoliz-
ine-1-carboxamide, [0047]
3-(5-chloro-2-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}ph-
enyl)-N-(4-hydroxyphenyl)-N-(1-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)indoli-
zine-1-carboxamide, [0048]
N-(4-hydroxyphenyl)-N-(2-methoxypyridin-4-yl)-3-(6-{[(3R)-3-methyl-3,4-di-
hydroisoquinolin-2(1H)-yl]carbonyl}-1,3-benzodioxol-5-yl)indolizine-1-carb-
oxamide,
[0049] their enantiomers and diastereoisomers, and addition salts
thereof with a pharmaceutically acceptable acid or base.
[0050] The invention relates also to a process for the preparation
of compounds of formula (I), which process is characterised in that
there is used as starting material the compound of formula
(II):
##STR00006##
[0051] wherein R.sub.a, R.sub.b, R.sub.c and R.sub.d are as defined
for formula (I),
[0052] which compound of formula (II) is subjected to a Heck
reaction, in an aqueous or organic medium, in the presence of a
palladium catalyst, of a base, of a phosphine and of the compound
of formula (III):
##STR00007##
[0053] wherein the groups X, Y and Het are as defined for formula
(I),
[0054] to obtain the compound of formula (IV):
##STR00008##
[0055] wherein R.sub.a, R.sub.b, R.sub.c, R.sub.d, X, Y and Het are
as defined for formula (I),
[0056] the aldehyde function of which compound of formula (IV) is
oxidised to a carboxylic acid to form the compound of formula
(V):
##STR00009##
[0057] wherein R.sub.a, R.sub.b, R.sub.c, R.sub.d, X, Y and Het are
as defined for formula (I),
[0058] which compound of formula (V) is then subjected to peptide
coupling with a compound of formula (VI):
##STR00010##
[0059] wherein T and R.sub.5 are as defined for formula (I),
[0060] to yield the compound of formula (VII):
##STR00011##
[0061] wherein R.sub.a, R.sub.b, R.sub.c, R.sub.d, T, R.sub.5, X, Y
and Het are as defined for formula (I),
[0062] the ester function of which compound of formula (VII) is
hydrolysed to yield the corresponding carboxylic acid or
carboxylate, which may be converted into an acid derivative such as
the corresponding acyl chloride or anhydride before being coupled
with an amine NHR.sub.3R.sub.4 wherein R.sub.3 and R.sub.4 have the
same meanings as for formula (I), to yield the compound of formula
(I),
[0063] which compound of formula (I) may be purified according to a
conventional separation technique, which is converted, if desired,
into its addition salts with a pharmaceutically acceptable acid or
base and which is optionally separated into its isomers according
to a conventional separation technique,
[0064] it being understood that, at any time considered appropriate
in the course of the above-described process, certain groups
(hydroxy, amino . . . ) of the reagents or intermediates of
synthesis may be protected and then deprotected according to the
requirements of synthesis.
[0065] More particularly, when one of the groups R.sub.3 or R.sub.4
of the amine NHR.sub.3R.sub.4 is substituted by a hydroxy function,
the latter may be subjected beforehand to a protection reaction
prior to any coupling with the carboxylic acid formed from the
compound of formula (VII), or with a corresponding acid derivative
thereof, the resulting protected compound of formula (I)
subsequently undergoes a deprotection reaction and is then
optionally converted into one of its addition salts with a
pharmaceutically acceptable acid or base.
[0066] The compounds of formulae (II), (III), (VI) and the amine
NHR.sub.3R.sub.4 are either commercially available or can be
obtained by the person skilled in the art using conventional
chemical reactions described in the literature.
[0067] Pharmacological study of the compounds of the invention has
shown that they have pro-apoptotic properties. The ability to
reactivate the apoptotic process in cancerous cells is of major
therapeutic interest in the treatment of cancers, auto-immune
diseases and diseases of the immune system.
[0068] More especially, the compounds according to the invention
will be useful in the treatment of chemo- or radio-resistant
cancers, and in malignant haemopathies and small-cell lung
cancer.
[0069] Among the cancer treatments envisaged there may be
mentioned, without implying any limitation, cancers of the bladder,
brain, breast and uterus, chronic lymphoid leukaemias, colorectal
cancer, cancers of the oesophagus and liver, lymphoblastic
leukaemias, non-Hodgkin lymphomas, melanomas, malignant
haemopathies, myelomas, ovarian cancer, non-small-cell lung cancer,
prostate cancer and small-cell lung cancer. Among non-Hodgkin
lymphomas, there may be mentioned more preferably follicular
lymphomas, mantle cell lymphomas, diffuse large B-cell lymphomas,
small lymphocytic lymphomas and marginal zone B-cell lymphomas.
[0070] The present invention relates also to pharmaceutical
compositions comprising at least one compound of formula (I) in
combination with one or more pharmaceutically acceptable
excipients.
[0071] Among the pharmaceutical compositions according to the
invention there may be mentioned more especially those that are
suitable for oral, parenteral, nasal, per- or trans-cutaneous,
rectal, perlingual, ocular or respiratory administration,
especially tablets or drages, sublingual tablets, sachets, paquets,
capsules, glossettes, lozenges, suppositories, creams, ointments,
dermal gels, and drinkable or injectable ampoules.
[0072] The dosage varies according to the sex, age and weight of
the patient, the administration route, the nature of the
therapeutic indication, or of any associated treatments, and ranges
from 0.01 mg to 1 g per 24 hours in one or more
administrations.
[0073] Furthermore, the present invention relates also to the
association of a compound of formula (I) with an anticancer agent
selected from genotoxic agents, mitotic poisons, anti-metabolites,
proteasome inhibitors, kinase inhibitors and antibodies, and also
to pharmaceutical compositions comprising that type of association
and their use in the manufacture of medicaments for use in the
treatment of cancer.
[0074] The compounds of the invention may also be used in
association with radiotherapy in the treatment of cancer.
[0075] Finally, the compounds of the invention may be linked to
monoclonal antibodies or fragments thereof or linked to scaffold
proteins that can be related or not to monoclonal antibodies.
[0076] Antibody fragments must be understood as fragments of Fv,
scFv, Fab, F(ab')2, F(ab'), scFv-Fc type or diabodies, which
generally have the same specificity of binding as the antibody from
which they are descended. According to the present invention,
antibody fragments of the invention can be obtained starting from
antibodies by methods such as digestion by enzymes, such as pepsin
or papain, and/or by cleavage of the disulfide bridges by chemical
reduction. In another manner, the antibody fragments comprised in
the present invention can be obtained by techniques of genetic
recombination likewise well known to the person skilled in the art
or else by peptide synthesis by means of, for example, automatic
peptide synthesizers such as those supplied by the company Applied
Biosystems, etc.
[0077] Scaffold proteins that can be related or not to monoclonal
antibodies are understood to mean a protein that contains or not an
immunoglobulin fold and that yields a binding capacity similar to a
monoclonal antibody. The man skilled in the art knows how to select
the protein scaffold. More particularly, it is known that, to be
selected, such a scaffold should display several features as follow
(Skerra A., J. Mol. Recogn., 13, 2000, 167-187): phylogenetically
good conservation, robust architecture with a well-known
three-dimensional molecular organization (such as, for example,
crystallography or NMR), small size, no or only a low degree of
post-translational modifications, easy to produce, express and
purify. Such a protein scaffold can be, but without limitation, a
structure selected from the group consisting in fibronectin and
preferentially the tenth fibronectin type III domain (FNfn10),
lipocalin, anticalin (Skerra A., J. Biotechnol., 2001,
74(4):257-75), the protein Z derivative from the domain B of
staphylococcal protein A, thioredoxin A or any protein with a
repeated domain such as an "ankyrin repeat" (Kohl et al., PNAS,
2003, vol. 100, No. 4, 1700-1705), "armadillo repeat",
"leucine-rich repeat" or "tetratricopeptide repeat". There could
also be mentioned a scaffold derivative from toxins (such as, for
example, scorpion, insect, plant or mollusc toxins) or protein
inhibitors of neuronal nitric oxide synthase (PIN).
[0078] The following Preparations and Examples illustrate the
invention without limiting it in any way.
[0079] General Procedures
[0080] All reagents and anhydrous solvents are obtained from
commercial sources and were used without further purification or
drying. Flash chromatography is performed on an ISCO CombiFlash Rf
200i apparatus with pre-packed silica-gel cartridges (SiliaSep.TM.
F60 (40-63 .mu.m, 60 .ANG.). Thin layer chromatography was
conducted with 5.times.10 cm plates coated with Merck Type 60
F.sub.254 silica gel. Microwave heating was performed with a CEM
Discover.RTM. SP apparatus.
[0081] Analytical LC-MS
[0082] The compounds of the invention were characterized by
high-performance liquid chromatography coupled with mass
spectroscopy (HPLC-MS) on either an Agilent HP1200 rapid-resolution
apparatus coupled to a 6140 mass detector with a multi-mode source
(m/z range 150 to 1000 atomic mass units or amu) or an Agilent
HP1100 apparatus coupled to a 1946D mass detector with an
electrospray ionisation source (m/z range 150 to 1000 amu). The
conditions and methods listed below are identical for both
machines. [0083] Detection: UV detection at 230, 254 and 270 nm.
[0084] Injection Volume: 2 .mu.L [0085] Mobile Phases: A--Water+10
mMol/ammonium formate+0.08% (v/v) formic acid at pH ca 3.5. [0086]
B--95% Acetonitrile+5% A+0.08% (v/v) formic acid
[0087] Method A (3.75 Min; either Positive (Pos) or Positive and
Negative (Pos/Neg) Ionisation)
[0088] Column: Gemini 5 .mu.m, C18, 30 mm.times.4.6 mm
(Phenomenex).
[0089] Temperature: 35.degree. C.
[0090] Gradient:
TABLE-US-00001 Time (min) Solvent A (%) Solvent B (%) Flow (mL/min)
0 95 5 2 0.25 95 5 2 2.50 95 5 2 2.55 5 95 3 3.60 5 95 3 3.65 5 95
2 3.70 95 5 2 3.75 95 5 2
[0091] Method B (1.9 Min; either Positive (Pos) or Positive and
Negative (Pos/Neg) Ionisation)
[0092] Column: Gemini 5 .mu.m, C18, 30 mm.times.4.6 mm
(Phenomenex).
[0093] Temperature: 35.degree. C.
[0094] Gradient:
TABLE-US-00002 Time (min) Solvent A (%) Solvent B (%) Flow (mL/min)
0 95 5 1.1 0.12 95 5 1.1 1.30 5 95 1.1 1.35 5 95 1.7 1.85 5 95 1.7
1.90 5 95 1.1 1.95 95 5 1.1
Preparation 1:
6-[1-(Methoxycarbonyl)-5,6,7,8-tetrahydro-3-indolizinyl]-1,3-benzodioxole-
-5-carboxylic acid
Step A: 1-Formyl-2-piperidine-carboxylic acid
[0095] To a solution of 40 g of a racemic mixture of
2-piperidine-carboxylic acid (0.310 mmol) in 300 mL of formic acid
placed at 0.degree. C. there are added, dropwise, 200 mL (2.15
mmol) of acetic anhydride. The batch is then stirred at ambient
temperature overnight. Then, the reaction mixture is cooled to
0.degree. C., hydrolysed by adding 250 mL of water, and stirred for
half an hour at 0.degree. C. before being concentrated to dryness.
The oil thereby obtained is taken up in 200 mL of methanol and then
concentrated to dryness. The title product is obtained in the form
of an oil in a yield of 98%. It is used directly, without being
otherwise purified, in the next Step.
[0096] .sup.1H NMR: .delta. (400 MHz; dmso-d6; 300K): 13.0 (m, 1H
OH); 8.0-8.05 (2s, 1H aldehyde); 4.9-4.5 (2d, 1H .alpha. to the N
and COOH); 4.1-2.6 (m, 2H .alpha. to the N); 2.2-1.2 (m, 6H
piperidine)
[0097] IR: v: --OH: 2000-3000 cm.sup.-1 acid; v: >C.dbd.O 1703
cm.sup.-1 wide band
Step B: Methyl 5,6,7,8-tetrahydro-1-indolizine-carboxylate
[0098] To a solution of 10 g of the carboxylic acid obtained in
Step A (63.6 mmol) in 65 mL of dichloromethane there are
successively added 13.4 g of tosyl chloride (70.4 mmol), 11.5 mL of
methyl 2-chloroacrylate (113.5 mmol) and then, dropwise, 17.8 mL of
N,N,N-triethylamine (127.2 mmol). The reaction mixture is then
refluxed for 1 hour 30 minutes. It is then placed at ambient
temperature, and there are then added 5 mL of methyl
2-chloroacrylate (48.9 mmol) and, dropwise, 9 mL of
N,N,N-triethylamine (64 mmol). The batch is refluxed overnight.
[0099] The reaction mixture is then diluted with methylene
chloride, washed successively with 1N HCl solution, saturated
NaHCO.sub.3 solution and then saturated NaCl solution until a
neutral pH is obtained. The organic phase is then dried over
MgSO.sub.4, filtered, concentrated to dryness and purified by
chromatography over silica gel (heptane/AcOEt gradient). The title
product is obtained in the form of an oil.
[0100] .sup.1H NMR: .delta. (400 MHz; CDCl.sub.3; 300K): 6.55-6.40
(d, 2H, tetrahydroindolizine); 3.91 (t, 3H methyl ester); 3.78 (s,
3H tetrahydroindolizine); 3.08 (t, 2H, tetrahydroindolizine);
1.95-1.85 (m, 4H, tetrahydroindolizine)
[0101] IR: v:>C.dbd.O 1692 cm.sup.-1 ester
Step C: Methyl
3-(6-formyl-1,3-benzodioxol-5-yl)-5,6,7,8-tetrahydro-1-indolizine-carboxy-
late
[0102] To a solution of 6.4 g of the ester obtained in Step B (35.7
mmol) in 12 mL of N,N-dimethylacetamide, there are successively
added 12.3 g of 6-bromo-1,3-benzodioxole-5-carbaldehyde (53.6 mmol)
and 7 g of potassium acetate (71.4 mmol), and then the batch is
stirred under argon for 20 minutes. There are then added 1.3 g of
palladium catalyst PdCl.sub.2(PPh.sub.3).sub.2 (1.8 mmol). The
reaction mixture is then heated at 130.degree. C. for one hour
before adding 139 .mu.L of H.sub.2O thereto. Heating is maintained
at that same temperature overnight. The mixture is allowed to
return to ambient temperature and it is then diluted with AcOEt.
Animal charcoal (2 g per g of product) is added and the batch is
stirred at ambient temperature for 1 hour and then filtered. The
organic phase is then washed with water, dried over magnesium
sulphate and concentrated to dryness. The crude product thereby
obtained is purified over silica gel (heptane/ACOEt gradient). The
title product is obtained in the form of an oil.
[0103] .sup.1H NMR: .delta.:(400 MHz; dmso-d6; 353.degree. K): 9.65
(s, 1H, H aldehyde); 7.3-7.15 (2s, 2H, aromatic Hs); 6.45 (s, 1H
tetrahydroindolizine); 6.20 (s, 2H methylenedioxy); 3.70 (s, 3H
methyl ester); 3.5-4.0 (m, 2H tetrahydroindolizine); 3.05 (m, 2H
tetrahydroindolizine); 1.85 (m, 4H tetrahydroindolizine)
[0104] IR: v: >C.dbd.O 1695 cm.sup.-1 ester; v: >C.dbd.O 1674
cm.sup.-1
Step D:
6-[1-(Methoxycarbonyl)-5,6,7,8-tetrahydro-3-indolizinyl]-1,3-benzo-
dioxole-5-carboxylic acid
[0105] A solution containing 3.37 g of the compound obtained in
Step C (10.3 mmol) in 9.3 mL of acetone and 8.8 mL (80.24 mmol) of
2-methyl-2-butene is prepared and placed at 0.degree. C. There are
added, dropwise, 9.3 mL of an aqueous solution containing a mixture
of 3.3 g of NaClO.sub.2 (36.05 mmol) and 3.6 g of Na.sub.2PO.sub.4
(25.75 mmol). The batch is then stirred at ambient temperature for
7 hours. The reaction mixture is then concentrated in order to
remove the acetone. Then solid then obtained is filtered off,
washed with water and then dried at 40.degree. C. in vacuo
overnight. The title product is obtained in the form of a solid,
which is subsequently used without being otherwise purified.
[0106] .sup.1H NMR: .delta. (400 MHz; dmso-d6; 300K): 12.10 (m, 1H,
H carboxylic acid); 7.40-6.88 (2s, 2H, aromatic Hs); 6.20 (s, 1H, H
tetrahydroindolizine); 6.18 (s, 2H, H methylenedioxy); 3.70 (s, 3H,
methyl ester); 3.55 (t, 2H tetrahydroindolizine); 3.00 (t, 2H
tetrahydroindolizine); 1.80 (m, 4H, H tetrahydroindolizine)
[0107] IR: v: --OH: 3000-2000 cm.sup.-1 acid; v: >C.dbd.O
1686-1676 cm.sup.-1 ester+acid; v: >C.dbd.C<1608
cm.sup.-1
Preparation 2:
2-[2-(tert-Butoxycarbonyl)-8-(methoxycarbonyl)-1,2,3,4-tetrahydropyrrolo[-
1,2-a]pyrazin-6-yl]-4-chlorobenzoic acid
Step A: 1-tert-Butyl 3-methyl
4-formyl-1,3-piperazinedicarboxylate
[0108] To a solution of pentafluorophenol in 520 mL of anhydrous
ether placed at 0.degree. C. there are successively added 49 g of
1-ethyl-3-(3'-dimethylaminopropyl)-carbodiimide (286 mmol) in
portions and 12 mL of formic acid (312 mmol). The batch is stirred
at ambient temperature for 2 hours. There is then added a mixture
of 32 g of 1-tert-butyl 3-methyl 1,3-piperazinedicarboxylate (130
mmol) and 18 mL of triethylamine (130 mmol) dissolved in 520 mL of
CH.sub.2Cl.sub.2. The batch is stirred overnight at ambient
temperature. The reaction mixture is hydrolysed with 1N aqueous HCl
solution and extracted with CH.sub.2Cl.sub.2. The organic phases
are then combined and then washed with saturated aqueous
NaHCO.sub.3 solution and then with saturated aqueous NaCl solution
until neutral. After drying over MgSO.sub.4, filtering and
concentrating to dryness, the product is isolated by chromatography
over silica gel (petroleum ether/AcOEt gradient: 0-30%). The title
product is obtained in the form of an oil.
[0109] IR: v: C.dbd.O: 1674-1745 cm.sup.-1
[0110] m/z (C.sub.12H.sub.20N.sub.2O.sub.5): 272.1(M+); 295.121
(M+Na).sup.+; 567.253 (2M+Na).sup.+
Step B: Lithium
4-(tert-butoxycarbonyl)-1-formyl-2-piperazinecarboxylate
[0111] To a solution of 28 g of the compound obtained in Step A
(103 mmol) in 515 mL of dioxane there are added 4.8 g of LiOH (113
mmol) dissolved in 100 mL of H.sub.2O. The batch is stirred at
ambient temperature for 4 hours. The reaction mixture is then
concentrated to dryness and then co-evaporated several times with
ethyl acetate. The title product is obtained in the form of a solid
and is used directly in the following cyclisation step.
[0112] .sup.13C NMR: .delta. (500 MHz; dmso-d6; 300K): 46 (s, C
piperazine); 42-38 (m, C piperazine); 58-53 (s, C piperazine); 28.5
(s, C .sup.tBu)
[0113] IR: v: C.dbd.O: 1650 cm.sup.-1; 2800 cm.sup.-1
Step C: 2-tert-Butyl 8-methyl
3,4-dihydropyrrolo[1,2-a]pyrazine-2,8(1H)-dicarboxylate
[0114] To a suspension of 29 g of the compound obtained in Step B
(103 mmol) in 800 mL of dichloromethane there are successively
added 24 g of tosyl chloride (124 mmol), 12.6 mL of methyl
2-chloroacrylate (124 mmol) and then 35 mL of triethylamine (247
mmol). The batch is stirred at reflux for 2 hours. After cooling,
the reaction mixture is diluted with ethyl acetate and the organic
phase is washed with saturated NaCl solution until neutral. After
drying over MgSO.sub.4, filtering and concentrating to dryness, the
title product is isolated by chromatography over silica gel
(petroleum ether/AcOEt gradient: 0-20%) in the form of a solid.
[0115] .sup.1H NMR: .delta. (400 MHz; dmso-d6; 300K): 6.8-6.43 (m,
2H, H pyrrole); 4.75-3.75 (m, 6H, H piperazine); 3.73 (s, 3H, H
COOCH3); 1.48 (s, 9H, H .sup.tBu)
[0116] IR: v: C.dbd.O (conjugated ester): 1712 cm.sup.-1; C.dbd.O
(carbamate): 1677 cm.sup.-1
Step D:
2-[2-(tert-Butoxycarbonyl)-8-(methoxycarbonyl)-1,2,3,4-tetrahydrop-
yrrolo[1,2-a]pyrazin-6-yl]-4-chlorobenzoic acid
[0117] The procedure is in accordance with the protocol described
in Steps C and D of Preparation 1, replacing the
6-bromo-1,3-benzodioxole-5-carbaldehyde used in Step C with
2-bromo-4-chlorobenzaldehyde.
Preparation 3:
4-Chloro-2-[1-(ethoxycarbonyl)-5,6,7,8-tetrahydro-3-indolizinyl]-benzoic
acid
[0118] The procedure is in accordance with the process of
Preparation 1, replacing the
6-bromo-1,3-benzodioxole-5-carbaldehyde used in Step C with
2-bromo-4-chlorobenzaldehyde.
Preparation 4:
7-[2-(tert-Butoxycarbonyl)-8-(methoxycarbonyl)-1,2,3,4-tetrahydro-pyrrolo-
[1,2-a]pyrazin-6-yl]-2,3-dihydro-1,4-benzodioxine-6-carboxylic
acid
Step A: 2-tert-Butyl 8-methyl
3,4-dihydropyrrolo[1,2-a]pyrazine-2,8(1H)-dicarboxylate
[0119] The procedure is in accordance with the process described in
Steps A-C of Preparation 2.
[0120] .sup.1H NMR: .delta. (400 MHz; dmso-d6; 300K): 6.8-6.43 (m,
2H, H pyrrole); 4.75-3.75 (m, 6H, H piperazine); 3.73 (s, 3H, H
COOCH3); 1.48 (s, 9H, H .sup.tBu)
[0121] IR: v: C.dbd.O (conjugated ester): 1712 cm.sup.-1; C.dbd.O
(carbamate): 1677 cm.sup.-1
Step B:
7-[2-(tert-Butoxycarbonyl)-8-(methoxycarbonyl)-1,2,3,4-tetrahydrop-
yrrolo[1,2-a]pyrazin-6-yl]-2,3-dihydro-1,4-benzodioxine-6-carboxylic
acid
[0122] The procedure is in accordance with the protocol described
in Steps C and D of Preparation 1, replacing the
6-bromo-1,3-benzodioxole-5-carbaldehyde used in Step C with
7-bromo-2,3-dihydro-1,4-benzodioxine-6-carbaldehyde.
Preparation 5:
4-Chloro-2-[1-(methoxycarbonyl)-3-indolizinyl]benzoic acid
Step A: 1-(Carboxymethyl)-1,2-dihydropyridinium bromide
[0123] To a solution of 16.2 mL of pyridine (200 mmol) in 120 mL of
ethyl acetate there are added, in portions, 27.8 g (200 mmol) of
bromoacetic acid. The batch is then stirred at ambient temperature
overnight. The precipitate thereby obtained is filtered off and
then washed with cold ethyl acetate. After drying, the title
product is obtained in the form of a powder which is used directly
in the next Step.
[0124] .sup.1H NMR: .delta. (400 MHz; dmso-d6; 300K): 9.15 (d, 2H,
aromatic Hs pyridine); 8.7 (t, 1H, aromatic H); 8.25 (t, 2H,
aromatic H); 5.65 (s, 2H, H CH.sub.2COOH)
[0125] IR: v: C.dbd.O: 1732 cm.sup.-1; --OH acid: 2800
cm.sup.-1
Step B: Methyl 1-indolizinecarboxylate
[0126] To a suspension of 6.55 g of the pyridinium salt obtained in
Step A (30 mmol) in 240 mL of toluene there are successively added
16.7 mL of methyl acrylate (150 mmol), 4.2 mL of triethylamine (30
mmol) and then, in portions, 20.9 g of MnO.sub.2 (240 mmol). The
batch is then heated at 90.degree. C. for 3 hours. After cooling,
the reaction mixture is filtered over a cake of Celite and
concentrated to dryness. The title product is then isolated by
purification over silica gel (heptane/AcOEt gradient: 0-10%) in the
form of an oil which crystallises in the cold state.
[0127] .sup.1H NMR: .delta. (300 MHz; dmso-d6; 300K): 8.5 (d, 1H, H
indolizine); 8.05 (d, 1H, H indolizine); 7.6 (s, 1H, H indolizine);
7.15 (m, 2H, H indolizine); 6.85 (m, 1H, H indolizine); 4.25 (q,
2H, --C(O)CH.sub.2CH.sub.3); 1.35 (t, 3H,
--C(O)CH.sub.2CH.sub.3)
[0128] IR: v: C.dbd.O ester: 1675 cm.sup.-1; aromatic C.dbd.C
moieties: 1634 cm.sup.-1
Step C: 4-Chloro-2-[1-(methoxycarbonyl)-3-indolizinyl]benzoic
acid
[0129] The procedure is in accordance with the protocol described
in Steps C and D of Preparation 1, replacing the
6-bromo-1,3-benzodioxole-5-carbaldehyde used in Step C with
2-bromo-4-chlorobenzaldehyde.
Preparation 6:
2-[2-(tert-Butoxycarbonyl)-8-(methoxycarbonyl)-2,3,4-tetrahydro-pyrrolo[1-
,2-a]pyrazin-6-yl]-4-fluorobenzoic acid
[0130] The procedure is in accordance with the protocol described
in Preparation 2, replacing the 2-bromo-4-chlorobenzaldehyde used
in Step D with 2-bromo-4-fluorobenzaldehyde.
Preparation 7:
6-[2-(tert-Butoxycarbonyl)-8-(methoxycarbonyl)-1,2,3,4-tetrahydro-pyrrolo-
[1,2-a]pyrazin-6-yl-1,3-benzodioxole-5-carboxylic acid
[0131] The procedure is in accordance with the protocol described
in Preparation 2, replacing the 2-bromo-4-chlorobenzaldehyde used
in Step D with 6-bromo-1,3-benzodioxole-5-carbaldehyde.
Preparation 8:
6-[1'-(Methoxycarbonyl)-5',6'-dihydro-8H-spiro[1,3-dioxolane-2,7'-indoliz-
in]-3'-yl]-1,3-benzodioxole-S-carboxylic acid
Step A: Methyl
8-formyl-1,4-dioxa-8-azaspiro[4.5]decane-7-carboxylate
[0132] 24 g of methyl 1,4-dioxa-8-azaspiro[4.5]decane-9-carboxylate
(111 mmol) are dissolved in 80 mL of ethyl acetate and 80 mL of
dichloromethane. There are added 26 g of (4-nitrophenyl)formate
(155 mmol) and the batch is stirred at ambient temperature for 1
hour. The reaction mixture is evaporated to dryness and taken up in
ethyl acetate. The organic phase is then successively washed with
1N NaOH solution, water and then with saturated NH.sub.4Cl solution
until a neutral pH is obtained. It is then dried over magnesium
sulphate, filtered and concentrated to dryness. The oil thereby
obtained is purified by flash chromatography (heptane/ethyl acetate
gradient). The title product is obtained in the form of an oil.
[0133] .sup.1H NMR: .delta. (400 MHz; dmso-d6; 300K): 8.15 (s, 1H,
CHO); 5.0-4.75 (m, 1H, tertiary H); 4.3-3.7 (m, 5H, 4H
ethylenedioxy+1H aliphatic piperidine); 3.70 (s, 3H, Me); 3.4-2.9
(2m, 1H, H aliphatic piperidine); 2.3-1.75 (m, 2H, H aliphatic
piperidine); 1.7-1.5 (m, 2H, H aliphatic piperidine)
Step B: 8-Formyl-1,4-dioxa-8-azaspiro[4.5]decane-7-carboxylic
acid
[0134] 15.25 g of the compound obtained in Step A (62.7 mmol) is
dissolved in 160 mL of dioxane. A solution of 125 mL of 1M KOH is
added dropwise and the batch is stirred at ambient temperature for
1 hour. There are then added 125 mL of 1M HCl and the compound is
extracted with dichloromethane. The organic phase is dried over
MgSO.sub.4, filtered and concentrated to dryness. The title product
is obtained in the form of a powder.
[0135] .sup.1H NMR: .delta. (400 MHz; dmso-d6; 300K) 13.5-12 (m,
1H, OH); 8.1+8.0 (2s, 1H, CHO); 4.9+4.6 (2m, 1H, tertiary H);
4.0-3.8 (m, 4H, ethylenedioxy); 4.2+3.7 (2ms, 1H, H aliphatic
piperidine); 3.4+2.9 (2m, 1H, H aliphatic piperidine); 2.4-1.5 (m,
4H, H aliphatic piperidine)
[0136] IR: v: OH: 3500-2000 cm.sup.-1; --C.dbd.O (acid+aldehyde):
1731+1655 cm.sup.-1
Step C: Methyl
5',6'-dihydro-8'H-spiro[1,3-dioxolane-2,7'-indolizine]-1'-carboxylate
[0137] To a solution of 13.5 g (62.7 mmol) of the acid obtained in
Step B in 380 mL of dichloromethane there are successively added
39.5 mL (238.4 mmol) of triethylamine and then, in portions, 12.5 g
(65.6 mmol) of para-toluenesulphonyl chloride and 23.7 mL (238.4
mmol) of methyl chloroacrylate. The batch is stirred at 80.degree.
C. for 18 hours. The reaction mixture is then filtered over Celite.
The filtrate is then washed with saturated NaHCO.sub.3 solution and
then with saturated NH.sub.4Cl solution. The organic phase is dried
over MgSO.sub.4, filtered and concentrated to dryness. The oil
thereby obtained is purified by flash chromatography (heptane/ethyl
acetate gradient). The product is obtained in the form of a
solid.
[0138] .sup.1H NMR: .delta. (400 MHz; dmso-d6; 300K) 6.70 (d, 1H,
pyrrole); 6.40 (d, 1H, pyrrole); 4.05 (t, 2H, H aliphatic,
piperidine); 4.00 (m, 4H, ethylenedioxy); 3.70 (s, 3H, methyl);
3.15 (s, 2H, H aliphatic piperidine); 2.05 (t, 2H, H aliphatic
piperidine)
[0139] IR: v: --C.dbd.O (ester): 1689 cm.sup.-1
Step D: Methyl
3'-(6-formyl-1,3-benzodioxol-5-yl)-5',6'-dihydro-8'H-spiro[1,3-dioxolane--
2,7'-indolizine]-1'-carboxylate
[0140] The procedure is in accordance with the process of Step C of
Preparation 1.
Step E:
6-[1'-(Methoxycarbonyl)-5',6'-dihydro-8'H-spiro[1,3-dioxolane-2,7--
indolizin]-3'-yl]-1,3-benzodioxole-5-carboxylic acid
[0141] The procedure is in accordance with the process of Step D of
Preparation 1.
Preparation 9:
6-[1-(Methoxycarbonyl)-3-indolizinyl]-1,3-benzodioxole-5-carboxylic
acid
[0142] The procedure is in accordance with the protocol described
in Preparation 5, replacing the 2-bromo-4-chlorobenzaldehyde used
in Step C with 6-bromo-1,3-benzodioxole-5-carbaldehyde.
Preparation 10:
4-Methyl-2-[1-(methoxycarbonyl)-5,6,7,8-tetrahydro-3-indolizinyl]-benzoic
acid
[0143] The procedure is in accordance with the protocol described
in Preparation 1, replacing the
6-bromo-1,3-benzodioxole-5-carbaldehyde used in Step C with
2-bromo-4-methylbenz-aldehyde.
Preparation 11:
2-[1-(Methoxycarbonyl)-5,6,7,8-tetrahydro-3-indolizinyl]benzoic
acid
[0144] The procedure is in accordance with the protocol described
in Preparation 1, replacing the
6-bromo-1,3-benzodioxole-5-carbaldehyde used in Step C with
2-bromo-benzaldehyde.
Preparation 12:
6-[8-(Methoxycarbonyl)pyrrolo[1,2-a]pyrimidin-6-yl]-3-benzo-dioxole-5-car-
boxylic acid
Step A: Methyl pyrrolo[1,2-a]pyrimidine-8-carboxylate
[0145] To a solution of 6.2 g of methyl 2-pyrimidin-2-ylacetate
(40.75 mmol) in 250 mL of acetone there are successively added
14.04 g (167 mmol) of NaHCO.sub.3 in the form of a powder, 13.2 mL
(203.75 mmol) of chloroacetaldehyde and then 3.54 g (40.75 mmol) of
lithium bromide. The batch is heated at 60.degree. C. for 24 hours.
The reaction mixture is then concentrated to dryness, taken up in
ethyl acetate, washed with water, dried over MgSO.sub.4, filtered
and then concentrated to dryness. The solid thereby obtained is
then purified by chromatography over silica gel (AcOEt). The
expected product is obtained in the form of an oil.
[0146] Mass spectrum:
[0147] Empirical formula: C.sub.8H.sub.8N.sub.2O.sub.2
[0148] LC/MS: m/z=[M+H].sup.+=177
Step B: Methyl
6-(6-formyl-1,3-benzodioxol-5-yl)pyrrolo[1,2-a]pyrimidine-8-carboxylate
[0149] To a solution of 3.93 g of the compound obtained in Step A
(22.3 mmol) in 80 mL of anhydrous dimethylacetamide there are added
7.66 g (33.45 mmol) of 6-bromo-1,3-benzodioxole-5-carbaldehyde and
4.4 g (44.6 mmol) of potassium acetate. The batch is degassed under
nitrogen for 15 minutes. There are then added 1.56 g (2.23 mmol) of
PdCl.sub.2(PPh.sub.3).sub.4 catalyst. The reaction mixture is
heated at 130.degree. C. for 16 hours under an inert atmosphere.
After drying, the residue is taken up in dichloromethane; the batch
is filtered over a cake of Celite and then the filtrate is washed
with water, dried over MgSO.sub.4 and concentrated to dryness. The
black solid is then chromatographed over silica gel
(CH.sub.2Cl.sub.2/MeOH 5%). The expected product is obtained in the
form of a solid.
[0150] Mass spectrum:
[0151] Empirical formula: C.sub.17H.sub.12N.sub.2O.sub.3
[0152] LC/MS: m/z=[M+H].sup.+=325
Step C:
6-[8-(Methoxycarbonyl)pyrrolo[1,2-a]pyrimidin-6-yl]-1,3-benzodioxo-
le-5-carboxylic acid
[0153] To a solution of 2.91 g (8.97 mmol) of the aldehyde obtained
in Step B in 140 mL of acetone cooled to 0.degree. C. there are
added 2-methylbutene and then, dropwise, a mixture of 2.8 g (17.94
mmol) of NaH.sub.2PO.sub.4.2H.sub.2O and 2.84 g (31.4 mmol) of
NaClO.sub.2 dissolved in 30 mL of water. The batch is stirred at
ambient temperature for 4 hours. The reaction mixture is then
concentrated in vacuo to remove the acetone, placed at 0.degree. C.
and then acidified to pH=2-3 by adding 5N HCl solution dropwise.
The formation of a precipitate is observed, which is filtered off,
washed with water and then with diethyl ether and dried in
vacuo.
[0154] .sup.1H NMR: .delta. (400 MHz; dmso-d6; 300K): 12.7 (m, 1H,
COOH); 8.45 (d, 1H, aromatic H, H pyrrolo [1,2-a]pyrimidine); 8.19
(d, 1H, aromatic H, H pyrrolo [1,2-a]pyrimidine); 6.9 (dd, 1H,
aromatic H, H pyrrolo [1,2-a]pyrimidine); 7.51 (s, 1H, aromatic H);
7.21 (s, 1H, aromatic H); 7.07 (s, 1H, aromatic H); 6.2 (s, 2H,
aliphatic Hs, O--CH.sub.2--O); 3.8 (s, 3H, aliphatic Hs,
COOCH.sub.3)
[0155] IR: v --OH--: 3300 to 1800 cm.sup.-1; v --CO--: 1705
cm.sup.-1, v >C.dbd.C<: 1616 cm.sup.-1
Preparation 13:
4-Methoxy-2-[1-(methoxycarbonyl)-5,6,7,8-tetrahydro-3-indolizinyl]-benzoi-
c add
[0156] The procedure is in accordance with the protocol described
in Preparation 1, replacing the
6-bromo-1,3-benzodioxole-5-carbaldehyde used in Step C with
2-bromo-4-methoxy-benzaldehyde.
Preparation 14:
5-Methoxy-2-[1-(methoxycarbonyl)-5,6,7,8-tetrahydro-3-indolizinyl]-benzoi-
c acid
[0157] The procedure is in accordance with the protocol described
in Preparation 1, replacing the
6-bromo-1,3-benzodioxole-5-carbaldehyde used in Step C with
2-bromo-5-methoxy-benzaldehyde.
Preparation 15:
7-[1-(Methoxycarbonyl)-5,6,7,8-tetrahydro-3-indolizinyl]-2,3-dihydro-1,4--
benzodioxine-6-carboxylic acid
[0158] The procedure is in accordance with the process of
Preparation 1, replacing the
6-bromo-1,3-benzodioxole-5-carbaldehyde used in Step C with
7-bromo-2,3-dihydro-1,4-benzodioxine-6-carbaldehyde.
Preparation 16: 2-[1-(Methoxycarbonyl)-3-indolizinyl]benzoic
acid
[0159] The procedure is in accordance with the process of
Preparation 5, replacing the 2-bromo-4-chlorobenzaldehyde used in
Step C with 2-bromo-benzaldehyde.
Preparation 17:
4-Fluoro-2-[1-(methoxycarbonyl)-3-indolizinyl]benzoic add
[0160] The procedure is in accordance with the process of
Preparation 5, replacing the 2-bromo-4-chlorobenzaldehyde used in
Step C with 2-bromo-4-fluorobenzaldehyde.
Preparation 18:
4-Fluoro-2-[1-(methoxycarbonyl)-5,6,7,8-tetrahydro-3-indolizinyl]-benzoic
acid
[0161] The procedure is in accordance with the process of
Preparation 1, replacing the
6-bromo-1,3-benzodioxole-5-carbaldehyde used in Step C with
2-bromo-4-fluorobenzaldehyde.
Preparation 1': (3R)-3-Methyl-1,2,3,4-tetrahydroisoquinoline
hydrochloride
Step A:
{(3S)-2-[(4-Methylphenyl)sulphonyl]-1,2,3,4-tetrahydroisoquinolin--
3-yl]methyl 4-methylbenzenesulphonate
[0162] To a solution of 30.2 g of
[(3S)-1,2,3,4-tetrahydroisoquinolin-3-yl]methanol (185 mmol) in 750
mL of dichloromethane there are successively added 91.71 g of tosyl
chloride (481 mmol) and then, dropwise, 122.3 mL of
N,N,N-triethylamine (740 mmol). The reaction mixture is then
stirred at ambient temperature for 20 hours. It is then diluted
with dichloromethane, washed successively with 1M HCl solution,
saturated NaHCO.sub.3 solution and then saturated NaCl solution
until neutral. The organic phase is then dried over MgSO.sub.4,
filtered and concentrated to dryness. The solid obtained is then
dissolved in a minimum volume of dichloromethane and then
cyclohexane is added until a precipitate is formed. This
precipitate is then filtered off and washed with cyclohexane. After
drying, the title product is obtained in the form of crystals.
[0163] .sup.1H NMR: .delta. (400 MHz; dmso-d6; 300K): 7.75 (d, 2H,
aromatic Hs, ortho O-tosyl); 7.6 (d, 2H, aromatic Hs, ortho
N-tosyl); 7.5 (d, 2H, aromatic Hs, meta O-tosyl); 7.3 (d, 2H,
aromatic Hs, meta N-tosyl); 7.15-6.9 (m, 4H, aromatic Hs,
tetrahydroisoquinoline); 4.4-4.15 (dd, 2H, aliphatic Hs,
tetrahydroisoquinoline); 4.25 (m, 1H, aliphatic H,
tetrahydroisoquinoline); 4.0-3.8 (2dd, 2H, aliphatic Hs,
CH.sub.2--O-tosyl); 2.7 (2dd, 2H, aliphatic Hs,
tetrahydroisoquinoline); 2.45 (s, 3H, O--SO.sub.2-Ph-CH.sub.3);
2.35 (s, 3H, N--SO.sub.2-Ph-CH.sub.3)
[0164] IR: v: --SO.sub.2: 1339-1165 cm.sup.-1
Step B:
(3R)-3-Methyl-2-[(4-methylphenyl)sulphonyl]-1,2,3,4-tetrahydroisoq-
uinoline
[0165] To a suspension of 8.15 g (214.8 mmol) of LiAlH.sub.4 in 800
mL of methyl tert-butyl ether (MTBE) there are added 101.2 g of the
ditosyl compound obtained in Step A (214.8 mmol) dissolved in 200
mL of MTBE. The batch is then heated at 50.degree. C. for 2 hours.
It is allowed to cool and placed at 0.degree. C., and there are
then added, dropwise, 12 mL of 5N NaOH solution. The batch is
stirred at ambient temperature for 45 minutes. The solid thereby
obtained is then filtered off and washed with MTBE and then with
dichloromethane. The filtrate is then concentrated to dryness. The
title product is then obtained in the form of a solid.
[0166] .sup.1H NMR: .delta. (400 MHz; dmso-d6; 300K): 7.70 (d, 2H,
aromatic Hs, ortho N-tosyl); 7.38 (d, 2H, aromatic Hs, meta
N-tosyl); 7.2-7.0 (m, 4H, aromatic Hs, tetrahydroisoquinoline); 4.4
(m, 2H, aliphatic Hs, tetrahydroisoquinoline); 4.3 (m, 1H,
aliphatic H, tetrahydroisoquinoline); 2.85-2.51 (2dd, 2H, aliphatic
Hs, tetrahydroisoquinoline); 2.35 (s, 3H, N--SO.sub.2-Ph-CH.sub.3);
0.90 (d, 3H, tetrahydroisoquinoline-CH.sub.3)
[0167] IR: v: --SO.sub.2: 1332-1154 cm.sup.-1
Step C: (3R)-3-Methyl-1,2,3,4-tetrahydroisoquinoline
[0168] To a solution of 31.15 g (103.15 mmol) of the monotosyl
compound obtained in Step B in 500 mL of anhydrous methanol there
are added, in portions, 3.92 g (161 mmol) of magnesium turnings.
The batch is stirred in the presence of ultrasound for 96 hours.
The reaction mixture is then filtered and the solid is washed
several times with methanol. The filtrate is then concentrated to
dryness. After purification by column chromatography over silica
gel (dichloromethane/EtOH/NH.sub.4OH), the title product is
obtained in the form of an oil.
[0169] .sup.1H NMR: .delta. (400 MHz; dmso-d6; 300K): 7.05 (m, 4H,
aromatic Hs, tetrahydroisoquinoline); 3.90 (m, 2H, aliphatic Hs,
tetrahydroisoquinoline); 2.85 (m, 1H, aliphatic H,
tetrahydroisoquinoline); 2.68-2.4 (2dd, 2H, aliphatic Hs,
tetrahydro-isoquinoline); 1.12 (d, 3H,
tetrahydroisoquinoline-CH.sub.3); 2.9-2.3 (m, broad, 1H, HN
(tetrahydroisoquinoline))
[0170] IR: v: --NH: 3248 cm.sup.-1
Step D: (3R)-3-Methyl-1,2,3,4-tetrahydroisoquinoline
hydrochloride
[0171] To a solution of 14.3 g (97.20 mmol) of the compound
obtained in Step C in 20 mL of anhydrous ethanol there are added,
dropwise, 100 mL of a 1M solution of HCl in ether. The batch is
stirred at ambient temperature for 1 hour and then filtered. The
crystals thereby obtained are washed with ethyl ether. After
drying, the title product is obtained in the form of crystals.
[0172] .sup.1H NMR: .delta. (400 MHz; dmso-d6; 300K): 9.57 (m,
broad, 2H, NH.sub.2.sup.+ (tetrahydro-isoquinoline); 7.22 (m, 4H,
aromatic Hs, tetrahydroisoquinoline); 4.27 (s, 2H, aliphatic Hs,
tetrahydroisoquinoline); 3.52 (m, 1H, aliphatic H,
tetrahydroisoquinoline); 3.03-2.85 (2dd, 2H, aliphatic Hs,
tetrahydroisoquinoline); 1.39 (d, 3H,
tetrahydroisoquinoline-CH.sub.3)
[0173] IR: v: --NH.sub.2.sup.+: 3000-2300 cm.sup.-1; v: aromatic
--CH: 766 cm.sup.-1
Preparation 2':
(3S)-3-[2-(Morpholin-4-yl)ethyl]-1,2,3,4-tetrahydroisoquinoline
hydrochloride
Step A: tert-Butyl
(3S)-3-(2-morpholino-2-oxo-ethyl)-3,4-dihydro-1H-isoquinoline-2-carboxyla-
te
[0174] To a solution of 3 g (10.30 mmol) of
[(3S)-2-(tert-butoxycarbonyl)-1,2,3,4-tetrahydroisoquinolin-3-yl]acetic
acid in 100 mL of dichloromethane there are added, dropwise, 1.10
mL (11.32 mmol) of morpholine and, still dropwise, 4.3 mL (30.9
mmol) of triethylamine, 2.20 g (12.40 mmol) of 1,2-dichloromethane
and 1.70 g (1.68 mmol) of hydroxybenzotriazole. The batch is
stirred at ambient temperature for 15 hours. The reaction mixture
is then diluted with dichloromethane and washed successively with
1M HCl solution, saturated NaHCO.sub.3 solution and then saturated
NaCl solution until neutral. The organic phase is then dried over
MgSO.sub.4, filtered and concentrated to dryness. After
purification by column chromatography over silica gel
(dichloromethane/MeOH), the title product is obtained in the form
of an oil.
[0175] .sup.1H NMR: .delta. (400 MHz; dmso-d6; 300K): 7.20-7.10 (m,
4H, aromatic Hs, tetrahydroisoquinoline); 4.70 (m, 1H, aliphatic
Hs, CH tetrahydroisoquinoline); 4.75-4.20 (2m, 2H, aliphatic Hs,
CH.sub.2 alpha to N tetrahydroisoquinoline); 3.60 (m, 8H, aliphatic
Hs, morpholine); 3.00 and 2.70 (2dd, 2H, aliphatic H,
tetrahydroisoquinoline); 2.50-2.20 (2d, 2H, aliphatic Hs,
CH.sub.2CO); 1.40 (s, 9H, .sup.tBu)
[0176] IR: v: C.dbd.O: 1687; 1625 cm.sup.-1
Step B:
1-(Morpholin-4-yl)-2-[(3S)-1,2,3,4-tetrahydroisoquinolin-3-yl]etha-
none hydro-chloride
[0177] To a solution of 2.88 g (7.18 mmol) of the compound obtained
in Step A in 16 mL of dichloromethane there are added, dropwise, 80
mL (80 mmol) of a 1M solution of HCl in ether. The batch is stirred
at ambient temperature for 15 hours and then the suspension is
filtered and the precipitate is washed with ether. After drying,
the title product is obtained in the form of a solid.
[0178] .sup.1H NMR: .delta. (400 MHz; dmso-d6; 300K): 9.80-9.50 (m,
2H, NH.sub.2.sup.+); 7.30-7.10 (m, 4H, aromatic Hs,
tetrahydroisoquinoline); 4.30 (m, 2H, aliphatic Hs, CH.sub.2 alpha
to N tetrahydroisoquinoline); 3.80 (m, 1H, aliphatic Hs, CH
tetrahydroisoquinoline); 3.70-3.40 (2m, 8H, aliphatic Hs,
morpholine); 3.15 and 2.8 (m, 4H, aliphatic H, CH.sub.2
tetrahydroisoquinoline and CH.sub.2CO)
[0179] IR: v: --NH.sub.2.sup.+: 2800-1900 cm.sup.-1; v: C.dbd.O:
1620 cm.sup.-1
Step C:
(3S)-3-[2-(Morpholin-4-yl)ethyl]-1,2,3,4-tetrahydroisoquinoline
hydrochloride
[0180] A solution of 2.2 g (7.44 mmol) of the compound obtained in
Step B in 22 mL of MTBE and 5 mL of dichloromethane is prepared.
After cooling in an ice bath at 0.degree. C., there are added
thereto, dropwise, 15 mL (15 mmol) of 1M LiAlH.sub.4 solution in
tetrahydrofuran. The batch is then stirred at ambient temperature
for 6 hours. It is placed at 0.degree. C., and there is then added,
dropwise, 1 mL of 5N NaOH solution. The batch is stirred at ambient
temperature for 45 minutes. The solid is then filtered off and
washed with MTBE and then with dichloromethane and the filtrate is
concentrated to dryness. The oil thereby obtained is diluted with
dichloromethane and there are added, dropwise, 6.3 mL of a 1M
solution of HCl in ether. The batch is stirred at ambient
temperature for 1 hour and then filtered. The crystals thereby
obtained are washed with ethyl ether. After drying, the title
product is obtained in the form of a solid.
[0181] .sup.1H NMR: .delta. (400 MHz; dmso-d6; 300K): 11.35+9.80
(2m, 2H, NH.sub.2.sup.+); 10.00 (m, H, NH.sup.+); 7.20 (m, 4H,
aromatic Hs, tetrahydroisoquinoline); 4.30 (s, 2H, aliphatic Hs,
CH.sub.2 alpha to N tetrahydroisoquinoline); 4.00+3.85 (2m, 4H,
aliphatic Hs, CH.sub.2 alpha to N morpholine); 3.70 (m, 1H,
aliphatic Hs, CH tetrahydroisoquinoline); 3.55-3.30 (m, 4H,
aliphatic Hs, CH alpha to O morpholine and CH.sub.2-morpholine);
3.15 (dd, 1H, aliphatic H, CH.sub.2 tetrahydroisoquinoline); 3.10
(m, 2H, aliphatic H, CH alpha to O morpholine); 2.90 (dd, 1H,
aliphatic H, CH.sub.2 tetrahydroisoquinoline); 2.30+2.15 (2m, 2H,
aliphatic H, CH.sub.2-tetrahydroisoquinoline)
[0182] IR: v: NH.sup.+/--NH.sub.2.sup.+: between 3500 and 2250
cm.sup.-1; v: C.dbd.C: weak 1593 cm.sup.-1; v: aromatic C--H: 765
cm.sup.-1
Preparation 3': tert-Butyl
{2-[(3S)-1,2,3,4-tetrahydroisoquinolin-3-yl]ethyl}-carbamate
Step A: Benzyl
(3S)-3-(2-hydroxyethyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate
[0183] The title compound is obtained starting from
(3S)-2-[(benzyloxy)carbonyl]-1,2,3,4-tetrahydroisoquinoline-3-carboxylic
acid based on a protocol from the literature (Jinlong Jiang et al
Bioorganic & Medicinal Chemistry Letters, 14, 1795, 2004).
Step B: Benzyl
(3S)-3-{2-[(methylsulphonyl)oxy]ethyl}-3,4-dihydroisoquinoline-2(1H)-carb-
oxylate
[0184] To a solution of 10.6 g of the compound of Step A (35.6
mmol) in 350 mL of anhydrous CH.sub.2Cl.sub.2 placed at 0.degree.
C. there are successively added 10.1 mL of triethylamine (71.2
mmol) and then, dropwise, 3.1 mL of methanesulphonyl chloride (39
mmol). The reaction mixture is then stirred at ambient temperature
for 2 hours. Hydrolysis is then carried out by slowly adding water.
The product is extracted several times with CH.sub.2Cl.sub.2. The
organic phases are then combined and successively washed with 1N
HCl solution, saturated NaCl solution, saturated NaHCO.sub.3
solution and saturated NaCl solution until neutral. They are then
dried over MgSO.sub.4 and concentrated to dryness. After
purification by chromatography over silica gel (petroleum
ether/AcOEt gradient), the expected product is obtained in the form
of a foam.
[0185] LC/MS: m/z=(M+H).sup.+=375
Step C: Benzyl
(3S)-3-(cyanomethyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate
[0186] To a solution of 15.4 g of the compound obtained in Step B
(41.02 mmol) in 250 mL of anhydrous DMSO there are added 22 g (449
mmol) of sodium cyanide. The batch is then heated at 60.degree. C.
for 12 hours. It is allowed to cool and then the reaction mixture
is diluted by adding ethyl acetate. Hydrolysis is then carried out
with saturated NaHCO.sub.3 solution. After extracting two more
times with ethyl acetate, the organic phases are combined, washed
with H.sub.2O, dried over MgSO.sub.4 and concentrated to dryness.
After purification by chromatography over silica gel (hexane/AcOEt
7/3), the expected product is obtained in the form of an oil.
[0187] LC/MS: m/z=[M+H].sup.+=307.1
Step D: Benzyl
(3S)-3-(2-aminoethyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate
[0188] To a solution of 15.4 g of the compound obtained in Step C
(50.3 mmol) in 300 mL of anhydrous THF placed at 0.degree. C. there
are added, dropwise, a 1N solution of BH.sub.3-THF. The reaction
mixture is allowed to come back to ambient temperature gradually
and then the batch is stirred for 14 hours. The reaction mixture is
then hydrolysed by slowly adding saturated NH.sub.4Cl solution.
After extracting twice with ethyl acetate, the organic phases are
combined and dried over MgSO.sub.4. After concentrating to dryness,
the expected product is obtained in the form of a foam which is
used directly without purification in the next protection step.
Step E: Benzyl
(3S)-3-{2-[(tert-butoxycarbonyl)amino]ethyl}-3,4-dihydroisoquinoline-2(1H-
)-carboxylate
[0189] To a solution of 15.6 g of the compound obtained in Step D
(50.3 mmol) in 670 mL of CH.sub.2Cl.sub.2 there are successively
added, in portions, 13.2 g (60.36 mmol) of Boc.sub.2O, 14 mL of
triethylamine (100.6 mmol) and DMAP in a catalytic amount. The
batch is stirred at ambient temperature for 5 hours. The reaction
mixture is then hydrolysed with water and extracted twice with
CH.sub.2Cl.sub.2. The organic phases are combined, washed with
water and dried over MgSO.sub.4. After concentration to dryness and
purification by chromatography over silica gel (heptane/AcOEt
gradient), the expected product is obtained in the form of an
oil.
[0190] LC/MS: m/z=(M+H).sup.+=411
Step F: tert-Butyl
{2-[(3S)-1,2,3,4-tetrahydroisoquinolin-3-yl]ethyl}carbamate
[0191] To a solution of 10.4 g of the compound obtained in Step E
(25.5 mmol) in 210 mL of anhydrous MeOH there are added 2.71 g
(2.55 mmol) of Pd/C 10%. The batch is degassed for 30 minutes and
is then stirred under a hydrogen atmosphere for 16 hours. The
reaction mixture is then filtered and concentrated to dryness. The
expected product is obtained in the form of a solid which is taken
up in a mixture of pentane/Et.sub.2O (90/10), triturated and
filtered. After drying, the product is obtained in the form of a
solid.
[0192] .sup.1H NMR: .delta. (400 MHz; dmso-d6; 300K): 7.1-6.98 (m,
4H, aromatic Hs, tetrahydroisoquinoline); 6.83 (m, 1H,
CH.sub.2NHBoc); 3.85 (s, 2H, aliphatic Hs, tetrahydroisoquinoline);
3.09 (q, 2H, CH.sub.2NHBoc); 2.73 (m, 1H, aliphatic Hs,
tetrahydroisoquinoline); 2.70 and 2.39 (2m, 2H, aliphatic Hs,
tetrahydroisoquinoline); 1.63 (m, 2H, aliphatic Hs); 1.38 (s, 9H,
NHCOOtBu)
[0193] IR: v: >NH: 3378, -3201 cm.sup.-1 (amine, amide); v:
>C.dbd.O: 1683 cm.sup.-1 (amide); v: >NH: 1524 cm.sup.-1
(amide); v: >C.dbd.O: 1168 cm.sup.-1
[0194] LC/MS: m/z=[M+H].sup.+=277
Preparation 4':
(3R)-3-[3-(Morpholin-4-yl)propyl]-1,2,3,4-tetrahydroisoquinoline
Step A:
{(3S)-2-[(4-Methylphenyl)sulphonyl]-1,2,3,4-tetrahydroisoquinolin--
3-yl}methyl 4-methylbenzenesulphonate
[0195] The procedure is the same as that of Step A of Preparation
1'.
Step B: tert-Butyl
2-({(3R)-2-[(4-methylphenyl)sulphonyl]-1,2,3,4-tetrahydroisoquinolin-3-yl-
}methyl)-3-(morpholin-4-yl)-3-oxopropanoate
[0196] To a suspension of 1 g of NaH (60%) (25.08 mmol) in 30 mL of
MTBE there are added, dropwise, a solution of 5 g of tert-butyl
3-morpholino-3-oxopropanoate (21.81 mmol) in 20 mL of anhydrous
MTBE. This suspension stirred at ambient temperature for 1 hour and
then the compound obtained in Step A is added in the form of a
powder. The batch is stirred at 60.degree. C. for 30 hours. 100 mL
of saturated ammonium chloride solution are added. The resulting
solution is extracted with dichloromethane. The organic phase is
then dried over MgSO.sub.4, filtered and concentrated to dryness.
After purification by column chromatography over silica gel
(dichloromethane/MeOH), the expected product is obtained in the
form of an oil.
[0197] .sup.1H NMR (500 MHz; dmso-d6) .delta. ppm: 7.63/7.59 (2d,
2H), 7.3/7.26 (2d, 2H); 7.13 (m, 2H), 7.09/6.97 (2t, 2H),
4.64/4.55/4.36/4.28 (2AB, 2H), 4.25/4.11 (2m, 1H), 3.81 (m, 1H),
3.73/3.48 (m, 4H), 3.57-3.32 (m, 4H), 2.51 (m, 2H), 2.32/2.31 (2s,
3H), 1.88/1.79 (2m, 2H), 1.39/1.38 (2s, 9H).
[0198] IR (ATR) cm.sup.-1: v: >C.dbd.O: 1731 (ester); v:
>C.dbd.O: 1644 (amide); v: --SO2: 1334-1156; v: >C--O--C<:
1155; .gamma.: >CH--Ar: 815-746-709
Step C:
2-({(3R)-2-[(4-Methylphenyl)sulphonyl]-1,2,3,4-tetrahydroisoquinol-
in-3-yl}methyl)-3-(morpholin-4-yl)-3-oxopropanoic acid
[0199] To a solution of 9.5 g (17.97 mmol) of the compound obtained
in Step B in 40 mL of dioxane there are added, dropwise, 20 mL of a
4M solution of HCl in dioxane. The batch is stirred at ambient
temperature for 48 hours and then the solution is concentrated to
dryness. After drying, the expected product is obtained in the form
of an oil.
[0200] .sup.1H NMR (400 MHz; dmso-d6) .delta. ppm: 12.75 (m, 1H),
7.6 (2*d, 2H); 7.3 (2*d, 2H), 7.1/6.95 (2*m, 4H), 4.7/4.2 (d, 2H),
4.25/4.12 (2*m, 1H), 3.9-3.3 (m, 9H), 2.55 (d, 2H), 2.3 (2*s, 3H),
1.8 (t, 2H)
[0201] IR (ATR) cm.sup.-1: v: --OH: 3500 to 2000; v: >C.dbd.O:
1727 (acid); v: >C.dbd.O: 1634 (amide); v: --SO2: 1330-1155
Step D:
3-{(3R)-2-[(4-Methylphenyl)sulphonyl]-1,2,3,4-tetrahydroisoquinoli-
n-3-yl}-1-(morpholin-4-yl)propan-1-one
[0202] To a solution of 7.80 g (16.51 mmol) of the compound
obtained in Step C in 100 mL of DMSO there are added 1.16 g (19.83
mmol) of solid sodium chloride and then, dropwise, 5 mL of water.
The batch is stirred at 130.degree. C. for 1 hour and then the
solution is concentrated to 3/4. The reaction mixture is then
diluted with dichloromethane and washed successively with saturated
lithium chloride solution and then with saturated NaCl solution.
The organic phase is then dried over MgSO.sub.4, filtered and
concentrated to dryness. After purification by column
chromatography over silica gel (cyclohexane/ethyl acetate), the
expected product is obtained in the form of an oil.
[0203] .sup.1H NMR (400 MHz; dmso-d6) .delta. ppm: 7.65 (d, 2H),
7.3 (d, 2H); 7.15/7 (2m, 4H), 4.6 (d, 1H), 4.25 (d, 1H), 4.2 (m,
1H), 3.5 (m, 4H), 3.4 (2 m, 4H), 2.6 (2 dd, 2H), 2.35 (s, 3H), 2.3
(m, 2H), 1.5 (quad., 2H)
[0204] IR (ATR) cm.sup.-1: v: >C.dbd.O: 1639; v: --SO2:
1331-1156; .gamma.: >CH--Ar: 815-675
Step E:
(3R)-2-[(4-Methylphenyl)sulphonyl]-3-[3-(morpholin-4-yl)propyl]-1,-
2,3,4-tetrahydroisoquinoline
[0205] To a solution of 6.0 g (14.0 mmol) of the compound obtained
in Step D in 60 mL of MTBE and 14 mL of dichloromethane there are
added 1.06 g (28 mmol) of LAH in portions over 5 minutes. The batch
is stirred at ambient temperature for 15 hours. There are added,
dropwise, 1.5 mL of water and stirring is carried out for 15
minutes. There are then added, dropwise, 1.5 mL of 5M sodium
hydroxide solution and stirring is carried out for 15 minutes. The
reaction mixture is then diluted with MTBE and dichloromethane. The
suspension is then filtered and the precipitate is washed with MTBE
and dichloromethane. The organic phase is then dried over
MgSO.sub.4, filtered and concentrated to dryness. After
purification by column chromatography over silica gel
(dichloromethane/EtOH/NH.sub.4OH), the expected product is obtained
in the form of an oil.
[0206] .sup.1H NMR (400 MHz; dmso-d6) .delta. ppm: 7.68 (d, 2H),
7.32 (d, 2H); 7.1 (unresolved peak, 4H), 4.65/4.23 (AB, 2H), 4.2
(m, 1H), 3.55 (t, 4H), 2.7/2.6 (ABx, 2H), 2.35 (s, 3H), 2.25 (t,
4H), 2.2 (t, 2H), 1.4/1.3 (2m, 4H)
[0207] IR (ATR) cm.sup.-1: v: --SO2: 1333-1158
Step F:
(3R)-3-[3-(Morpholin-4-yl)propyl]-1,2,3,4-tetrahydroisoquinoline
[0208] To a solution of 1.50 g (3.62 mmol) of the compound obtained
in Step E in 20 mL of anhydrous methanol there are added 2.0 g
(82.3 mmol), in portions, of magnesium turnings. The batch is
stirred in the presence of ultrasound for 96 hours. The reaction
mixture is then filtered, the solid is washed several times with
methanol, and the filtrate is concentrated to dryness. After
purification by column chromatography over silica gel
(dichloromethane/EtOH/NH.sub.4OH), the expected product is obtained
in the form of an oil.
[0209] .sup.1H NMR (400 MHz; dmso-d6) .delta. ppm: 7.3 (d, 2H), 7.1
(t, 2H); 7.1 (d+t, 3H), 7 (d, 2H), 3.9 (s, 2H), 3.55 (t, 4H), 2.75
(m, 1H), 2.72/2.45 (dd, 2H), 2.35 (t, 4H), 2.25 (t, 2H), 1.6 (m,
2H), 1.45 (m, 2H)
[0210] IR (ATR) cm.sup.-1: v: >NH2+/NH+: 3500-2300; v:
>C--O--C<: 1115
[0211] High-resolution mass spectroscopy (ESI+-/FIA/HR):
[0212] Empirical formula: C.sub.16H.sub.24N.sub.2O
[0213] [M+H].sup.+, calculated: 261.1961
[0214] [M+H].sup.+, measured: 261.1959
Preparation 5':
(3S)-3-[2-(3,3-Difluoropiperidin-1-yl)ethyl]-1,2,3,4-tetrahydroiso-quinol-
ine hydrochloride
[0215] The procedure is in accordance with the process of
Preparation 2', replacing the morpholine used in Step A with
3,3-difluoro-1-piperidine.
[0216] .sup.1H NMR: .delta. (400 MHz; dmso-d6; 300K): 11.3 (m, 1H,
NH.sup.+); 10.2-9.8 (m, 2H, NH.sub.2.sup.+); 7.25 (m, 4H, aromatic
Hs, tetrahydroisoquinoline); 4.3 (broad s, 2H, aliphatic Hs, CH
tetrahydroisoquinoline); 4.0-3.3 (m, 7H, aliphatic Hs); 3.15-2.95
(dd, 2H, aliphatic Hs, CH tetrahydroisoquinoline); 2.4-1.9 (m, 6H,
aliphatic Hs, H 3,3-difluoro-1-piperidine)
[0217] IR: v: NH.sup.+/NH.sub.2.sup.+: between 300 and 2500
cm.sup.-1; v: C--F: 1204 cm.sup.-1
Preparation 6':
(3S)-3-[2-(3-Methoxyazetidin-1-yl)ethyl]-1,2,3,4-tetrahydroiso-quinoline
hydrochloride
[0218] The procedure is in accordance with the process of
Preparation 2', replacing the morpholine used in Step A with
3-methoxyazetidine.
[0219] .sup.1H NMR: .delta. (400 MHz; dmso-d6; 300K): 11.3 (m, 1H,
NH.sup.+); 10.00 (m, 2H, NH.sub.2.sup.+); 7.20 (m, 4H, aromatic Hs,
tetrahydroisoquinoline); 4.4 (m, 1H, aliphatic H, 3-methoxy
azetidine); 4.30 (s, 2H, aliphatic Hs, tetrahydroisoquinoline);
4.2-3.45 (m, 4H, 3-methoxyazetidine); 4.2-3.6 (m, 3H, aliphatic
Hs); 3.1 and 2.95 (dd, 2H, aliphatic Hs); 3.25 (s, 3H,
OCH.sub.3)
Preparation 7': (3S)-3-Methyl-1,2,3,4-tetrahydroisoquinoline
hydrochloride
[0220] The procedure is in accordance with the process of
Preparation 1', replacing the
[(3S)-1,2,3,4-tetrahydroisoquinolin-3-yl[methanol used in Step A
with [(3R)-1,2,3,4-tetrahydro-isoquinolin-3-yl] methanol.
Preparation 1'':
N-(4-{[tert-Butyl(dimethyl)silyl]oxy}phenyl)-1-methyl-1H-pyrazol-4-amine
Step A: 4-{[tert-Butyl(dimethyl)silyl]oxy}aniline
[0221] The title compound is obtained starting from 4-aminophenol
in THF in the presence of imidazole and tert-butyl(dimethyl)silyl
chloride in accordance with the protocol described in the
literature (S. Knaggs et al, Organic & Biomolecular Chemistry,
3(21), 4002-4010; 2005).
[0222] .sup.1H NMR: .delta. (400 MHz; dmso-d6; 300K): 6.45-6.55
(dd, 4H, aromatic Hs); 4.60 (m, 2H, NH.sub.2-Ph); 0.90 (s, 9H, Si
(CH.sub.2).sub.2CH(CH.sub.3).sub.2); 0.10 (s, 6H, Si
(CH.sub.2).sub.2CH(CH.sub.3).sub.2)
[0223] IR: v: --NH.sub.2.sup.+: 3300-3400 cm.sup.-1
Step B:
N-[4-[tert-Butyl(dimethyl)silyl]oxyphenyl]-1-methyl-pyrazol-4-amin-
e
[0224] To a solution of 30.8 g (0.137 mol) of the compound of Step
A in 525 mL of anhydrous toluene there are successively added 29.8
g of sodium tert-butylate (0.310 mol), 4.55 g of
Pd.sub.2(dba).sub.3 (also referred to as
tris(dibenzylideneacetone)dipalladium(0)) (4.96 mmol), 4.81 g of
2-di-tert-butylphosphino-2',4',6'-tri-isopropyl-1,1'-biphenyl (9.91
mmol) and 12.8 mL of 4-bromo-1-methyl-1H-pyrazole (0.124 mol). The
batch is degassed under argon for 30 minutes and then refluxed for
3 hours. It is allowed to cool. The reaction mixture is
concentrated to dryness and then taken up in dichloromethane,
filtered over Celite and then concentrated to dryness again. The
residue is then purified by chromatography over silica gel
(gradient CH.sub.2Cl.sub.2/AcOEt) to provide the expected product
in the form of a solid.
[0225] .sup.1H NMR: .delta. (400 MHz; dmso-d6; 300K): 7.55 (s, 1H,
pyrazole); 7.23 (s, 1H, pyrazole); 7.18 (broad s, 1H, NH.sub.2-Ph);
6.64 (m, 4H, aromatic Hs); 3.77 (s, 3H, CH.sub.3-pyrazole); 0.90
(s, 9H, Si (CH.sub.2).sub.2CH(CH.sub.3).sub.2); 0.12 (s, 6H, Si
(CH.sub.2).sub.2CH(CH.sub.3).sub.2)
[0226] IR: v --NH.sup.+: 3275 cm.sup.-1; v Ar and C.dbd.N: 1577 and
1502 cm.sup.-1; v --Si--C--: 1236 cm.sup.-1; v --Si--O--: 898
cm.sup.-1; v --Si--C--: 828, 774 cm.sup.-1
Preparation 2'':
N-(4-{[tert-Butyl(dimethyl)silyl]oxy}phenyl)-1-methyl-1H-indol-5-amine
[0227] The procedure is in accordance with the process of
Preparation 1'', replacing the 4-bromo-1-methyl-1H-pyrazole used in
Step B with 5-bromo-1-methyl-1H-indole.
Preparation 3'':
N-(4-{[tert-Butyl(dimethyl)silyl]oxy}phenyl)-1-[2-(morpholin-4-yl)ethyl]--
1H-indol-5-amine
Step A: 5-Bromo-1-[2-(morpholin-4-yl)ethyl]-1H-indole
[0228] To a suspension of NaH (4.5 g; 112 mmol) in anhydrous THF
(300 mL) placed at 0.degree. C. there are added, in portions,
5-bromo-1H-indole (10.4 g; 51 mmol). After stirring for 20 minutes
at 0.degree. C., 4-(2-chloroethyl)morpholine hydrochloride (10.4 g;
56 mmol) is added in portions over 1 hour. After stirring overnight
at ambient temperature, the reaction mixture is placed at
80.degree. C. for 5 hours. It is then poured over a mixture of
aqueous sodium bicarbonate and dichloromethane. The aqueous phase
is extracted with dichloromethane. The organic phase is dried over
MgSO.sub.4 and concentrated to dryness, and the residue is purified
by chromatography over silica gel (CH.sub.2Cl.sub.2/MeOH gradient)
to provide the expected product in the form of an oil.
[0229] .sup.1H NMR: .delta. (400 MHz; CDCl3; 300K): 7.75 (d, 1H);
7.30 (dd, 1H); 7.20 (d, 1H); 7.15 (d, 1H); 6.40 (d, 1H); 4.20 (t,
2H); 3.70 (m, 4H); 2.75 (t, 2H); 2.45 (m, 4H)
Step B: 5-Bromo-1-[2-(morpholin-4-yl)ethyl]-1H-indole
[0230] The procedure is in accordance with the process of
Preparation 1'', replacing the 4-bromo-1-methyl-1H-pyrazole used in
Step B with the compound obtained in Step A.
[0231] .sup.1H NMR: .delta. (400 MHz; dmso-d6; 300K): 7.35 (d, 1H);
7.15 (s, 1H); 6.85 (d, 3H); 6.70 (d, 2H); 7.30 (d, 1H); 6.25 (d,
1H), 4.20 (t, 2H); 3.55 (m, 4H); 2.65 (t, 2H); 2.45 (m, 4H); 1.45
(s, 9H), 0.15 (s, 6H)
Preparation 4'':
N-(4-{[tert-Butyl(dimethyl)silyl]oxy}phenyl)-1-[2-(morpholin-4-yl)ethyl]--
2,3-dihydro-1H-indol-5-amine
[0232] The procedure is in accordance with the process of
Preparation 2'', replacing the 5-bromoindole used in Step A with
5-bromo-2,3-dihydro-1H-indole.
Preparation 5'':
N-(4-{[tert-Butyl(dimethyl)silyl]oxy}phenyl)-4-fluoroaniline
[0233] The procedure is in accordance with the process of
Preparation 1'', replacing the 4-bromo-1-methyl-1H-pyrazole used in
Step B with 1-bromo-4-fluorobenzene.
Preparation 6'':
N-(4-{[tert-Butyl(dimethyl)silyl]oxy}phenyl)-3-fluoro-4-methylaniline
[0234] The procedure is in accordance with the process of
Preparation 1'', replacing the 4-bromo-1-methyl-1H-pyrazole used in
Step B with 4-bromo-2-fluoro-1-methylbenzene.
Preparation 7'':
N-(4-{[tert-Butyl(dimethyl)silyl]oxy}phenyl)-1-methyl-1H-indazol-5-amine
[0235] The procedure is in accordance with the process of
Preparation 1'', replacing the 4-bromo-1-methyl-1H-pyrazole used in
Step B with 5-bromo-1-methyl-1H-indazole.
Preparation 8'':
4-{[tert-Butyl(dimethyl)silyl]oxy}-N-phenylaniline
[0236] To a solution of 12 g of 4-anilinophenol (64.7 mmol) in 200
mL of acetonitrile there are added, at ambient temperature, 6.7 g
of imidazole (97.05 mmol) and 11.7 g of
tert-butyl-(chloro)dimethylsilane (77.64 mmol). The batch is
stirred at 70.degree. C. for 4 hours. The reaction mixture is then
poured into water and extracted with ether. The organic phase is
then dried over magnesium sulphate, then filtered and evaporated to
dryness. The crude product thereby obtained is then purified by
chromatography over silica gel (petroleum ether/dichloromethane
gradient). The title product is obtained in the form of a
powder.
[0237] .sup.1H NMR: .delta. (400 MHz; dmso-d6; 300K): 7.84 (s, 1H
NH); 7.17 (t, 2H aniline); 6.98 (d, 2H phenoxy); 6.94 (d, 2H
aniline); 6.76 (d, 2H phenoxy); 6.72 (t, 1H aniline); 0.95 (s, 9H
tert-butyl); 0.15 (s, 6H dimethyl)
[0238] IR: v: >NH: 3403 cm.sup.-1; >Ar: 1597 cm.sup.-1
Preparation 9'': 4-Benzyloxy-N-phenyl-aniline
[0239] To a solution of 4-hydroxy-N-phenyl-aniline (30 g; 162 mmol)
in acetonitrile (400 mL) there are added 58 g of Cs.sub.2CO.sub.3
(178 mmol) and stirring is carried out for 15 minutes at ambient
temperature. Benzyl bromide (22.5 mL; 178 mmol) is then added
dropwise and then the reaction mixture is refluxed for 4 hours.
After filtering and rinsing with acetonitrile, the filtrate is
concentrated and chromatographed over silica gel (petroleum
ether/AcOEt gradient). The title product is then obtained in the
form of a colourless solid.
Preparation 10'':
N-(4-{[tert-Butyl(dimethyl)silyl]oxy}phenyl)-3-fluoro-4-[2-(morpholin-4-y-
l)ethoxy]aniline
[0240] The procedure is in accordance with the process of
Preparation 3'', replacing the 5-bromo-1H-indole used in Step A by
4-bromo-2-fluorophenol.
[0241] .sup.1H NMR: .delta. (400 MHz; dmso-d6; 300K): 7.75 (d, 1H);
7 (dd, 1H); 6.9 (d, 2H); 6.75 (m, 3H); 6.7 (ddd, 1H); 4.05 (t, 2H);
3.6 (t, 4H); 2.65 (t, 2H); 2.45 (t, 4H); 0.95 (s, 9H); 0.2 (s,
6H)
Preparation 11'':
N-(4-{[tert-Butyl(dimethyl)silyl]oxy}phenyl)pyridin-4-amine
[0242] The procedure is in accordance with the process of
Preparation 1'', replacing the 4-bromo-1-methyl-1H-pyrazole used in
Step B with 4-bromopyridine.
[0243] IR: v --NH--: 3200 and 2500 cm.sup.-1; v --Si--O--: 902
cm.sup.-1; v --Si--C--: 820 cm.sup.-1
Preparation 12'':
3-[(4-{[tert-Butyl(dimethyl)silyl]oxy}phenyl)amino]benzonitrile
[0244] The procedure is in accordance with the process of
Preparation 1'', replacing the 4-bromo-1-methyl-1H-pyrazole used in
Step B with 3-bromobenzonitrile.
Preparation 13'':
N-(4-{[tert-Butyl(dimethyl)silyl]oxy}phenyl)-3-fluoroaniline
[0245] The procedure is in accordance with the process of
Preparation 1'', replacing the 4-bromo-1-methyl-1H-pyrazole used in
Step B with 1-bromo-3-fluorobenzene.
Preparation 14'':
N-(4-{[tert-Butyl(dimethyl)silyl]oxy}phenyl)-3,4-difluoroaniline
[0246] The procedure is in accordance with the process of
Preparation 1'', replacing the 4-bromo-1-methyl-1H-pyrazole used in
Step B with 4-bromo-1,2-difluorobenzene.
Preparation 15'':
4-{[tert-Butyl(dimethyl)silyl]oxy}-N-{4-[(3,3-difluoropiperidin-1-yl)meth-
yl]phenyl}aniline
Step A: 1-(4-Bromobenzyl)-3,3-difluoropiperidine
[0247] To a solution of 4-bromobenzaldehyde (500 mg; 2.7 mmol) in
12 mL of dichloromethane there are added, in the order stated,
3,3-difluoropiperidine hydrochloride (470 mg; 3 mmol), sodium
triacetoxyborohydride (860 mg; 4 mmol) and acetic acid (0.17 mL; 3
mmol). After stirring for 1 hour at ambient temperature, the
reaction mixture is poured over a mixture of aqueous sodium
bicarbonate and dichloromethane. The aqueous phase is extracted
with dichloromethane. The organic phase is dried over MgSO.sub.4,
concentrated to dryness and the residue is purified by
chromatography over silica gel (CH.sub.2Cl.sub.2/MeOH gradient) to
provide the expected product in the form of an oil.
[0248] .sup.1H NMR: .delta. (400 MHz; dmso-d6; 300K):7.55 (dd, 2H);
7.25 (dd, 2H); 3.55 (s, 2H); 2.7 (t, 2H); 2.35 (t, 2H); 1.85 (m,
2H); 1.65 (m, 2H)
Step B:
4-{[tert-Butyl(dimethyl)silyl]oxy}-N-{4-[(3,3-difluoropiperidin-1--
yl)methyl]-phenyl}aniline
[0249] The procedure is in accordance with the process of
Preparation 1'', replacing the 4-bromo-1-methyl-1H-pyrazole used in
Step B with 1-[(4-bromophenyl)methyl]-3,3-difluoro-piperidine.
Preparation 16'':
N-(4-{[tert-Butyl(dimethyl)silyl]oxy}phenyl)quinolin-6-amine
[0250] The procedure is in accordance with the process of
Preparation 1'', replacing the 4-bromo-1-methyl-1H-pyrazole used in
Step B with 6-bromo-quinoline.
[0251] IR: v --NH--: 3300 cm.sup.-1
Preparation 17'':
N-(4-{[tert-Butyl(dimethyl)silyl]oxy}phenyl)-2-methylpyridin-4-amine
[0252] The procedure is in accordance with the process of
Preparation 1'', replacing the 4-bromo-1-methyl-1H-pyrazole used in
Step B with 4-bromo-2-methyl-pyridine.
[0253] IR: v --NH--: 3200 and 3100 cm.sup.-1
Preparation 18'':
N-(4-{[tert-Butyl(dimethyl)silyl]oxy}phenyl)-1-methyl-1H-pyrrolo[2,3-b]py-
ridin-5-amine
[0254] The procedure is in accordance with the process of
Preparation 1'', replacing the 4-bromo-1-methyl-1H-pyrazole used in
Step B with 5-bromo-1-methyl-1H-pyrrolo[2,3-b]pyridine (obtained in
accordance with a protocol from the literature: Heterocycles,
60(4), 865, 2003).
[0255] IR: v: --NH--: 3278 cm.sup.-1; v: aromatic --C.dbd.C--
moieties: 1605 cm.sup.-1
Preparation 19'':
N-(4-{[tert-Butyl(dimethyl)silyl]oxy}phenyl)pyridin-3-amine
[0256] The procedure is in accordance with the process of
Preparation 1'', replacing the 4-bromo-1-methyl-1H-pyrazole used in
Step B with 3-bromo-pyridine.
Preparation 20'':
4-{[tert-Butyl(dimethyl)silyl]oxy}-N-{4-[(3,3-difluoropiperidin-1-yl)-eth-
yl]phenyl}aniline
Step A:
2-(4-Bromophenyl)-1-(3,3-difluoropiperidin-1-yl)ethanone
[0257] To a solution of 4-bromophenylacetic acid (4 g; 18.6 mmol)
and 3,3-difluoropiperidine hydrochloride (2.5 g; 20.4 mmol) in
dichloromethane (190 mL) there are added EDC (3.8 g; 22.3 mmol),
HOBt (3 g; 22.3 mmol) and triethylamine (1.3 mL; 593 mmol). The
reaction mixture is stirred for 17 hours at ambient temperature and
is then poured over a mixture of aqueous sodium bicarbonate and
ethyl acetate. The aqueous phase is extracted with ethyl acetate.
The organic phase is washed with 0.1N hydrochloric acid, with water
and with brine before being dried over MgSO.sub.4 and concentrated
to dryness. The residue is purified by chromatography over silica
gel (petroleum ether/ethyl acetate gradient) to provide the
expected product in the form of a solid.
[0258] .sup.1H NMR: .delta. (400 MHz; dmso-d6; 300K):7.5 (d, 2H);
7.2 (d, 2H); 3.8 (t, 2H); 3.7 (s, 3H); 3.5 (t, 2H); 2 (m, 2H); 1.6
(m, 2H)
Step B: 1-[2-(4-Bromophenyl)ethyl]-3,3-difluoropiperidine
[0259] To a solution of the compound of Step A (4.6 g; 14.5 mmol)
in anhydrous THF (145 mL) there is added a 1M solution of borane
dimethyl sulphide in THF (14.5 mL; 14.5 mmol). The reaction mixture
is heated at 80.degree. C. over 3 hours and then the solvent is
evaporated off under reduced pressure. The residue is treated with
methanol (50 mL) and then with 5N HCl (5.8 mL). After stirring
overnight at ambient temperature and refluxing for 3 hours, the pH
of the reaction mixture is adjusted to 8 with saturated sodium
bicarbonate solution; the aqueous phase is then extracted with
dichloromethane. The organic phase is dried over MgSO.sub.4 and
concentrated to dryness, and the residue is purified by
chromatography over silica gel (CH.sub.2Cl.sub.2/MeOH gradient) to
provide the expected product in the form of an oil.
[0260] .sup.1H NMR: .delta. (400 MHz; dmso-d6; 300K):7.45 (d, 2H);
7.20 (d, 2H); 2.71 (m, 2H); 2.69 (t, 2H); 2.58 (dd, 2H); 2.45 (dd,
2H); 1.86 (m, 2H); 1.63 (m, 2H)
Step C:
4-{[tert-Butyl(dimethyl)silyl]oxy}-N-{4-[(3,3-difluoropiperidin-1--
yl)ethyl]-phenyl}aniline
[0261] The procedure is in accordance with the process of
Preparation 1'', replacing the 4-bromo-1-methyl-1H-pyrazole used in
Step B by the compound of Step B.
[0262] .sup.1H NMR: .delta. (400 MHz; dmso-d6; 300K): 7.7 (s, 1H);
7.45 (d, 2H); 7.39 (t, 2H); 7.31 (t, 1H); 7.0 (m, 4H); 6.9 (d, 2H);
6.81 (d, 2H); 5.05 (s, 2H); 2.7 (t, 2H); 2.6 (t, 2H); 2.5 (t, 2H);
2.45 (t, 2H); 1.89 (m, 2H); 1.68 (m, 2H)
Preparation 21'':
4-{[tert-Butyl(dimethyl)silyl]oxy}-N-{4-[2-(3,3-difluoropyrrolidin-1-yl)e-
thyl]phenyl}aniline
[0263] The procedure is in accordance with the process of
Preparation 19'', replacing the 3,3-difluoropiperidine
hydrochloride in Step A with 3,3-difluoropyrrolidine
hydrochloride.
[0264] .sup.1H NMR: .delta. (400 MHz; dmso-d6; 300K): 7.7 (s, 1H);
7.45 (d, 2H); 7.35 (t, 2H); 7.34 (t, 1H); 7.05-6.85 (m, 8H); 5.05
(s, 2H); 2.9 (t, 2H); 2.75-2.25 (m, 8H)
Preparation 22'':
N-(4-{[tert-Butyl(dimethyl)silyl]oxy}phenyl)-2,6-dimethylpyridin-4-amine
[0265] The procedure is in accordance with the process of
Preparation 1'', replacing the 4-bromo-1-methyl-1H-pyrazole used in
Step B with 4-bromo-2,6-dimethylpyridine.
[0266] IR: v: --NH--: 3300 and 2700 cm.sup.-1; v: --Si--O--: 900
cm.sup.-1; v: --Si--C--: 823 cm.sup.-1
Preparation 23'':
N-(4-{[tert-Butyl(dimethyl)silyl]oxy}phenyl)-1-[2-(morpholin-4-yl)-ethyl]-
-1H-pyrazol-4-amine
[0267] The procedure is in accordance with the process of
Preparation 2'', replacing the 5-bromoindole used in Step A with
4-bromo-1H-pyrazole.
[0268] .sup.1H NMR: .delta. (400 MHz; dmso-d6; 300K): 7.61 (s, 1H);
7.25 (s, 1H); 7.18 (s, 1H); 6.65 (m, 4H); 4.15 (t, 2H); 3.55 (t,
4H); 2.7 (t, 2H); 2.4 (t, 4H); 0.95 (s, 9H); 0.15 (s, 6h)
Preparation 24'':
N-(4-{[tert-Butyl(dimethyl)silyl]oxy}phenyl)-3-fluoropyridin-4-amine
[0269] The procedure is in accordance with the process of
Preparation 1'', replacing the 4-bromo-1-methyl-1H-pyrazole used in
Step B with 4-bromo-3-fluoro-pyridine.
[0270] IR: v --NH--: 3200 and 3000 cm.sup.-1; v --Si--O--: 900
cm.sup.-1; v --Si--C--: 820 cm.sup.-1
Preparation 25'':
N-(4-{[tert-Butyl(dimethyl)silyl]oxy}phenyl)imidazo[1,2-a]-pyridin-7-amin-
e
[0271] The procedure is in accordance with the process of
Preparation 1'', replacing the 4-bromo-1-methyl-1H-pyrazole used in
Step B with 7-bromoimidazo[1,2-a]pyridine (prepared starting from
4-bromopyridin-2-amine in accordance with a protocol in the
literature: WO 2008124323 A1).
[0272] IR: v --NH--: 3300-3000 cm.sup.-1; v --C.dbd.N--: 1652
cm.sup.-1; v --C.dbd.C--: 1610 cm.sup.-1;
[0273] v --Si--C--: 1236 cm.sup.-1; v --Si--O--: 898 cm.sup.-1; v
--Si--C--: 828, 774 cm.sup.-1
Preparation 26'':
N-(4-{[tert-Butyl(dimethyl)silyl]oxy}phenyl)-2-methyl-imidazo[1,2-a]pyrid-
in-7-amine
[0274] The procedure is in accordance with the process of
Preparation 1'', replacing the 4-bromo-1-methyl-1H-pyrazole used in
Step B with 7-bromo-2-methyl-imidazo[1,2-a[pyridine (prepared
starting from 4-bromopyridin-2-amine in accordance with a protocol
in the literature: A. J. Helliot et al J. Heterocyclic Chemistry
19, 1437, 1982).
[0275] IR: v --NH--: 3300-3000 cm.sup.-1; v --C.dbd.N--: 1652
cm.sup.-1; v --C.dbd.C--: 1610 cm.sup.-1;
[0276] v --Si--C--: 1236 cm.sup.-1; v --Si--O--: 898 cm.sup.-1; v
--Si--C--: 828, 774 cm.sup.-1
Preparation 27'': N-(4-55
[tert-Butyl(dimethyl)silyl]oxy}phenyl)-6-methylpyridin-3-amine
[0277] The procedure is in accordance with the process of
Preparation 1'', replacing the 4-bromo-1-methyl-1H-pyrazole used in
Step B with 3-bromo-6-methyl-pyridine.
[0278] IR: v --NH--: 3251 cm.sup.-1; v aromatic --C.dbd.C--
moieties: 1605 cm.sup.-1
Preparation 28'':
N-(4-{[tert-Butyl(dimethyl)silyl]oxy}phenyl)-5-fluoropyridin-3-amine
[0279] The procedure is in accordance with the process of
Preparation 1'', replacing the 4-bromo-1-methyl-1H-pyrazole used in
Step B with 3-bromo-5-fluoro-pyridine.
[0280] IR: v --NH--: 3400-3000 cm.sup.-1; v --C--F--: 1245
cm.sup.-1
Preparation 29'':
N-(4-{[tert-Butyl(dimethyl)silyl]oxy}phenyl)-2-methoxypyridin-4-amine
[0281] The procedure is in accordance with the process of
Preparation 1'', replacing the 4-bromo-1-methyl-1H-pyrazole used in
Step B with 4-bromo-2-methoxy-pyridine.
[0282] IR: v --NH--: 3200 and 3000 cm.sup.-1; v aromatic
--C.dbd.C-- moieties: 1618, 1601 cm.sup.-1
Preparation 30'':
N-(4-{[tert-Butyl(dimethyl)silyl]oxy}phenyl)-2-(propan-2-yl)pyridin-4-ami-
ne
[0283] The procedure is in accordance with the process of
Preparation 1'', replacing the 4-bromo-1-methyl-1H-pyrazole used in
Step B with 4-bromo-2-(propan-2-yl)pyridine.
[0284] IR: v --NH--: 3300 and 3100 cm.sup.-1
Preparation 31'':
N-(4-{[tert-Butyl(dimethyl)silyl]oxy}phenyl)pyrazolo[1,5-a]-pyrimidin-6-a-
mine
[0285] The procedure is in accordance with the process of
Preparation 1'', replacing the 4-bromo-1-methyl-1H-pyrazole used in
Step B with 6-bromopyrazolo[1,5-a[pyrimidine.
[0286] IR: v --NH--: 3272 cm.sup.-1; v --C.dbd.N--: 1634 cm.sup.-1;
v --C.dbd.C--: 1616 cm.sup.-1
Preparation 32'':
N-(4-{[tert-Butyl(dimethyl)silyl]oxy}phenyl)-3,3a-dihydro[1,2,4]triazolo[-
1,5-a]pyrimidin-6-amine
[0287] The procedure is in accordance with the process of
Preparation 1'', replacing the 4-bromo-1-methyl-1H-pyrazole used in
Step B with 6-bromo-3,3a-dihydro[1,2,4[triazolo[1,5-a[-pyrimidine
prepared in accordance with the literature (WO 2011015343) starting
from 4H-1,2,4-triazol-3-amine and 2-bromopropanedial.
[0288] IR: v --NH--: 3244 cm.sup.-1
Preparation 33'':
N-(4-{[tert-Butyl(dimethyl)silyl]oxy}phenyl)pyridin-4-amine
1-oxide
[0289] The procedure is in accordance with the process of
Preparation 1'', replacing the 4-bromo-1-methyl-1H-pyrazole used in
Step B with 4-bromopyridine 1-oxide prepared in accordance with the
literature (WO 2009117269) starting from 4-bromopyridine.
[0290] IR: v --NH--: 3246 cm.sup.-1; v aromatic --C.dbd.C--
moieties: 1618 cm.sup.-1
[0291] Mass spectrum:
[0292] Empirical formula: C.sub.17H.sub.24N.sub.2O.sub.2Si
[0293] [M].sup.+. measured m/z: 316
[0294] [M-O].sup.+. measured m/z: 300
[0295] [M-C.sub.4H.sub.9].sup.+. measured m/z: 259
Preparation 34'':
N-[4-[tert-Butyl(dimethyl)silyl]oxyphenyl]-1-methyl-pyridin-1-ium-4-amine
chloride
[0296] The procedure is in accordance with the process of
Preparation 1'', replacing the 4-bromo-1-methyl-1H-pyrazole used in
Step B with 4-bromo-1-methyl-pyridin-1-ium chloride prepared in
accordance with the literature starting from 4-bromopyridine.
Preparation 35'':
N-[4-[tert-Butyl(dimethyl)silyl]oxyphenyl]-1-methyl-pyrazolo[3,4-b]pyridi-
n-5-amine
[0297] The procedure is in accordance with the process of
Preparation 1'', replacing the 4-bromo-1-methyl-1H-pyrazole used in
Step B with 5-bromo-1-methyl-pyrazolo[3,4-b[pyridine prepared in
accordance with the literature (WO 2006052568).
[0298] .sup.1H NMR (400 MHz, dmso-d6) .delta. ppm: 8.33 (d, 1H),
7.94 (bs, 1H), 7.92 (s, 1H), 7.71 (d, 1H), 6.95 (d, 2H), 6.76 (d,
2H), 4.01 (s, 3H), 0.95 (s, 9H), 0.17 (s, 6H)
[0299] IR (ATR) cm.sup.-1: 3290 v >OH; 1503 v Ar; 1249
.gamma.-Si--CH.sub.3
Preparation 36'':
N-[4-[tert-Butyl(dimethyl)silyl]oxyphenyl]-3-methyl-pyrazolo[1,5-a]pyrimi-
din-6-amine
[0300] The procedure is in accordance with the process of
Preparation 1'', replacing the 4-bromo-1-methyl-1H-pyrazole used in
Step B with 6-bromo-3-methyl-pyrazolo[1,5-a[pyrimidine prepared in
accordance with the literature (WO 2011015343 and
WO2011049917).
[0301] .sup.1H NMR (400 MHz, dmso-d6) .delta. ppm: 8.49 (d, 1H),
8.4 (d, 1H), 7.98 (m, 1H), 7.87 (s, 1H), 7 (d, 2H), 6.81 (d, 2H),
2.29 (s, 3H), 0.98 (s, 9H), 0.2 (s, 6H)
[0302] IR (ATR) cm.sup.-1: 3257 v >NH
[0303] The amines NHR.sub.3R.sub.4 wherein R.sub.3 and R.sub.4,
each independently of the other, represent an aryl or heteroaryl
group are obtained in accordance with processes described in the
literature (Surry D. S. et al., Chemical Science, 2011, 2, 27-50,
Charles M. D. et al., Organic Letters, 2005, 7, 3965-3968). The
reaction protecting the hydroxy function of the 4-anilinophenol
described in Preparation 8'' can be applied to various secondary
amines NHR.sub.3R.sub.4 (as defined hereinbefore) having one or
more hydroxy functions, when they are available commercially.
Alternatively, the secondary amines having at least one hydroxy
substituent may be synthesised directly in a protected form, i.e.
starting from reagents whose hydroxy function has been protected
beforehand. Among the protecting groups,
tert-butyl(dimethyl)silyloxy and benzyloxy are especially
preferred.
[0304] Among the amines NHR.sub.3R.sub.4 having a hydroxy
substituent that are used for synthesising the compounds of the
invention there may be mentioned: 4-(4-toluidino)phenol,
4-(4-chloroanilino)phenol, 4-(3-fluoro-4-methylanilino)phenol,
4-[4-(trifluoromethoxy)anilino]-phenol,
4-[4-hydroxyanilinol]phenol,
{4-[(1-methyl-1H-indol-6-yl)amino[phenyl}-methanol,
4-(2,3-dihydro-1H-indol-6-ylamino)phenol,
4-[(1-methyl-2,3-dihydro-1H-indol-6-yl)amino]phenol,
4-[(1-methyl-1H-indol-6-yl)amino]phenol,
4-[(1-methyl-1H-indol-6-yl)amino]cyclohexanol,
4-[(1-methyl-1,2,3,4-tetrahydro-6-quinolinyl)amino]phenol,
4-[(4-methyl-3,4-dihydro-2H-1,4-benzoxazin-7-yl)amino]phenol,
4-[4-(diethylamino)anilino]-phenol,
4-(2,3-dihydro-1H-inden-5-ylamino)phenol,
4-[(1-methyl-1H-indazol-5-yl)amino]-phenol,
4-[(1'-methyl-1',2'-dihydrospiro[cyclopropane-1,3'-indol]-5'-yl)amino]phe-
nol, 4-[(1,3,3-trimethyl-2,3-dihydro-1H-indol-5-yl)amino]phenol,
4-[4-methoxy-3-(trifluoro-methyl)anilino]phenol,
4-[4-(methylsulphanyl)-3-(trifluoromethyl)anilino]phenol,
2-fluoro-4-[(1-methyl-1H-indol-5-yl)amino]phenol,
4-[(1-ethyl-1H-indol-5-yl)amino]phenol,
4-[(1-ethyl-2,3-dihydro-1H-indol-5-yl)amino]phenol,
4-[(1-isopropyl-2,3-dihydro-1H-indol-5-yl)amino]phenol,
4-(butylamino)phenol, 3-[(1-methyl-1H-indol-5-yl)amino]-1-propanol,
4-[(1-methyl-1H-indol-5-yl)amino]-1-butanol,
4-[(3-fluoro-4-methylphenyl)-amino]phenol,
4-[(3-chloro-4-methylphenyl)amino]phenol,
4-[(4-fluorophenyl)amino]-phenol,
4-[(1-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)amino]phenol,
4-[(4-fluorophenyl)-amino]phenol, 4-[(2-fluorophenyl)amino]phenol,
4-[(3-fluorophenyl)amino]phenol,
4-[(2,4-difluorophenyl)amino]phenol,
4-[(3,4-difluorophenyl)amino]phenol,
3-[(4-hydroxy-phenyl)amino]benzonitrile,
4-[(3-methoxyphenyl)amino]phenol,
4-[(3,5-difluorophenyl)-amino]phenol,
4-[(3-methylphenyl)amino]phenol,
4-[(4-hydroxyphenyl)amino]benzo-nitrile,
4-[(3-chlorophenyl)amino]phenol, 4-(pyrimidin-2-ylamino)phenol,
4-[(cyclobutyl-methyl)amino]phenol,
2-[(4-hydroxyphenyl)amino]benzonitrile,
4-{[(1-methyl-1H-pyrazol-4-yl)methyl]amino}phenol,
4-[(cyclopropylmethyl)amino]phenol,
4-{[(1-methyl-1H-pyrazol-3-yl)methyl]amino}phenol,
4-(but-2-yn-1-ylamino)phenol, 4-(pyrazin-2-yl-amino)phenol,
4-(pyridin-2-ylamino)phenol, 4-(pyridazin-3-ylamino)phenol,
4-(pyrimidin-5-ylamino)phenol, 4-(pyridin-3-ylamino)phenol,
4-[(3,5-difluoro-4-methoxyphenyl)-amino]phenol,
4-(pyridin-4-ylamino)phenol,
4-[(3-fluoro-4-methoxyphenyl)amino]phenol,
2-(phenylamino)pyrimidin-5-ol,
5-[(4-hydroxyphenyl)amino]-2-methoxybenzonitrile,
4-{[3-(trifluoromethyl)phenyl]amino}phenol, 4-(methylamino)phenol,
4-(ethylamino)phenol and 4-(propan-2-ylamino)phenol.
[0305] The hydroxy function(s) of the secondary amines listed above
is (are) protected beforehand by a suitable protecting group prior
to any coupling to an acid derivative of the compound of formula
(VII) as defined in the preceding general process.
EXAMPLE 1
N-(4-Hydroxyphenyl)-3-(6-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]c-
arbonyl}-1,3-benzodioxol-5-yl)-N-(1-methyl-1H-indol-5-yl)-5,6,7,8-tetrahyd-
ro-indolizine-1-carboxamide
Step A: Methyl
3-(6-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}-1,3-benzod-
ioxol-5-yl)-5,6,7,8-tetrahydroindolizine-1-carboxylate
[0306] To a solution of 2 g of the compound of Preparation 1 in 20
mL of dichloromethane there are added, at ambient temperature, 5.5
mL of N,N,N-triethylamine (6.96 mmol), the compound of Preparation
1' (6.96 mmol), and then 0.94 g of hydroxybenzotriazole (HOB T) and
1.34 g of 1-ethyl-3-(3'-dimethylaminopropyl)-carbodiimide (EDC)
(6.96 mmol). The reaction mixture is then stirred at ambient
temperature overnight; it is then poured onto a solution of
ammonium chloride and extracted with ethyl acetate. The organic
phase is then dried over magnesium sulphate, and then filtered and
evaporated to dryness. The crude product thereby obtained is then
purified by chromatography over silica gel (heptane/AcOEt gradient)
to yield the expected product.
[0307] .sup.1H NMR: .delta. (400 MHz; dmso-d6; 300K): 7.2-6.8 (m,
4H, aromatic Hs, H tetrahydroisoquinoline); 7.10 (s, 1H, aromatic
H, benzodioxole); 6.92 (s, 1H, aromatic H, benzodioxole); 6.25 (m,
1H, H tetrahydroindolizine); 6.10 (s, 2H, aliphatic Hs,
OCH.sub.2O); 4.80 (m, 1H, aliphatic H, H tetrahydroisoquinoline);
4.20 (m, 1H, aliphatic H, H tetrahydroisoquinoline); 4.1-3.5 (m,
3H); 3.60 (s, 3H, COOCH.sub.3); 2.90 (m, 2H, aliphatic Hs, H
tetrahydroindolizine); 2.45 (m, 2H, aliphatic Hs, H
tetrahydroisoquinoline); 1.70 (m, 4H, aliphatic Hs, H
tetrahydroindolizine); 0.80 (m, 3H, aliphatic Hs,
CH.sub.3-THIQ).
[0308] IR: v: >C.dbd.O 1694 cm.sup.-1 (conjugated ester); v:
>C.dbd.O 1624 cm.sup.-1 (amide);
[0309] v: >C--Ar 772-742 cm.sup.-1
Step B: Lithium
3-(6-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}-1,3-benzod-
ioxol-5-yl)-5,6,7,8-tetrahydroindolizine-1-carboxylate
[0310] To a solution containing 8.26 mmol of the compound of Step A
in 24 mL of dioxane there is added a solution of lithium hydroxide
(675 mg, 16.1 mmol). The batch is placed in a microwave oven at 140
W, 100.degree. C. for a period of 2 hours 30 minutes. The reaction
mixture is then filtered and evaporated. The solid thereby obtained
is dried at 40.degree. C. in an oven in the presence of
P.sub.2O.sub.5.
Step C:
N-(4-{[tert-Butyl(dimethyl)silyl]oxy}phenyl)-3-(6-{[(3R)-3-methyl--
3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}-1,3-benzodioxol-5-yl)-N-(1-methy-
l-1H-indol-5-yl)-5,6,7,8-tetrahydroindolizine-1-carboxamide
[0311] To a solution containing 4.73 mmol of the compound of Step B
in 47 mL of dichloromethane there are added, dropwise, 1.2 mL of
oxalyl chloride at 0.degree. C. The reaction mixture is stirred at
ambient temperature for 11 hours and is then co-evaporated several
times with dichloromethane. The product thereby obtained is
suspended in 37 mL of dichloromethane and is then added to a
solution containing 7.1 mmol of the compound obtained in
Preparation 2'' in 10 mL of dichloromethane in the presence of 0.6
mL of pyridine (7.1 mmol). The batch is stirred at ambient
temperature overnight. The reaction mixture is concentrated,
purified by chromatography over silica gel
(dichloromethane/methanol gradient) to yield the expected
product.
Step D:
N-(4-Hydroxyphenyl)-3-(6-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(-
1H)-yl]-carbonyl}-1,3-benzodioxol-5-yl)-N-(1-methyl-1H-indol-5-yl)-5,6,7,8-
-tetrahydro-indolizine-1-carboxamide
[0312] To a solution containing 2.3 mmol of the compound obtained
in Step C in 4 mL of methanol there is added 0.646 g (11.5 mmol) of
potassium hydroxide dissolved in 8 mL of methanol. The batch is
stirred at ambient temperature for 30 minutes. The reaction mixture
is then diluted with dichloromethane and washed successively with
1N HCl solution, saturated NaHCO.sub.3 solution and then saturated
NaCl solution until a neutral pH is obtained. The organic phase is
then dried over magnesium sulphate, filtered and evaporated. The
crude product thereby obtained is purified over silica gel
(dichloromethane/methanol gradient) and then lyophilised to provide
the expected product.
[0313] High-resolution mass spectroscopy (ESI+):
[0314] Empirical formula: C.sub.42H.sub.38CN.sub.4O.sub.5
[0315] [M+H].sup.+, calculated: 679.2920
[0316] [M+H].sup.+, measured: 679.2908
EXAMPLE 2
N-(4-Hydroxyphenyl)-3-(6-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]c-
arbonyl}-1,3-benzodioxol-5-yl)-N-{1-[2-(morpholin-4-yl)ethyl]-1H-indol-5-y-
l}-5,6,7,8-tetrahydroindolizine-1-carboxamide hydrochloride
[0317] The procedure is in accordance with the processes described
in Steps A-D of Example 1 using the appropriate reagents. After the
step of purification over silica gel (cf. Step D), the solid is
then dissolved in dichloromethane and 2 mL of 1N HCl in ether are
added. The entire batch is stirred for 1 hour and then evaporated
to dryness. The hydrochloride thereby obtained is dissolved in a
mixture of water/acetonitrile until dissolution is complete and is
then lyophilised.
[0318] Elemental microanalysis: (%, theoretical:measured)
[0319] % C=69.32:68.93; % H=5.94:5.74; % N=8.6:8.51; %
Cl-=4.35:4.6
[0320] Unless otherwise mentioned, the compounds of the following
Examples are synthesised in accordance with the process of Example
1 using, in Step A: (i) the appropriate acid obtained according to
one of Preparations 1 to 18 and (ii) the appropriate
tetrahydroisoquinoline compound obtained according to one of
Preparations 1' to 7' and, in Step C: (iii) the suitable
NHR.sub.3R.sub.4 amine (a non-exhaustive list is proposed in
Preparations 1'' to 36'').
EXAMPLE 3
6-(5-Chloro-2-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]-carbonyl}ph-
enyl)-N-(4-hydroxyphenyl)-N-(1-methyl-1H-indol-5-yl)-1,2,3,4-tetrahydropyr-
rolo[1,2-a]pyrazine-8-carboxamide hydrochloride
[0321] The procedure is in accordance with the process of Example
1, replacing, on the one hand, the compound of Preparation 1 used
in Step A with the compound of Preparation 2 and, on the other
hand, the compound of Preparation 1'' used in Step C with
N-(4-{[tert-butyl(dimethyl)silyl]oxy}phenyl)-1-methyl-1H-indol-5-amine,
it being understood that the product thereby obtained is not
subjected to a step of conversion into a salt in the presence of
HCl in ether as is described in Step D of Example 1. The compound
thereby obtained is deprotected in the presence of 10 equivalents
of trifluoroacetic acid in dichloromethane (10 mL/mmol) at ambient
temperature overnight. The product is then isolated by
concentrating the reaction mixture to dryness. Finally, it is
subjected to a step of conversion into a salt in the presence of
HCl in ether.
[0322] Elemental microanalysis: (%, theoretical:measured)
[0323] % C=67.99:65.52; % H=5.28:4.49; % N=9.91:9.24; %
C1=10.03:9.95; % Cl-=5.02:5.45
[0324] High-Resolution Mass spectroscopy (ESI-F):
[0325] Empirical formula: C.sub.40H.sub.36ClN.sub.5O.sub.3
[0326] [M+H].sup.+, calculated: 670.2585
[0327] [M+H].sup.+, measured: 670.2587
EXAMPLE 4
3-[5-Chloro-2-(3,4-dihydroisoquinolin-2(1H)-ylcarbonyl)phenyl]-N-(4-hydrox-
yphenyl)-N-{1-[2-(morpholin-4-yl)ethyl]-1H-indol-5-yl}-5,6,7,8-tetrahydro--
indolizine-1-carboxamide
[0328] Elemental Microanalysis: % Measured (Theoretical)
[0329] % C=70.85(71.65); % H=5.39(5.88); % N=9.11(9.28); %
Cl=4.48(4.7)
EXAMPLE 5
3-[5-Chloro-2-(3,4-dihydroisaquinolin-2(1H)-ylcarbonyl)phenyl]-N-(4-hydrox-
yphenyl)-N-{1-[2-(morpholin-4-yl)ethyl]-2,3-dihydro-1H-indol-5-yl)-5,6,7,8-
-tetrahydroindolizine-1-carboxamide
Step A:
N-(4-{[tert-Butyl(dimethyl)silyl]oxy}phenyl)-3-[5-chloro-2-(3,4-di-
hydro-isoquinolin-2(1H)-ylcarbonyl)phenyl]-N-{1-[2-(morpholin-4-yl)ethyl]--
2,3-dihydro-1H-indol-5-yl}-5,6,7,8-tetrahydroindolizine-1-carboxamide
[0330] The procedure is in accordance with the protocols described
in Steps A-C of Example 1 using the compound of Preparation 3 and
1,2,3,4-tetrahydroisoquinoline in Step A, and the compound of
Preparation 4'' in Step C.
Step B:
3-[5-Chloro-2-(3,4-dihydroisoquinolin-2(1H)-ylcarbonyl)phenyl]-N-(-
4-hydroxy-phenyl)-N-{1-[2-(morpholin-4-yl)ethyl]-2,3-dihydro-1H-indol-5-yl-
}-5,6,7,8-tetrahydro-indolizine-1-carboxamide
[0331] To a solution of 1.3 g (1.45 mmol) of the compound of Step A
in 13 mL of acetic acid there is added, at ambient temperature,
sodium cyanoborohydride (900 mg; 15 mmol). After stirring for 2
hours, the reaction mixture is concentrated to dryness, and then
diluted with methanol (8 mL) and treated with a 1M solution of
potassium hydroxide in methanol (6.3 mL; 6.3 mmol). After 1 hour at
ambient temperature, the reaction mixture is concentrated to
dryness, and then chromatographed over silica gel
(dichloromethane/methanol gradient) and then lyophilised to provide
the expected product in the form of a powder.
[0332] Elemental microanalysis: % measured (theoretical)
[0333] % C=70.74(71.46); % H=5.74(6.13); % N=9(9.26); %
Cl=4.46(4.69)
EXAMPLE 6
N-(4-Hydroxyphenyl)-2-methyl-6-(7-{[(3R)-3-methyl-3,4-dihydroiso-quinolin--
2(1H)-yl]carbonyl}-2,3-dihydro-1,4-benzodioxin-6-yl)-N-(1-methyl-1H-indol--
5-yl)-1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-8-carboxamide
hydrochloride
[0334] The procedure is analogous to that described for Example 7,
in Step A substituting the compound of Preparation 2 with the
compound of Preparation 4.
[0335] Elemental microanalysis: (%, theoretical:measured)
[0336] % C=69.39:69.13; % H=5.69:4.98; % N=9.41:9.37; %
Cl-=4.76:4.65
EXAMPLE 7
6-(5-Chloro-2-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]-carbonyl}ph-
enyl)-N-(4-hydroxyphenyl)-2-methyl-N-(1-methyl-1H-indol-5-yl)-1,2,3,4-tetr-
ahydropyrrolo[1,2-a]pyrazine-8-carboxamide
Step A: tert-Butyl
8-[(4-{[tert-butyl(dimethyl)silyl]oxy}phenyl)(1-methyl-1H-indol-5-yl)-car-
bamoyl]-6-(5-chloro-2-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]carb-
onyl}-phenyl)-3,4-dihydropyrrolo[1,2-a]pyrazine-2(1H)-carboxylate
[0337] The procedure is in accordance with the protocols described
in Steps A-C of Example 1 using the compounds of Preparations 2 and
1' in Step A, and the compound of Preparation 2'' in Step C.
Step B: tert-Butyl
6-(5-chloro-2-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]-carbonyl}p-
henyl)-8-[(4-hydroxyphenyl)(1-methyl-1H-indol-5-yl)carbamoyl]-3,4-dihydrop-
yrrolo[1,2-a]pyrazine-2(1H)-carboxylate
[0338] To a solution of the compound of Step A (1.1 g; 1.25 mmol)
in methanol (6 mL) there is added a 1M solution of potassium
hydroxide in methanol (6.2 mL; 6.2 mmol). After 2 hours at ambient
temperature, the methanol is evaporated off in vacuo and the
residue is taken up in a mixture composed of dichloromethane and
saturated sodium bicarbonate solution. The combined organic phases
are dried over MgSO.sub.4 and concentrated to dryness. The residue
obtained is purified by chromatography over silica gel
(CH.sub.2Cl.sub.2/MeOH gradient) to provide the expected product in
the form of a solid.
[0339] IR: v: NH: 3450 cm.sup.-1; v: CO: 1745-1620 cm.sup.-1
Step C: tert-Butyl
6-(5-chloro-2-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]-carbonyl}p-
henyl)-8-{[4-[(2,2-dimethylpropanoyl)oxy]phenyl}(1-methyl-1H-indol-5-yl)ca-
rbamoyl]-3,4-dihydropyrrolo[1,2-a]pyrazine-2(1H)-carboxylate
[0340] To a solution of the compound of Step B (0.7 g; 0.93 mmol)
in dichloromethane (7 mL) there are added, at ambient temperature,
triethylamine (0.2 mL; 1.39 mmol) and then pivaloyl chloride (0.11
mL; 0.93 mmol). After stirring for 2 hours at ambient temperature,
the reaction mixture is washed with water and with brine, dried
over MgSO.sub.4 and concentrated to dryness. The residue obtained
is used as is in the next Step without being analysed.
Step D: 2,2-Dimethyl
4-[{[6-(5-chloro-2-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]carbon-
yl}phenyl)-1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazin-8-yl]carbonyl}(1-methyl-
-1H-indol-5-yl)amino]phenyl propanoate
[0341] To a solution of the compound of the preceding Step (0.82 g;
0.93 mmol) in dichloromethane (9 mL) there is added, at 0.degree.
C., trifluoroacetic acid (0.7 mL; 13.9 mmol) dropwise. After
stirring for 15 hours at ambient temperature, saturated sodium
bicarbonate solution is slowly added to the reaction mixture and
then the phases are separated. The aqueous phase is extracted with
dichloromethane. The combined organic phases are dried over
MgSO.sub.4 and concentrated to dryness. The residue obtained is
purified by chromatography over silica gel (CH.sub.2Cl.sub.2/MeOH
gradient) to provide the expected product in the form of a
solid.
[0342] LC/MS: m/z=[M+H].sup.+=754.30
Step E: 2,2-Dimethyl
4-[{[6-(5-chloro-2-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]carbon-
yl}phenyl)-2-methyl-1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazin-8-yl]carbonyl}-
(1-methyl-1H-indol-5-yl)amino]phenyl propanoate
[0343] To a solution of the compound of the preceding Step (0.41 g;
0.54 mmol) in dichloromethane (2 mL) there are added, at ambient
temperature, formaldehyde (48 .mu.L; 1.74 mmol) and then sodium
triacetoxyborohydride (161 mg; 0.76 mmol). After stirring for 2
hours at ambient temperature, the reaction mixture is diluted with
dichloromethane and then washed with saturated sodium bicarbonate
solution. The organic phase is dried over MgSO.sub.4 and
concentrated to dryness. The residue obtained is purified by
chromatography over silica gel (CH.sub.2Cl.sub.2/MeOH gradient).
The expected product is obtained in the form of a solid.
[0344] LC/MS: m/z=[M+H].sup.+=768.32
Step F:
6-(5-Chloro-2-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]carb-
onyl}-phenyl)-N-(4-hydroxyphenyl)-2-methyl-N-(1-methyl-1H-indol-5-yl)-1,2,-
3,4-tetrahydro-pyrrolo[1,2-a]pyrazine-8-carboxamide
[0345] To a solution of the compound of the preceding Step (0.25 g;
0.32 mmol) in dioxane (1 mL) there is added a solution of lithium
hydroxide (27 mg; 0.65 mmol) in water (1 mL). After stirring for 5
hours at ambient temperature, the reaction mixture is concentrated
and diluted with saturated sodium bicarbonate solution. The aqueous
phase is extracted with CH.sub.2Cl.sub.2. The organic phase is
dried over MgSO.sub.4 and concentrated to dryness. The residue
obtained is purified by chromatography over silica gel
(CH.sub.2Cl.sub.2/MeOH gradient). The expected product is then
obtained in the form of a solid.
[0346] Elemental microanalysis: (%, theoretical:measured)
[0347] % C=71.97:71.51; % H=5.6:5.25; % N=10.24:10.12
EXAMPLE 8
3-(5-Chloro-2-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]-carbonyl}ph-
enyl)-N-(4-hydroxyphenyl)-N-{1-[2-(morpholin-4-yl)ethyl]-1H-indol-5-yl}ind-
olizine-1-carboxamide hydrochloride
[0348] Elemental microanalysis: (%, theoretical:measured)
[0349] % C=69:69.16; % H=5.41:4.82; % N=8.75:8.69; %
Cl-=4.43:4.13
EXAMPLE 9
6-(5-Fluoro-2-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}-ph-
enyl)-N-(4-fluorophenyl)-N-(4-hydroxyphenyl)-1,2,3,4-tetrahydropyrrolo[1,2-
-a]-pyrazine-8-carboxamide hydrochloride
[0350] The procedure is in accordance with the process of Example
1, replacing, on the one hand, the compound of Preparation 1 used
in Step A with the compound of Preparation 6 and, on the other
hand, the compound of Preparation 1'' used in Step C with the
compound of Preparation 5'', it being understood that the product
thereby obtained is not subjected to a step of conversion into a
salt in the presence of HCl in ether as is described in Step D of
Example 1. The compound thereby obtained is deprotected in the
presence of 10 equivalents of trifluoroacetic acid in
dichloromethane (10 mL/mmol) at ambient temperature overnight. The
product is then isolated by concentrating the reaction mixture to
dryness. Finally, it is subjected to a step of conversion into a
salt in the presence of HCl in ether.
[0351] Elemental microanalysis: (%, theoretical:measured)
[0352] % C=67.83:67.41; % H=5.08:4.61; % N=8.55:8.39; %
Cl-=5.41:5.28
EXAMPLE 10
6-(5-Fluoro-2-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]-carbonyl}ph-
enyl)-N-(3-fluoro-4-methylphenyl)-N-(4-hydroxyphenyl)-1,2,3,4-tetrahydropy-
rrolo[1,2-a] pyrazine-8-carboxamide hydrochloride
[0353] The procedure is in accordance with the process of Example
1, replacing, on the one hand, the compound of Preparation 1 used
in Step A with the compound of Preparation 6 and, on the other
hand, the compound of Preparation 1'' used in Step C with the
compound of Preparation 6'', it being understood that the product
thereby obtained is not subjected to a step of conversion into a
salt in the presence of HCl in ether as is described in Step D of
Example 1. The compound thereby obtained is deprotected in the
presence of 10 equivalents of trifluoroacetic acid in
dichloromethane (10 mL/mmol) at ambient temperature overnight. The
product is then isolated by concentrating the reaction mixture to
dryness. Finally, it is subjected to a step of conversion into a
salt in the presence of HCl in ether.
[0354] Elemental microanalysis: (%, theoretical:measured)
[0355] % C=68.21:68.29; % H=5.27:4.91; % N=8.37:8.34; %
Cl-=5.3:5.17
EXAMPLE 11
N-(4-Hydroxyphenyl)-6-(6-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]c-
arbonyl}-1,3-benzodioxol-5-yl)-N-(1-methyl-1H-indazol-5-yl)-1,2,3,4-tetrah-
ydropyrrolo[1,2-a]pyrazine-8-carboxamide hydrochloride
[0356] The procedure is in accordance with the process of Example
1, replacing, on the one hand, the compound of Preparation 1 used
in Step A with the compound of Preparation 7 and, on the other
hand, the compound of Preparation 1'' used in Step C with
N-(4-{[tert-butyl(dimethyl)silyl]oxy}phenyl)-1-methyl-1H-indazol-5-amine,
it being understood that the product thereby obtained is not
subjected to a step of conversion into a salt in the presence of
HCl in ether as is described in Step D of Example 1. The compound
thereby obtained is deprotected in the presence of 10 equivalents
of trifluoroacetic acid in dichloromethane (10 mL/mmol) at ambient
temperature overnight. The product is then isolated by
concentrating the reaction mixture to dryness. Finally, it is
subjected to a step of conversion into a salt in the presence of
HCl in ether.
[0357] Elemental microanalysis: (%, theoretical:measured)
[0358] % H=5.2:4.83; % N=11.72:11.64; % Cl-=4.94:5.34; %
C=66.99:66.19
EXAMPLE 12
6-(5-Chloro-2-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]-carbonyl}ph-
enyl)-N-(4-hydroxyphenyl)-N-(1-methyl-1H-indazol-5-yl)-1,2,3,4-tetrahydrop-
yrrolo[1,2-a]pyrazine-8-carboxamide hydrochloride
[0359] The procedure is in accordance with the process of Example
1, replacing, on the one hand, the compound of Preparation 1 used
in Step A with the compound of Preparation 2 and, on the other
hand, the compound of Preparation 1'' used in Step C with
N-(4-{[tert-butyl(dimethyl)silyl]oxy}phenyl)-1-methyl-1H-indazol-5-amine,
it being understood that the product thereby obtained is not
subjected to a step of conversion into a salt in the presence of
HCl in ether as is described in Step D of Example 1. The compound
thereby obtained is deprotected in the presence of 10 equivalents
of trifluoroacetic acid in dichloromethane (10 mL/mmol) at ambient
temperature overnight. The product is then isolated by
concentrating the reaction mixture to dryness. Finally, it is
subjected to a step of conversion into a salt in the presence of
HCl in ether.
[0360] Elemental microanalysis: (%, theoretical:measured)
[0361] % C=66.19:65.83; % H=5.13:4.99; % N=11.88:11.85; %
Cl-=5.01:5.36
EXAMPLE 13
N-(4-Hydroxyphenyl)-3-(6-{[(3S)-3-[2-(morpholin-4-yl)ethyl]-3,4-dihydroiso-
quinolin-2(1H)-yl]carbonyl}-1,3-benzodioxol-5-yl)-N-phenyl-5,6,7,8-tetrahy-
droindolizine-1-carboxamide hydrochloride
[0362] Elemental microanalysis: (%, theoretical:measured)
[0363] % C=69.42:69.47; % H=5.96:5.58; % N=7.36:7.36; %
Cl-=4.66:4.42
EXAMPLE 14
N-(4-Hydroxyphenyl)-N-(1-methyl-1H-indazol-5-yl)-3-(6-{[(3S)-3-[2-(morphol-
in-4-yl)ethyl]-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}-1,3-benzodioxol-5-
-yl)-5,6,7,8-tetrahydroindolizine-1-carboxamide hydrochloride
[0364] Elemental microanalysis: (%, theoretical:measured)
[0365] % C=67.76:67.81; % H=5.81:5.63; % N=10.31:10.13; %
Cl-=4.35:4.22
EXAMPLE 15
7-Amino-N-(4-hydroxyphenyl)-3-(6-{[(3R)-3-methyl-3,4-dihydroiso-quinolin-2-
(1H)-yl]carbonyl}-1,3-benzodioxol-5-yl)-N-phenyl-5,6,7,8-tetrahydro-indoli-
zine-1-carboxamide hydrochloride
Step A: Methyl
3'-(6-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}-1,3-benzo-
dioxol-5-yl)-5',6'-dihydro-8'H-spiro[1,3-dioxolane-2,7'-indolizine]-1'-car-
boxylate
[0366] The procedure is in accordance with the protocol of Step A
of Example 1, replacing the compound of Preparation 1 with the
compound of Preparation 8.
Step B: Methyl
3-(6-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}-1,3-benzod-
ioxol-5-yl)-7-oxo-5,6,7,8-tetrahydroindolizine-1-carboxylate
[0367] 4.47 mmol of the compound of Step A dissolved in 75 mL of
THF are stirred in the presence of 37 mL of 1M HCl at reflux for 15
hours. 100 mL of water and 100 mL of ethyl acetate are added to the
reaction mixture. There are then added 4 g of NaHCO.sub.3 (4.7
mmol) in the form of a powder until a basic pH is obtained. The
compound is extracted with ethyl acetate; the organic phase is
dried over MgSO.sub.4, filtered and concentrated to dryness.
Step C: Methyl
7-hydroxy-3-(6-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]-carbonyl}-
-1,3-benzodioxol-5-yl)-5,6,7,8-tetrahydroindolizine-1-carboxylate
[0368] To a solution of 4.47 mmol of the compound obtained in Step
B in 30 mL of methanol there are added, in portions, 558 mg (14.75
mmol) of sodium borohydride. The reaction mixture is stirred for 1
hour at ambient temperature. 50 mL of 1M HCl are then added and the
methanol is evaporated off. The aqueous phase is then neutralised
using NaHCO.sub.3 and then extracted with dichloromethane. The
organic phase is successively washed with H.sub.2O, dried over
MgSO.sub.4, filtered and concentrated to dryness. The oil thereby
obtained is purified by flash chromatography
(dichloromethane/ethanol-ammonia gradient) to yield the expected
product.
Step D: Methyl
3-(6-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}-1,3-benzod-
ioxol-5-yl)-7-(prop-2-en-1-yloxy)-5,6,7,8-tetrahydroindolizine-1-carboxyla-
te
[0369] To a suspension of 331 mg (8.26 mmol) of sodium hydride in
15 mL of anhydrous THF cooled to 0.degree. C. there are added 4.13
mmol of the compound obtained in Step C. The resulting suspension
is stirred for 15 minutes at 0.degree. C. and then a solution of
790 .mu.L, (9.1 mmol) of allyl bromide in 10 mL of THF is slowly
added (over 15 minutes). The reaction mixture is stirred for 1 hour
at 0.degree. C., and then for 15 hours at ambient temperature. The
resulting solution is hydrolysed with saturated aqueous NH.sub.4Cl
solution. The compound is extracted with ethyl acetate; the organic
phase is dried over MgSO.sub.4, filtered and concentrated to
dryness. The oil thereby obtained is purified by flash
chromatography (cyclohexane/ethyl acetate gradient) to yield the
expected product.
Step E:
N-(4-{[tert-Butyl(dimethyl)silyl]oxy}phenyl)-3-(6-{[(3R)-3-methyl--
3,4-dihydro-isoquinolin-2(1H)-yl]carbonyl}-1,3-benzodioxol-5-yl)-N-phenyl--
7-(prop-2-en-1-yloxy)-5,6,7,8-tetrahydroindolizine-1-carboxamide
[0370] The procedure is in accordance with the processes described
in Steps B and C of Example 1 using the appropriate reagents.
Step F:
N-(4-{[tert-Butyl(dimethyl)silyl]oxy}phenyl)-7-hydroxy-3-(6-{[(3R)-
-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}-1,3-benzodioxol-5-yl)--
N-phenyl-5,6,7,8-tetrahydroindolizine-1-carboxamide
[0371] There is then carried out a reaction deprotecting the allyl
group in the presence of
1,3-dimethylpyrimidine-2,4,6(1H,3H,5H)-trione (also called
dimethylbarbiturate) and tetrakis(triphenylphosphine)palladium in a
mixture of methanol and dichloromethane.
Step G:
7-Azido-N-(4-{[tert-butyl(dimethyl)silyl]oxy}phenyl)-3-(6-{[(3R)-3-
-methyl-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}-1,3-benzodioxol-5-yl)-N--
phenyl-5,6,7,8-tetrahydroindolizine-1-carboxamide
[0372] To a solution of the compound of Step F (550 mg; 0.72 mmol)
in methylene chloride (6 mL) there are added, at ambient
temperature, triethylamine (300 .mu.L; 1.8 mmol) and mesyl chloride
(0.14 mL; 1.8 mmol). After stirring for 20 minutes, the reaction
mixture is concentrated to dryness and then diluted with 10 mL of
DMSO. 470 mg of NaN.sub.3 in powder form (7.2 mmol) are added
thereto. The reaction mixture is left for 20 hours at ambient
temperature and then for 20 hours at 50.degree. C. It is then
poured onto a mixture of dichloromethane and water. The organic
phase is washed 3 times with water and then with brine, dried over
MgSO.sub.4, and then concentrated to dryness to yield the expected
product which is used as is in the next Step.
Step H:
7-Amino-N-(4-hydroxyphenyl)-3-(6-{[(3R)-3-methyl-3,4-dihydroisoqui-
nolin-2(1H)-yl]carbonyl}-1,3-benzodioxol-5-yl)-N-phenyl-5,6,7,8-tetrahydro-
indolizine-1-carboxamide hydrochloride
[0373] To a solution of 550 mg of the compound of Step G (0.7 mmol)
in ethanol (10 mL) there are added, at ambient temperature, 20 mg
of Pd/C 10%. After stirring for 15 hours under 1 bar of hydrogen,
the reaction mixture is passed through a Whatman filter and
concentrated to dryness. After purification by column
chromatography over silica gel (dichloromethane/methanol gradient),
the solid is then dissolved in dichloromethane, and 2 mL of 1N HCl
in ether are added. The entire batch is stirred for 1 hour and then
evaporated to dryness. The hydrochloride thereby obtained is
dissolved in a mixture of water/acetonitrile until dissolution is
complete and then lyophilised to yield the expected compound in the
form of a powder.
[0374] Elemental microanalysis: (%, theoretical:measured)
[0375] % C=69.17:68.68; % H=5.51:5.09; % N=8.27:8.41; %
Cl-=5.24:5.28
EXAMPLE 16
3-(6-{[(3S)-3-(Hydraxymethyl)-3,4-dihydraisoquinalin-2(1H)-yl]-carbonyl}-1-
,3-benzodioxol-5-yl)-N-(4-hydroxyphenyl)-N-phenyl-5,6,7,8-tetrahydro-indol-
izine-1-carboxamide
Step A: Methyl
3-(6-{[(3S)-3-(hydroxymethyl)-3,4-dihydroisoquinolin-2(1H)-yl]-carbonyl}--
1,3-benzodioxol-5-yl)-5,6,7,8-tetrahydroindolizine-1-carboxylate
[0376] The procedure is in accordance with the process in Step A of
Example 1 using
(3S)-1,2,3,4-tetrahydroisoquinolin-3-ylmethanol.
Step B: Methyl
3-(6-{[(3S)-3-[(prop-2-en-1-yloxy)methyl]-3,4-dihydroisoquinolin-2(1H)-yl-
]carbonyl}-1,3-benzodioxol-5-yl)-5,6,7,8-tetrahydroindolizine-1-carboxylat-
e
[0377] To a suspension of NaH (703 mg; 17.6 mmol) in THF (20 mL)
there is added a solution of 7.8 g of the compound of Step A (16
mmol) dissolved in a mixture of THF (50 mL) and DMF (30 mL). After
stirring for 1 hour there is added allyl bromide (1.7 mL; 19 mmol).
The reaction mixture is stirred for 48 hours at ambient temperature
and is then poured onto a mixture of ethyl acetate and water. The
organic phase is washed 3 times with water, and with saturated LiOH
solution, dried over MgSO.sub.4 and concentrated to dryness. After
purification by chromatography over silica gel
(dichloromethane/methanol gradient), the expected product is
obtained in the form of a solid.
[0378] .sup.1H NMR: .delta.: (500 MHz; dmso-d6; 300K): 7.2-6.9 (m,
4H); 7.05 (m, 1H); 6.9 (m, 1H); 6.45-6.1 (m, 1H); 6.15 (m, 2H);
5.9-5.65 (m, 1H); 5.2-5.0 (m, 2H); 5.05-3.8 (m, 1H); 4.85-4.25 (m,
2H); 4.3-3.45 (m, 7H); 3.4-2.4 (m, 6H); 1.95-1.45 (m, 4H)
Step C:
N-[4-(Benzyloxy)phenyl]-N-phenyl-3-(6-{[(3S)-3-[(prop-2-n-1-yloxy)-
methyl]-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}-1,3-benzodioxol-5-yl)-5,-
6,7,8-tetrahydro-indolizine-1-carboxamide
[0379] The procedure is in accordance with the processes of Steps B
and C of Example 1 using 4-(benzyloxy)-N-phenylaniline (cf.
Preparation 9'').
Step D:
3-(6-{[(3S)-3-(Hydroxymethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carb-
onyl}-1,3-benzodioxol-5-yl)-N-(4-hydroxyphenyl)-N-phenyl-5,6,7,8-tetrahydr-
oindolizine-1-carboxamide
[0380] To a suspension of 5.1 g (6.65 mmol) of the compound of Step
C in a mixture of dichloromethane (7 mL) and methanol (2 mL) there
are added dimethylbarbituric acid (2.1 g; 13.3 mmol) and
tetrakis(triphenylphosphine)palladium(0) (300 mg; 0.3 mmol). After
stirring for 15 hours at 45.degree. C., the reaction mixture is
poured onto a mixture of ethyl acetate and water. The organic phase
is washed twice with water, dried over MgSO.sub.4, concentrated to
dryness and diluted with methanol (5 mL). The batch is then stirred
for 24 hours under a hydrogen atmosphere in the presence of Pd/C
(100 mg). The reaction mixture is then passed through a Whatman
filter, concentrated to dryness, then chromatographed over silica
gel (dichloromethane/methanol gradient) and finally lyophilised to
yield the expected product in the form of a powder.
[0381] Elemental microanalysis: %, measured (theoretical)
[0382] % C=72.38(73); % H=5.22(5.5); % N=6.59(6.55)
EXAMPLE 17
N-{3-Fluoro-4-[2-(morpholin-4-yl)ethoxy]phenyl}-N-(4-hydroxyphenyl)-3-(6-{-
[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}-1,3-benzodioxol-5-
-yl)indolizine-1-carboxamide hydrochloride
[0383] Elemental microanalysis: (%, theoretical:measured)
[0384] % C=67.12:66.79; % H=5.26:4.98; % N=6.96:7.17; %
Cl-=4.4:4.77
EXAMPLE 18
3-[6-(3,4-Dihydroisoquinolin-2(1H)-ylcarbonyl)-1,3-benzodioxol-5-yl]-N-{3--
fluoro-4-[2-(morpholin-4-yl)ethoxy]phenyl}-N-(4-hydroxyphenyl)indolizine-1-
-carboxamide hydrochloride
[0385] Elemental microanalysis: %, measured (theoretical)
[0386] % C=66.99(66.79); % H=4.93(5.1); % N=7.11(7.08); %
Cl-=4.46(4.48)
EXAMPLE 19
N-(4-flydroxyphenyl)-3-(5-methyl-2-{[(3S)-3-[2-(morpholin-4-yl)ethyl]-3,4--
dihydroisoquinolin-2(1H)-yl]carbonyl}phenyl)-N-phenyl-5,6,7,8-tetrahydro-i-
ndolizine-1-carboxamide hydrochloride
[0387] Elemental microanalysis: (%, theoretical:measured)
[0388] % C=72.26:72.51; % H=6.48:6.13; % N=7.66:7.71; %
C1=4.85:4.95; % Cl-=4.85:4.64
EXAMPLE 20
N-(4-Hydroxyphenyl)-3-(2-{[(3S)-3-[2-(morpholin-4-yl)ethyl]-3,4-dihydroiso-
quinolin-2(1H)-yl]carbonyl}phenyl)-N-phenyl-5,6,7,8-tetrahydroindolizine-1-
-carboxamide hydrochloride
[0389] Elemental microanalysis: (%, theoretical:measured)
[0390] % C=72:71.11; % H=6.32:5.94; % N=7.81:7.65; %
Cl-=4.94:5.08
EXAMPLE 21
N-(4-Hydroxyphenyl)-3-(6-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]c-
arbonyl}-1,3-benzodioxol-5-yl)-N-(pyridin-4-yl)indolizine-1-carboxamide
hydrochloride
[0391] Elemental microanalysis: (%, theoretical:measured)
[0392] % C=69.24:69.12; % H=4.74:4.23; % N=8.5:8.45; %
Cl-=5.38:5.2
EXAMPLE 22
N-(4-Hydroxyphenyl)-6-(6-{[(3S)-3-[2-(morpholin-4-yl)ethyl]-3,4-dihydroiso-
quinolin-2(1H)-yl]carbonyl}-1,3-benzodioxol-5-yl)-N-phenylpyrrolo[1,2-a]-p-
yrimidine-8-carboxamide hydrochloride
[0393] Elemental microanalysis: (%, theoretical:measured)
[0394] % C=68.11:66.66; % H=5.32:4.93; % N=9.24:8.84; %
Cl-=4.68:5.78
[0395] High-resolution mass spectroscopy (ESI-F):
[0396] Empirical formula: C.sub.43H.sub.39N.sub.5O.sub.6
[0397] [M+H].sup.+, calculated: 655.2915
[0398] [M+H].sup.+, measured: 655.2915
EXAMPLE 23
N-(3-Cyanophenyl)-N-(4-hydroxyphenyl)-3-(6-{[(3S)-3-[2-(morpholin-4-yl)eth-
yl]-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}-1,3-benzodioxol-5-yl)-5,6,7,-
8-tetrahydroindolizine-1-carboxamide hydrochloride
[0399] Elemental microanalysis: (%, theoretical:measured)
[0400] % C=68.74:68.59; % H=5.64:5.5; % N=8.91:8.98; %
Cl-=4.51:4.48
EXAMPLE 24
N-(3-Fluorophenyl)-N-(4-hydroxyphenyl)-3-(6-{[(3S)-3-[2-(morpholin-4-yl)et-
hyl]-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}-1,3-benzodioxol-5-yl)-5,6,7-
,8-tetrahydroindolizine-1-carboxamide hydrochloride
[0401] Elemental microanalysis: (%, theoretical:measured)
[0402] % C=67.81:67.45; % H=5.69:5.61; % N=7.19:7.42; %
Cl-=4.55:4.84
EXAMPLE 25
N-(3,4-Difluorophenyl)-N-(4-hydroxyphenyl)-3-(6-{[(3S)-3-[2-(morpholin-4-y-
l)ethyl]-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}-1,3-benzodioxol-5-yl)-5-
,6,7,8-tetrahydroindolizine-1-carboxamide hydrochloride
[0403] Elemental microanalysis: (%, theoretical:measured)
[0404] % C=66.28:66.56; % H=5.44:5.25; % N=7.03:7.21; %
Cl-=4.45:4.32
EXAMPLE 26
N-(3-Fluorophenyl)-3-(6-{[(3S)-3-[2-(morpholin-4-yl)ethyl]-3,4-dihydro-iso-
quinolin-2(1H)-yl]carbonyl}-1,3-benzodioxol-5-yl)-N-phenyl-5,6,7,8-tetrahy-
dro-indolizine-1-carboxamide hydrochloride
[0405] Elemental microanalysis: (%, theoretical:measured)
[0406] % C=69.24:70.16; % H=5.81:5.79; % N=7.34:7.47; %
Cl-=4.64:4.58
EXAMPLE 27
3-(5-Chloro-2-{[(3S)-3-[2-(morpholin-4-yl)ethyl]-3,4-dihydroisoquinolin-2(-
1H)-yl]carbonyl}phenyl)-N-(3-fluorophenyl)-N-(4-hydroxyphenyl)-5,6,7,8-tet-
rahydroindolizine-1-carboxamide hydrochloride
[0407] Elemental microanalysis: (%, theoretical:measured)
[0408] % C=67.1:67.68; % H=5.63:5.4; % N=7.28:7.34; %
Cl-=4.61:4.59
EXAMPLE 28
N-(4-Hydroxyphenyl)-3-(5-methoxy-2-{[(3S)-3-[2-(morpholin-4-yl)ethyl]-3,4--
dihydroisoquinolin-2(1H)-yl]carbonyl}phenyl)-N-phenyl-5,6,7,8-tetrahydro-i-
ndolizine-1-carboxamide hydrochloride
[0409] Elemental microanalysis: (%, theoretical:measured)
[0410] % C=70.72:70.05; % H=6.34:5.95; % N=7.5:7.33; %
Cl-=4.74:4.74
EXAMPLE 29
N-(4-Hydroxyphenyl)-3-(4-methoxy-2-{[(3S)-3-[2-(morpholin-4-yl)ethyl]-3,4--
dihydroisoquinolin-2(1H)-yl]carbonyl}phenyl)-N-phenyl-5,6,7,8-tetrahydro-i-
ndolizine-1-carboxamide hydrochloride
[0411] Elemental microanalysis: (%, theoretical:measured)
[0412] % C=70.72:68.96; % H=6.34:5.78; % N=7.5:7.24; %
Cl-=4.74:4.62
[0413] High-resolution mass spectroscopy (ESI-F):
[0414] Empirical formula: C.sub.44H.sub.46N.sub.4O.sub.5
[0415] [M+H].sup.+, calculated: 711.3546
[0416] [M+H].sup.+, measured: 711.3540
EXAMPLE 30
N-{4-[(3,3-Difluoropiperidin-1-yl)methyl]phenyl}-N-(4-hydroxyphenyl)-3-(6--
{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}-1,3-benzodioxol--
5-yl)indolizine-1-carboxamide hydrochloride
[0417] Elemental microanalysis: (%, theoretical:measured)
[0418] % C=68.31:69.12; % H=5.22:4.93; % N=7.08:6.96; %
Cl-=4.48:4.07
EXAMPLE 31
N-(4-Hydroxyphenyl)-3-(6-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]c-
arbonyl}-1,3-benzodioxol-5-yl)-N-(quinolin-6-yl)indolizine-1-carboxamide
hydrochloride
[0419] Elemental microanalysis: (%, theoretical:measured)
[0420] % C=71.13:71.29; % H=4.69:4.39; % N=7.9:8.14; %
Cl-=5:4.5
EXAMPLE 32
N-(4-Hydroxyphenyl)-3-(6-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]c-
arbonyl}-1,3-benzodioxol-5-yl)-N-(2-methylpyriclin-4-yl)indolizine-1-carbo-
xamide hydrochloride
[0421] Elemental microanalysis: (%, theoretical:measured)
[0422] % C=69.59:69.81; % H=4.94:4.53; % N=8.32:8.59; %
Cl-=5.27:5.01
EXAMPLE 33
N-(4-Hydroxyphenyl)-3-(6-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]c-
arbonyl}-1,3-benzodioxol-5-yl)-N-(1-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)i-
ndolizine-1-carboxamide hydrochloride
[0423] Elemental microanalysis: (%, theoretical:measured)
[0424] % C=69.14:70.09; % H=4.81:4.55; % N=9.83:10.09; %
Cl-=4.98:3.26
EXAMPLE 34
N-(4-Hydroxyphenyl)-3-(6-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]c-
arbonyl}-1,3-benzodioxol-5-yl)-N-(pyridin-3-yl)indolizine-1-carboxamide
hydrochloride
[0425] Elemental microanalysis: (%, theoretical:measured)
[0426] % C=69.24:70.21; % H=4.74:4.42; % N=8.5:8.51; %
Cl-=5.38:3.33
EXAMPLE 35
N-{4-[2-(3,3-Difluoropiperidin-1-yl)ethyl]phenyl}-N-(4-hydroxyphenyl)-3-(6-
-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}-1,3-benzodioxol-
-5-yl)indolizine-1-carboxamide hydrochloride
[0427] Elemental microanalysis: (%, theoretical:measured)
[0428] % C=68.61:67.96; % H=5.38:5.14; % N=6.96:6.76; %
Cl-=4.4:4.36
EXAMPLE 36
N-{4-[2-(3,3-Difluoropyrrolidin-1-yl)ethyl]phenyl}-N-(4-hydroxyphenyl)-3-(-
6-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}-1,3-benzodioxo-
l-5-yl)indolizine-1-carboxamide hydrochloride
[0429] Elemental microanalysis: (%, theoretical:measured)
[0430] % C=68.31:68.51; % H=5.22:4.85; % N=7.08:6.83; %
Cl-=4.48:4.48
EXAMPLE 37
3-(6-{[(3S)-3-(2-Aminoethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}-1,3-
-benzodioxol-5-yl)-N-(4-hydroxyphenyl)-N-phenyl-5,6,7,8-tetrahydroindolizi-
ne-1-carboxamide hydrochloride
Step A: Methyl
3-(6-{[(3S)-3-[2-[(tert-butoxycarbonyl)amino]ethyl}-3,4-dihydro-isoquinol-
in-2(1H)-yl]carbonyl}-1,3-benzodioxol-5-yl)-5,6,7,8-tetrahydroindolizine-1-
-carboxylate
[0431] To a solution of 2 g of the compound of Preparation 1 in 20
mL of dichloromethane there are added, at ambient temperature, 5.5
mL of N,N,N-triethylamine (6.96 mmol), the compound of Preparation
3' (6.96 mmol), and then 0.94 g of hydroxybenzotriazole (HOBT) and
1.34 g of 1-ethyl-3-(3'-dimethylaminopropyl)-carbodiimide (EDC)
(6.96 mmol). The reaction mixture is then stirred at ambient
temperature overnight, and it is then poured onto ammonium chloride
solution and extracted with ethyl acetate. The organic phase is
then dried over magnesium sulphate, and then filtered and
evaporated to dryness. The crude product thereby obtained is then
purified by chromatography over silica gel (heptane/AcOEt gradient)
to yield the expected product.
[0432] .sup.1H NMR: .delta. (400 MHz; dmso-d6; 300K): 7.2-6.8 (m,
4H, aromatic Hs, H tetrahydroisoquinoline); 7.15-6.90 (m, 4H,
aromatic H, tetrahydroisoquinoline); 7.00-6.80 (m, 2H, aromatic H,
benzodioxole); 6.68+6.55+6.25 (m, 1H, NH); 6.50-6.05 (m, 1H,
aromatic H, tetrahydroindolizine); 6.12 (m, 2H, aliphatic Hs,
OCH.sub.2O); 4.95+4.20+4.10 (m, 2H, aliphatic H, CH.sub.2N
tetrahydroisoquinoline); 4.85+4.78+3.80 (m, 1H, aliphatic H, CH
tetrahydroisoquinoline); 4.00-3.40 (m, 2H, aliphatic Hs, CH.sub.2N
tetrahydroindolizine); 3.70-3.50 (m, 3H, COOCH.sub.3); 2.95-2.45
(m, 2H, aliphatic Hs, CH.sub.2NHBoc); 2.98-2.30 (m, 2H, aliphatic
Hs, CH.sub.2C tetrahydroindolizine); 3.00+2.60+2.42 (m, 2H,
aliphatic Hs, CH.sub.2CH tetrahydroindolizine); 1.95-1.40 (m, 4H,
aliphatic Hs, CH.sub.2CH.sub.2 tetrahydroindolizine); 1.35-1.25 (m,
9H, aliphatic Hs, tBu); 1.50-1.15 (m, 2H, aliphatic Hs,
CH.sub.2CH.sub.2NHBoc)
Step B: Lithium
3-(6-{[(3S)-3-{2-[(tert-butoxycarbonyl)amino]ethyl}-3,4-dihydroiso-quinol-
in-2(1H)-yl]carbonyl}-1,3-benzodioxol-5-yl)-5,6,7,8-tetrahydroindolizine-1-
-carboxylate
[0433] To a solution containing 8.26 mmol of the compound of Step A
in 24 mL of dioxane there is added a solution of lithium hydroxide
(675 mg, 16.1 mmol). The batch is placed in a microwave oven at 140
W, 100.degree. C. for a period of 2 hours 30 minutes. The reaction
mixture is then filtered and evaporated. The solid thereby obtained
is dried at 40.degree. C. in an oven in the presence of
P.sub.2O.sub.5.
Step C: tert-Butyl
(2-{(3S)-2-[(6-{1-[(4-{[tert-butyl(dimethyl)silyl]oxy}phenyl)-(phenyl)car-
bamoyl]-5,6,7,8-tetrahydroindolizin-3-yl}-1,3-benzodioxol-5-yl)carbonyl]-1-
,2,3,4-tetrahydroisoquinolin-3-yl}ethyl)carbamate
[0434] To a solution containing 4.73 mmol of the compound of Step B
in 47 mL of dichloromethane there are added, dropwise, 1.2 mL of
oxalyl chloride at 0.degree. C. The reaction mixture is stirred at
ambient temperature for 11 hours and is then co-evaporated several
times with dichloromethane. The product thereby obtained is
suspended in 37 mL of dichloromethane, and is then added to a
solution containing 7.1 mmol of the compound obtained in
Preparation 8'' in 10 mL of dichloromethane in the presence of 0.6
mL of pyridine (7.1 mmol). The batch is stirred at ambient
temperature overnight. The reaction mixture is concentrated and
purified by chromatography over silica gel
(dichloromethane/methanol gradient) to yield the expected
product.
[0435] .sup.1H NMR: .delta. (400 MHz; dmso-d6; 300K): 7.0 (m, 11H,
aromatic Hs, Ph+4H, tetrahydroisoquinoline+2H, PhO); 6.80-6.65 (m,
2H, aromatic Hs, PhO); 6.95-6.85 (m, 2H, aromatic H, benzodioxole);
6.70+6.40 (3tl, 1H, NH); 6.10 (m, 2H, aliphatic Hs, OCH.sub.2O);
5.25-4.85 (m, 1H, aromatic H, tetrahydroindolizine); 5.00+4.00 (m,
2H, aliphatic H, CH.sub.2N tetrahydroisoquinoline); 4.90-3.60 (m,
1H, aliphatic H, CH tetrahydro-isoquinoline); 4.10-3.40 (m, 2H,
aliphatic Hs, CH.sub.2N tetrahydroindolizine); 3.00-2.50 (m, 2H,
aliphatic Hs, CH.sub.2C tetrahydroindolizine); 3.00+2.40 (m, 2H,
aliphatic Hs, CH.sub.2CH tetrahydroindolizine); 3.00-2.50 (m, 2H,
aliphatic Hs, CH.sub.2NHBoc); 1.80-1.50 (m, 4H, aliphatic Hs,
CH.sub.2CH.sub.2 tetrahydroindolizine); 1.50-1.30 (m, 2H, aliphatic
Hs, CH.sub.2CH.sub.2NHBoc); 1.35 (2s, 9H, aliphatic Hs, tBu); 0.90
(s, 9H, aliphatic Hs, tBu-Si); 0.10 (m, 6H, aliphatic Hs,
Me-Si)
Step D:
3-(6-{[(3S)-3-(2-Aminoethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbo-
nyl}-1,3-benzodioxol-5-yl)-N-(4-hydroxyphenyl)-N-phenyl-5,6,7,8-tetrahydro-
indolizine-1-carboxamide hydrochloride
[0436] To a solution of 800 mg (0.92 mmol) of the compound of Step
C in 10 mL of methanol there are added 258 mg (4.60 mmol) of KOH.
After stirring for 3 hours at ambient temperature, the reaction
mixture is treated with 4M HCl solution in 6 mL of dioxane. After
stirring for 2 hours at ambient temperature, the reaction mixture
is concentrated and treated with saturated aqueous NaHCO.sub.3
solution and extracted with methylene chloride. The organic phase
is then dried over magnesium sulphate, and then filtered and
evaporated to dryness. The crude product thereby obtained is then
purified by chromatography over silica gel
(dichloromethane/methanol gradient). The compound is then dissolved
in 5 mL of dichloromethane, and 2.5 mL of 1M HCl in ether are
added. The compound is filtered off and dried in vacuo. The
expected product is obtained in the form of a foam.
[0437] Elemental microanalysis: (%, theoretical:measured)
[0438] % C=69.51:69.53; % H=5.69:5.27; % N=8.11:8.04; %
Cl-=5.13:5.2
[0439] High-resolution mass spectroscopy (ESI+):
[0440] Empirical formula: C.sub.40H.sub.38N.sub.4O.sub.5
[0441] [M+H].sup.+, calculated: 655.2915
[0442] [M+H].sup.+, measured: 655.2915
[0443] .sup.1H NMR: .delta. (400 MHz; dmso-d6; 300K): 9.55+9.45
(2s, 1H, OH); 7.80+7.75 (2s, 3H, NH3.sup.+); 7.46-6.55 (m, 11H,
aromatic Hs, Ph+4H, tetrahydroisoquinoline+2H, PhO); 6.90-6.55 (m,
2H, aromatic Hs, PhO); 7.00-6.70 (several s, 2H, aromatic H,
benzodioxole); 5.35-5.00 (several s, 1H, aromatic H,
tetrahydroindolizine); 6.10 (several s, 2H, aliphatic Hs,
OCH.sub.2O); 5.00-3.35 (several m, 4H, aliphatic H, CH.sub.2N
tetrahydroisoquinoline+CH.sub.2N tetrahydroindolizine);
4.85+4.75+3.60 (several m, 1H, aliphatic H, CH
tetrahydroisoquinoline); 2.85-2.45 (several m, 2H, aliphatic Hs,
CH.sub.2NH.sub.2); 3.00-2.45 (several m, 2H, aliphatic Hs,
CH.sub.2C tetrahydroindolizine); 3.05+2.30 (several m, 2H,
aliphatic Hs, CH.sub.2CH tetrahydroisoquinoline); 1.85-1.40
(several m, 2H, aliphatic Hs, CH.sub.2 tetrahydroisoquinoline);
1.95-1.35 (several m, 2H, aliphatic Hs, CH.sub.2
tetrahydroisoquinoline); 1.75-1.40 (several m, 2H, aliphatic Hs,
CH.sub.2CH.sub.2NH.sub.2)
[0444] IR: v: --OH: 3375 cm.sup.-1 (phenol); v: --NH3.sup.+:
3500-2300 cm.sup.-1 (salt of primary amine);
[0445] v: >C.dbd.O 1612 cm.sup.-1+shoulder (amide)
EXAMPLE 38
N-(4-Hydroxyphenyl)-3-(6-{[(3R)-3-[3-(morpholin-4-yl)propyl]-3,4-dihydrois-
oquinolin-2(1H)-yl]carbonyl}-1,3-benzodioxol-5-yl)-N-phenyl-5,6,7,8-tetrah-
ydroindolizine-1-carboxamide hydrochloride
[0446] Elemental microanalysis: (%, theoretical:measured)
[0447] % C=69.71:69.62; % H=6.11:5.67; % N=7.23:7.12; %
Cl-=4.57:4.81
EXAMPLE 39
N-(2,6-Dimethylpyridin-4-yl)-N-(4-hydroxyphenyl)-3-(6-{[(3R)-3-methyl-3,4--
dihydroisoquinolin-2(1H)-yl]carbonyl}-1,3-benzodioxol-5-yl)indolizine-1-ca-
rboxamide hydrochloride
[0448] Elemental microanalysis: (%, theoretical:measured)
[0449] % C=69.91:69.68; % H=5.13:4.78; % N=8.15:8.03; %
Cl-=5.16:5.16
EXAMPLE 40
N-(4-Hydroxyphenyl)-3-(6-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]c-
arbonyl}-1,3-benzodioxol-5-yl)-N-phenyl-5,6,7,8-tetrahydroindolizine-1-car-
boxamide
[0450] Elemental microanalysis: (%, theoretical:measured)
[0451] % C=74.86:74.88; % H=5.64:5.31; % N=6.72:6.78
EXAMPLE 41
3-(6-{[(3S)-3-[2-(3,3-Difluoropiperidin-1-yl)ethyl]-3,4-dihydroiso-quinoli-
n-2(1H)-yl]carbonyl}-1,3-benzodioxol-5-yl)-N-(4-hydroxyphenyl)-N-phenyl-5,-
6,7,8-tetrahydroindolizine-1-carboxamide hydrochloride
[0452] Elemental microanalysis: (%, theoretical:measured)
[0453] % C=67.96:68.34; % H=5.7:5.4; % N=7.04:6.97; %
Cl-=4.46:4.27
EXAMPLE 42
N-(4-Hydroxyphenyl)-3-(6-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]c-
arbonyl}-1,3-benzodioxol-5-yl)-N-(pyridin-4-yl)-5,6,7,8-tetrahydro-indoliz-
ine-1-carboxamide hydrochloride
[0454] Elemental microanalysis: (%, theoretical:measured)
[0455] % C=68.82:69.46; % H=5.32:4.95; % N=8.45:8.48; %
Cl-=5.35:4.6
EXAMPLE 43
3-(6-{[(3S)-3-[2-[(2,2-Difluoroethyl)amino]ethyl}-3,4-dihydroisoquinolin-2-
(1H)-yl]carbonyl}-1,3-benzodioxol-5-yl)-N-(4-hydroxyphenyl)-N-phenyl-5,6,7-
,8-tetrahydroindolizine-1-carboxamide
Step A: Ethyl
3-(6-{[(3S)-3-{2-[(tert-butoxycarbonyl)amino]ethyl}-3,4-dihydroiso-quinol-
in-2(1H)-yl]carbonyl}-1,3-benzodioxol-5-yl)-5,6,7,8-tetrahydroindolizine-1-
-carboxylate
[0456] The process is analogous to that described in Step A of
Example 37.
Step B: Ethyl
3-(6-{[(3S)-3-{2-[(tert-butoxycarbonyl)(2,2-difluoroethyl)amino]-ethyl}-3-
,4-dihydroisoquinolin-2(1H)-yl]carbonyl}-1,3-benzodioxol-5-yl)-5,6,7,8-tet-
rahydroindolizine-1-carboxylate
[0457] To a suspension of 337 mg of NaH (60%) (8.41 mmol) in 13 mL
of dimethylformamide there is added, dropwise, a solution of 1.01 g
(1.68 mmol) of the compound of Step A in 13 mL of
dimethylformamide. The resulting suspension is stirred at ambient
temperature for 15 minutes and there are then added 1.08 g (5.04
mmol) of 2,2-difluoroethyl trifluoromethanesulphonate in 13 mL of
dimethylformamide. The batch is stirred at ambient temperature for
2 hours. A solution of 20 mL of saturated ammonium chloride is
added. The solution is extracted with ethyl acetate. The organic
phase is then dried over MgSO.sub.4, filtered and concentrated to
dryness. After purification by column chromatography over silica
gel (cyclohexane/ethyl acetate), the expected product is obtained
in the form of an oil.
[0458] High-resolution mass spectroscopy (ESI+):
[0459] Empirical formula: C.sub.37H.sub.43CN.sub.3O.sub.7
[0460] [M+H].sup.+, calculated: 680.3142
[0461] [M+H].sup.+, measured: 680.3145
[0462] .sup.1H NMR: .delta. (400 MHz; dmso-d6; 300K): 7.25-6.90 (m,
4H, aromatic Hs, tetrahydroisoquinoline); 7.10-6.75 (m, 2H,
aromatic H, benzodioxole); 0.40-6.05 (m, 1H, aromatic H,
tetrahydroindolizine); 6.10 (m, 2H, aliphatic Hs, OCH.sub.2O);
6.25-5.90 (m, 1H, aliphatic Hs, CHF.sub.2); 4.95-4.10 (m, 2H,
aliphatic H, CH.sub.2N tetrahydroisoquinoline); 4.80+3.80 (2m, 1H,
aliphatic H, CH tetrahydroisoquinoline); 4.10-4.00 (m, 2H, CH.sub.2
Et); 4.05-3.40 (m, 2H, aliphatic H, CH.sub.2N
tetrahydroindolizine); 3.60-2.60 (m, 4H, aliphatic H,
CH.sub.2CHF.sub.2+CH.sub.2NBoc); 3.00-2.35 (m, 2H, aliphatic Hs,
CH.sub.2C tetrahydroindolizine); 3.00+2.45 (m, 2H, aliphatic Hs,
CH.sub.2CH tetrahydroisoquinoline); 1.95+1.40 (m, 4H, aliphatic Hs,
CH.sub.2CH.sub.2 tetrahydroindolizine); 1.40 (m, 9H, aliphatic Hs,
.sup.tBu); 1.65-1.20 (m, 2H, aliphatic Hs, CH.sub.2CH.sub.2NBoc);
1.18+1.10 (2t, 3H, aliphatic Hs CH.sub.3Et)
Step C: tert-Butyl
(2-{(3S)-2-[(6-{1-[(4-{[tert-butyl(dimethyl)silyl]oxy}phenyl)(phenyl)-car-
bamoyl]-5,6,7,8-tetrahydroindolizin-3-yl}-1,3-benzodioxol-5-yl)carbonyl]-1-
,2,3,4-tetrahydroisoquinolin-3-yl}ethyl)(2,2-difluoroethyl)carbamate
[0463] The process is analogous to that described in Steps B and C
of Example 37.
[0464] .sup.1H NMR: .delta. (400 MHz; dmso-d6; 300K): 7.30-6.60 (m,
9H, aromatic Hs, 4H tetrahydroisoquinoline+Ph); 6.90-6.70 (m, 2H,
aromatic H, benzodioxole); 6.80-6.60 (m, 4H, PhO); 6.10 (m, 2H,
aliphatic Hs, OCH.sub.2O); 6.20-5.90 (m, 1H, aliphatic Hs,
CHF.sub.2); 5.50-4.80 (4s, 1H, aromatic H, tetrahydroindolizine);
5.20-4.00 (m, 2H, aliphatic H, CH.sub.2N tetrahydroisoquinoline);
4.80+4.70+3.50 (3m, 1H, aliphatic H, CH tetrahydroisoquinoline);
4.20-3.40 (m, 2H, aliphatic H, CH.sub.2N tetrahydroindolizine);
3.60-3.10 (m, 4H, aliphatic H, CH.sub.2CHF.sub.2+CH.sub.2NBoc);
3.00+2.60 (m, 2H, aliphatic Hs, CH.sub.2CH tetrahydroisoquinoline);
3.00-2.50 (m, 2H, aliphatic Hs, CH.sub.2C tetrahydroindolizine);
1.80+1.50 (m, 4H, aliphatic Hs, CH.sub.2CH.sub.2
tetrahydroindolizine); 1.60-1.30 (m, 2H, aliphatic Hs,
CH.sub.2CH.sub.2NBoc); 1.40-1.30 (m, 9H, aliphatic Hs, tBu); 0.90
(4s, 9H, aliphatic Hs, tBu-Si); 0.10 (4s, 6H, aliphatic Hs,
Me-Si)
Step D:
3-(6-{[(3S)-3-{2-[(2,2-Difluoroethyl)amino]ethyl}-3,4-dihydroisoqu-
inolin-2(1H)-yl]carbonyl}-1,3-benzodioxol-5-yl)-N-(4-hydroxyphenyl)-N-phen-
yl-5,6,7,8-tetrahydroindolizine-1-carboxamide
[0465] To a solution of 933 mg (1.00 mmol) of the compound of Step
C in 10 mL of methanol there are added 280 mg (5.00 mmol) of KOH.
After stirring for 3 hours at ambient temperature, the reaction
mixture is treated with 4M HCl solution in 6 mL of dioxane. After
stirring for 2 hours at ambient temperature, the reaction mixture
is concentrated and treated with aqueous saturated NaHCO.sub.3
solution and then extracted with methylene chloride. The organic
phase is then dried over magnesium sulphate, and then filtered and
evaporated to dryness. The crude product thereby obtained is then
purified by chromatography over silica gel
(dichloromethane/methanol gradient) to yield the expected product
in the form of a foam.
[0466] Elemental microanalysis: (%, theoretical:measured)
[0467] % C=70.18:69.79; % H=5.61:5.67; % N=7.79:7.7
[0468] High-resolution mass spectroscopy (ESI+):
[0469] Empirical formula: C.sub.42H.sub.40F.sub.2N.sub.4O.sub.5
[0470] [M+H].sup.+, calculated: 655.2915
[0471] [M+H].sup.+, measured: 655.2915
EXAMPLE 44
N-(4-Hydroxyphenyl)-3-(6-{[(3S)-3-[2-(3-methoxyazetidin-1-yl)ethyl]-3,4-di-
hydroisoquinolin-2(1H)-yl]carbonyl}-1,3-benzodioxol-5-yl)-N-phenyl-5,6,7,8-
-tetrahydroindolizine-1-carboxamide
[0472] Elemental microanalysis: (%, theoretical:measured)
[0473] % C=72.91:72.73; % H=6.12:5.67; % N=7.73:7.74
EXAMPLE 45
N-(4-Hydroxyphenyl)-3-(6-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]c-
arbonyl}-1,3-benzodioxol-5-yl)-N-{1-[2-(morpholin-4-yl)ethyl]-1H-pyrazol-4-
-yl}indolizine-1-carboxamide hydrochloride
[0474] Elemental microanalysis: (%, theoretical:measured)
[0475] % C=66.27:66.05; % H=5.43:5.27; % N=11.04:11.07; %
Cl-=4.66:4.61
EXAMPLE 46
N-(3-Fluoropyridin-4-yl)-N-(4-hydroxyphenyl)-3-(6-{[(3R)-3-methyl-3,4-dihy-
droisoquinolin-2(1H)-yl]carbonyl}-1,3-benzodioxol-5-yl)indolizine-1-carbox-
amide hydrochloride
[0476] High-resolution mass spectroscopy (ESI-F):
[0477] Empirical formula: C.sub.38H.sub.29FN.sub.4O.sub.5
[0478] [M+H].sup.+, calculated: 641.2195
[0479] [M+H].sup.+, measured: 641.2195
EXAMPLE 47
3-(5-Chloro-2-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]-carbonyl}ph-
enyl)-N-(4-hydroxyphenyl)-N-(1-methyl-1H-pyrazol-4-yl)-5,6,7,8-tetrahydroi-
ndolizine-1-carboxamide
[0480] Elemental microanalysis: (%, theoretical:measured)
[0481] % C=69.72:69.53; % H=5.53:5.6; % N=11.29:10.85
EXAMPLE 48
N-(4-Hydroxyphenyl)-3-(7-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]c-
arbonyl}-2,3-dihydro-1,4-benzodioxin-6-yl)-N-(1-methyl-1H-pyrazol-4-yl)-5,-
6,7,8-tetrahydroindolizine-1-carboxamide
[0482] Elemental microanalysis: (%, theoretical:measured)
[0483] % C=70.9:70.89; % H=5.79:5.56; % N=10.88:10.8
EXAMPLE 49
3-(5-Chloro-2-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]-carbonyl}ph-
enyl)-N-(4-hydroxyphenyl)-N-(pyridin-4-yl)indolizine-1-carboxamide
hydrochloride
[0484] Elemental microanalysis: (%, theoretical:measured)
[0485] % C=68.42:68.17; % H=4.65:4.48; % N=8.63:8.48; %
Cl-=5.46:5.13
EXAMPLE 50
3-(5-Chloro-2-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]-carbonyl}ph-
enyl)-N-(4-hydroxyphenyl)-N-(1-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)indoli-
zine-1-carboxamide
[0486] Elemental microanalysis: (%, theoretical:measured)
[0487] % C=72.12:71.58; % H=4.84:4.84; % N=10.51:10.48
EXAMPLE 51
N-(4-Hydroxyphenyl)-N-(imidazo[1,2-a]pyridin-7-yl)-3-(6-{[(3R)-3-methyl-3,-
4-dihydroisoquinolin-2(1H)-yl]carbonyl}-1,3-benzodioxol-5-yl)indolizine-1--
carboxamide hydrochloride
[0488] Elemental microanalysis: (%, theoretical:measured)
[0489] % C=68.81:68.28; % H=4.62:4.59; % N=10.03:9.66; %
Cl-=5.08:4.81
EXAMPLE 52
N-(4-Hydroxyphenyl)-3-(2-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]c-
arbonyl}phenyl)-N-(1-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)indolizine-1-car-
boxamide
[0490] Elemental microanalysis: (%, theoretical:measured)
[0491] % C=76.05:75.88; % H=5.26:5.24; % N=11.09:11.09
EXAMPLE 53
N-(4-Hydroxyphenyl)-3-(6-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]c-
arbonyl}-1,3-benzodioxol-5-yl)-N-(2-methylimidazo[1,2-a]pyridin-7-yl)indol-
izine-1-carboxamide hydrochloride
[0492] Elemental microanalysis: (%, theoretical:measured)
[0493] % C=69.14:69.65; % H=4.81:4.75; % N=9.83:9.79; %
Cl-=4.98:4.7
EXAMPLE 54
N-(4-Hydroxyphenyl)-3-(6-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]c-
arbonyl}-1,3-benzodioxol-5-yl)-N-(6-methylpyridin-3-yl)indolizine-1-carbox-
amide hydrochloride
[0494] Elemental microanalysis: (%, theoretical:measured)
[0495] % C=69.59:68.78; % H=4.94:5; % N=8.32:8.33; %
Cl-=5.27:5.18
EXAMPLE 55
N-(5-Fluoropyridin-3-yl)-N-(4-hydroxyphenyl)-3-(6-{[(3R)-3-methyl-3,4-dihy-
droisoquinolin-2(1H)-yl]carbonyl}-1,3-benzodioxol-5-yl)indolizine-1-carbox-
amide
[0496] Elemental microanalysis: (%, theoretical:measured)
[0497] % C=71.24:70.77; % H=4.56:4.36; % N=8.75:8.82
EXAMPLE 56
N-(4-Hydroxyphenyl)-N-(2-methoxypyridin-4-yl)-3-(6-{[(3R)-3-methyl-3,4-dih-
ydroisoquinolin-2(1H)-yl]carbonyl}-1,3-benzodioxol-5-yl)indolizine-1-carbo-
xamide
[0498] High-resolution mass spectroscopy (ESI-F):
[0499] Empirical formula: C.sub.39H.sub.32N.sub.4O.sub.6
[0500] [M+H].sup.+, calculated: 653.2395
[0501] [M+H].sup.+, measured: 653.2385
EXAMPLE 57
3-[6-(3,4-Dihydroisoquinolin-2(1H)-ylcarbonyl)-1,3-benzodioxol-5-yl]-N-(4--
hydroxyphenyl)-N-phenyl-5,6,7,8-tetrahydroindolizine-1-carboxamide
[0502] Elemental microanalysis: %, measured (theoretical)
[0503] % C=74.17(74.62); % H=5.43(5.44); % N=6.87(6.87)
EXAMPLE 58
N-(4-Hydroxyphenyl)-3-(6-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]c-
arbonyl}-1,3-benzodioxol-5-yl)-N-[2-(propan-2-yl)pyridin-4-yl]indolizine-1-
-carboxamide hydrochloride
[0504] Elemental microanalysis: (%, theoretical:measured)
[0505] % C=70.23:69.95; % H=5.32:5.4; % N=7.99:7.99; %
Cl-=5.06:4.92
EXAMPLE 59
N-(4-Hydroxyphenyl)-3-(6-{[(3R)-3-methyl-3,4-dihydroisaquinolin-2(1H)-yl]c-
arbonyl}-1,3-benzadiaxol-5-yl)-N-(pyrazolo[1,5-a]pyrimidin-6-yl)indolizine-
-1-carboxamide
[0506] Elemental microanalysis: (%, theoretical:measured)
[0507] % C=70.68:70.47; % H=4.56:4.61; % N=12.68:12.45
EXAMPLE 60
3-(5-Fluoro-2-{[(3R)-3-methyl-3,4-dihydraisoquinolin-2(1H)-yl]-carbonyl}ph-
enyl)-N-(4-hydroxyphenyl)-N-(1-methyl-1H-pyrazol-4-yl)indolizine-1-carboxa-
mide
[0508] Elemental microanalysis: %, measured (theoretical)
[0509] % C=71.85(72.11); % H=4.78(5.04); % N=10.79(11.68)
EXAMPLE 61
3-(5-Fluoro-2-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]-carbonyl}ph-
enyl)-N-(4-hydroxyphenyl)-N-(1-methyl-1H-pyrazol-4-yl)-5,6,7,8-tetrahydroi-
ndolizine-1-carboxamide
[0510] Elemental microanalysis: %, measured (theoretical)
[0511] % C=72.31(71.62); % H=5.6(5.68); % N=10.94(11.6)
EXAMPLE 62
3-(5-Fluoro-2-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]-carbonyl}ph-
enyl)-N-(4-hydroxyphenyl)-N-(pyridin-4-yl)indolizine-1-carboxamide
[0512] Elemental microanalysis: %, measured (theoretical)
[0513] % C=74.08(74.48); % H=4.82(4.9); % N=8.59(9.39)
EXAMPLE 63
3-(5-Fluoro-2-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]-carbonyl}ph-
enyl)-N-(4-hydroxyphenyl)-N-(1-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)indoli-
zine-1-carboxamide
[0514] Elemental microanalysis: %, measured (theoretical)
[0515] % C=73.14(73.95); % H=4.83(4.96); % N=10.29(10.78)
EXAMPLE 64
3-(5-Fluoro-2-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]-carbonyl}ph-
enyl)-N-(4-hydroxyphenyl)-N-(pyridin-4-yl)-5,6,7,8-tetrahydroindolizine-1--
carboxamide
[0516] Elemental microanalysis: %, measured (theoretical)
[0517] % C=74.61(73.98); % H=5.26(5.54); % N=8.94(9.33)
EXAMPLE 65
3-(5-Fluoro-2-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]-carbonyl}ph-
enyl)-N-(4-hydroxyphenyl)-N-(1-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-5,6,7-
,8-tetrahydroindolizine-1-carboxamide
[0518] Elemental microanalysis: %, measured (theoretical)
[0519] % C=73.59(73.49); % H=5.22(5.55); % N=9.93(10.71)
EXAMPLE 66
N-(4-Hydroxyphenyl)-3-(6-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]c-
arbonyl}-1,3-benzodioxol-5-yl)-N-([1,2,4]triazolo[1,5-a]pyrimidin-6-yl)-in-
dolizine-1-carboxamide
[0520] Elemental microanalysis: %, measured (theoretical)
[0521] % C=68.57(68.77); % H=3.92(4.4); % N=14.21(14.77)
[0522] High-resolution mass spectroscopy (ESI-F):
[0523] Empirical formula: C.sub.38H.sub.29N.sub.7O.sub.5
[0524] [M+H].sup.+, calculated: 664.2303
[0525] [M+H].sup.+, measured: 664.2310
EXAMPLE 67
N-(4-Hydroxyphenyl)-3-(6-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]c-
arbonyl}-1,3-benzodioxol-5-yl)-N-(1-oxidopyridin-4-yl)indolizine-1-carboxa-
mide
[0526] Elemental microanalysis: %, measured (theoretical)
[0527] % C=69.7(71.46); %% H=4.43(4.73); % N=8.54(8.77)
[0528] High-resolution mass spectroscopy (ESI-F):
[0529] Empirical formula: C.sub.38H.sub.30N.sub.4O.sub.6
[0530] [M+H].sup.+, calculated: 639.2238
[0531] [M+H].sup.+, measured: 639.2234
EXAMPLE 68
N-(4-Hydroxyphenyl)-3-(2-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]c-
arbonyl}phenyl)-N-(pyridin-4-yl)indolizine-1-carboxamide
hydrochloride
[0532] Elemental microanalysis: %, measured (theoretical)
[0533] % C=71.97(72.25); % H=5.21(5.08); % N=8.99(9.11); %
Cl-=5.32(5.76)
[0534] High-resolution mass spectroscopy (ESI-F):
[0535] Empirical formula: C.sub.37H.sub.30N.sub.4O.sub.3
[0536] [M+H].sup.+, calculated: 579.2391
[0537] [M+H].sup.+, measured: 579.2403
EXAMPLE 69
N-(4-Hydroxyphenyl)-N-(1-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-3-(6-{[(3R)-
-3-[3-(morpholin-4-yl)propyl]-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}-1,-
3-benzodioxol-5-yl)-5,6,7,8-tetrahydroindolizine-1-carboxamide
hydrochloride
[0538] Elemental microanalysis: %, measured (theoretical)
[0539] % C=67.63(68.06); % H=5.27(5.95); % N=10.08(10.13); %
Cl-=4.53(4.27)
[0540] High-resolution mass spectroscopy (ESI-F):
[0541] Empirical formula: C.sub.47H.sub.48N.sub.6O.sub.6
[0542] [M+H].sup.+, calculated: 793.3708
[0543] [M+H].sup.+, measured: 793.3704
EXAMPLE 70
N-(4-Hydroxyphenyl)-3-(6-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]c-
arbonyl}-1,3-benzodioxol-5-yl)-N-(1-methyl-1H-pyrazolo[3,4-b]pyridin-5-yl)-
indolizine-1-carboxamide
Step A:
N-[4-[tert-Butyl(dimethyl)silyl]oxyphenyl]-3-[6-[(3R)-3-methyl-3,4-
-dihydro-1H-isoquinoline-2-carbonyl]-1,3-benzodioxol-5-yl]-N-(1-methyl-1H--
pyrazolo[3,4-b]pyridin-5-yl)indolizine-1-carboxamide
[0544] The title product is obtained in accordance with the process
of Step A of Example 86, replacing the compound of Preparation 36''
with that of Preparation 35''.
[0545] LCMS: [M+H].sup.+=791.4 vs. 791.3 calculated
Step B:
N-(4-Hydroxyphenyl)-3-(6-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(-
1H)-yl]-carbonyl}-1,3-benzodioxol-5-yl)-N-(1-methyl-1H-pyrazolo[3,4-b]pyri-
din-5-yl)indolizine-1-carboxamide
[0546] The procedure is in accordance with a protocol analogous to
that described in Step D of Example 1. The product thereby obtained
is subjected to a step of conversion into a salt in the presence of
HCl in ether.
[0547] IR (ATR) cm.sup.-1: 2500 to 3000 v-OH, 1614 v >C.dbd.O
amides, 1236 v >C--O--C<, 740 .gamma.>CH--Ar
[0548] Elemental microanalysis: %, measured (theoretical)
[0549] % C=71.07(70.99); % H=4.45(4.77); % N=12.37(12.42)
[0550] High-resolution mass spectroscopy (ESI+):
[0551] Empirical formula: C.sub.40H.sub.32N.sub.6O.sub.5
[0552] [M+H].sup.+, calculated: 677.2507
[0553] [M+H].sup.+, measured: 677.2510
EXAMPLE 71
4-[(4-Hydroxyphenyl){[3-(6-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl-
]carbonyl}-1,3-benzodioxol-5-yl)indolizin-1-yl]carbonyl}amino]-1-methyl-py-
ridinium chloride
Step A:
4-[(4-Hydroxyphenyl){[3-(6-{[(3R)-3-methyl-3,4-dihydroisoquinolin--
2(1H)-yl]-carbonyl}-1,3-benzodioxol-5-yl)indolizin-1-yl]carbonyl}amino]-1--
methyl pyridinium iodide
[0554] The compound of Example 21 (311 mg, 0.5 mmol) is dissolved
in dichloromethane and washed with saturated aqueous sodium
hydrogen carbonate solution. After drying the organic phase over
magnesium sulphate and evaporating to dryness, the residue is
dissolved in ethanol (30 mL). Methyl iodide (45 .mu.L, 0.7 mmol) is
then added and the reaction mixture is heated to 40.degree. C. The
solution thereby obtained is evaporated to dryness. The crude
reaction product is purified over a silica gel column using
dichloromethane and methanol as solvents. The compound is obtained
in the form of a white powder which is used directly in the next
Step.
[0555] .sup.1H NMR (500 MHz, dmso-d6) .delta. ppm: 9.95 (bs, 1H),
8.6-8.45 (m, 2H), 8.35-8.05 (several m, 1H), 8.3-8 (several m, 1H),
7.45-6.7 (several m, 8H), 7.4-6.9 (several m, 4H), 6.45-6.3
(several s, 1H), 6.45-6.3 (m, 2H), 6.15 (s, 2H), 5.05-3.55 (several
d, 2H), 4.75/3.8 (m+m, 1H), 4.15 (2*s, 3H), 2.95-2.1 (several m,
2H), 1-0.15 (several m, 3H)
Step B:
4-[(4-Hydroxyphenyl){[3-(6-{[(3R)-3-methyl-3,4-dihydroisoquinolin--
2(1H)-yl]-carbonyl}-1,3-benzodioxol-5-yl)indolizin-1-yl]carbonyl}amino]-1--
methyl pyridinium chloride
[0556] The compound of the preceding Step (320 mg, 0.42 mmol) is
dissolved in methanol (20 mL), and then silver carbonate (173 mg,
0.628 mmol) is added, in portions, over 10 minutes. The resulting
suspension is stirred for 1 hour at ambient temperature; the
precipitate is filtered off and washed with methanol. The filtrate
is concentrated to dryness, and then treated with 50 mL of 2N
hydrochloric acid solution, heated at 60.degree. C. for 30 minutes
and then evaporated to dryness. The final product is obtained after
purification over a silica C18 column using a 0.1% hydrochloric
acid solution and acetonitrile as solvents. The title compound is
obtained in the form of a white powder which is lyophilised in a
mixture of water/acetonitrile.
[0557] IR (ATR) cm.sup.-1: 3388 v --OH phenol, 1650+1627 v
>C.dbd.O amides
[0558] High-resolution mass spectroscopy (ESI-F):
[0559] Empirical formula: C.sub.39H.sub.33N.sub.4O.sub.5
[0560] [M].sup.+, calculated=637.2445.
[0561] [M].sup.+, measured=637.2431
[0562] The compounds of Examples 72, 73, 77, 78-80, 84 and 85 are
synthesised in accordance with the process of Example 3 using the
acid of Preparation 7, the appropriate
1,2,3,4-tetrahydroisoquinoline or the appropriate compound obtained
in accordance with one of Preparations 1' to 7', and the suitable
NHR.sub.3R.sub.4 amine.
EXAMPLE 72
N-(4-Hydroxyphenyl)-N-methyl-6-(6-{[(3R)-3-methyl-3,4-dihydroiso-quinolin--
2(1H)-yl]carbonyl}-1,3-benzodioxol-5-yl)-1,2,3,4-tetrahydropyrrolo[1,2-a]--
pyrazine-8-carboxamide
[0563] LC/MS (C.sub.33H.sub.32N.sub.4O.sub.5) 565 [M+H].sup.+; RT
1.47 (Method B), it being understood that RT denotes retention
time
EXAMPLE 73
N-Ethyl-N-(4-hydroxyphenyl)-6-(6{[(3R)-3-methyl-3,4-dihydroiso-quinolin-2(-
1H)-yl]carbonyl}-1,3-benzodioxol-5-yl)-1,2,3,4-tetrahydropyrrolo[1,2-a]-py-
razine-8-carboxamide
[0564] LC/MS (C.sub.34H.sub.34N.sub.4O.sub.5) 579 [M+H[.sup.+; RT
1.55 (Method B)
EXAMPLE 74
3-[6-(3,4-Dihydroisoquinolin-2(1H)-ylcarbonyl)-1,3-benzodioxol-5-yl]-N-(4--
hydroxyphenyl)-N-methyl-5,6,7,8-tetrahydroindolizine-1-carboxamide
[0565] LC/MS (C.sub.33H.sub.31N.sub.3O.sub.5) 550 [M+H].sup.+; RT
1.24 (Method B)
EXAMPLE 75
3-[6-(3,4-Dihydroisoquinolin-2(1H)-ylcarbonyl)-1,3-benzodioxol-5-yl]-N-eth-
yl-N-(4-hydroxyphenyl)-5,6,7,8-tetrahydroindolizine-1-carboxamide
[0566] LC/MS (C.sub.34H.sub.33N.sub.3O.sub.5) 564 [M+H[.sup.+; RT
1.30 (Method B)
EXAMPLE 76
N-Butyl-3-[6-(3,4-dihydroisoquinolin-2(1H)-ylcarbonyl)-1,3-benzo-dioxol-5--
yl]-N-(4-hydroxyphenyl)-5,6
7,8-tetrahydroindolizine-1-carboxamide
[0567] LC/MS (C.sub.36H.sub.37N.sub.3O.sub.5) 592 [M+H].sup.+; RT
1.39 (Method B)
EXAMPLE 77
N-Ethyl-N-(4-hydroxyphenyl)-6-(6-{[(3S)-3-methyl-3,4-dihydroiso-quinolin-2-
(1H)-yl]carbonyl}-1,3-benzodioxol-5-yl)-1,2,3,4-tetrahydropyrrolo[1,2-a]-p-
yrazine-8-carboxamide
[0568] LC/MS (C.sub.34H.sub.34N.sub.4O.sub.5) 579 [M+H].sup.+; RT
1.50 (Method B)
EXAMPLE 78
N,N-Dibutyl-6-(6-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]-carbonyl-
}-1,3-benzodioxol-5-yl)-1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-8-carboxa-
mide
[0569] LC/MS (C.sub.34H.sub.42N.sub.4O.sub.4) 571 [M+H].sup.+; RT
1.79 (Method B)
EXAMPLE 79
N-Butyl-N-(4-hydroxyphenyl)-6-(6-{[(3R)-3-methyl-3,4-dihydroiso-quinolin-2-
(1H)-yl]carbonyl}-1,3-benzodioxol-5-yl)-1,2,3,4-tetrahydropyrrolo[1,2-a]-p-
yrazine-8-carboxamide
[0570] LC/MS (C.sub.36H.sub.38N.sub.4O.sub.5) 607 [M+H].sup.+; RT
1.65 (Method B)
EXAMPLE 80
N-(4-Hydroxyphenyl)-6-(6-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]c-
arbonyl]-1,3-benzodioxol-5-yl)-N-(propan-2-yl)-1,2,3,4-tetrahydro-pyrrolo[-
1,2-a]pyrazine-8-carboxamide
[0571] LC/MS (C.sub.35H.sub.36N.sub.4O.sub.5) 593 [M+H].sup.+; RT
1.58 (Method B)
EXAMPLE 81
N-(4-Hydroxyphenyl)-N-methyl-3-(6-{[(3R)-3-methyl-3,4-dihydroiso-quinolin--
2(1H)-yl]carbonyl}-1,3-benzodioxol-5-yl)-5,6,7,8-tetrahydroindolizine-1-ca-
rboxamide
[0572] LC/MS (C.sub.34H.sub.33N.sub.3O.sub.5) 564 [M+H].sup.+; RT
2.48 (Method A)
EXAMPLE 82
N-(4-Hydroxyphenyl)-N-methyl-3-(6-{[(3S)-3-methyl-3,4-dihydroiso-quinolin--
2(1H)-yl]carbonyl}-1,3-benzodioxol-5-yl)-5,6,7,8-tetrahydroindolizine-1-ca-
rboxamide
[0573] LC/MS (C.sub.34H.sub.33N.sub.3O.sub.5) 564 [M+H].sup.+; RT
2.55 (Method A)
EXAMPLE 83
3-[6-(3,4-Dihydroisoquinolin-2(1H)-ylcarbonyl)-1,3-benzodioxol-5-yl]-N-(4--
hydroxyphenyl)-N-methylindolizine-1-carboxamide
[0574] LC/MS (C.sub.33H.sub.27N.sub.3O.sub.5) 546 [M+H].sup.+; RT
2.40 (Method A)
EXAMPLE 84
6-[6-(3,4-Dihydroisoquinolin-2(1H)-ylcarbonyl)-1,3-benzodioxol-5-yl]-N-(4--
hydroxyphenyl)-N-methyl-1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-8-carboxa-
mide
[0575] LC/MS (C.sub.32H.sub.30N.sub.4O.sub.5) 551 [M+H].sup.+; RT
1.45 (Method B)
EXAMPLE 85
6-[6-(3,4-Dihydroisoquinolin-2(1H)-ylcarbonyl)-1,3-benzodioxol-5-yl]-N-eth-
yl-N-(4-hydroxyphenyl)-1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-8-carboxam-
ide
[0576] LC/MS (C.sub.33H.sub.32N.sub.4O.sub.5) 565 [M+H].sup.+; RT
1.49 (Method B)
EXAMPLE 86
N-(4-Hydroxyphenyl)-3-[6-[(3R)-3-methyl-3,4-dihydro-1H-isoquinoline-2-carb-
onyl]-1,3-benzodioxol-5-yl]-N-(3-methylpyrazolo[1,5-a]pyrimidin-6-yl)-indo-
lizine-1-carboxamide hydrochloride
Step A:
N-[4-[tert-Butyl(dimethyl)silyl]oxyphenyl]-3-[6-[(3R)-3-methyl-3,4-
-dihydro-1H-isoquinoline-2-carbonyl]-1,3-benzodioxol-5-yl]-N-(3-methylpyra-
zolo[1,5-a]pyrimidin-6-yl)indolizine-1-carboxamide
[0577] To a solution of 0.6 g of
3-(6-{[(3R)-3-methyl-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}-1,3-benzod-
ioxol-5-yl)indolizine-1-carboxylic acid (1.3 mmol) in 6 mL of
dichloroethane there is added 0.18 mL of
1-chloro-N,N,2-trimethyl-prop-1-en-1-amine (2 mmol). The reaction
mixture is stirred at ambient temperature for 2 hours and there is
then added 0.8 g of the compound of Preparation 36'' (2.2 mmol).
The batch is refluxed for 20 hours and is then cooled and diluted
with a mixture of dichloromethane and saturated NaHCO.sub.3
solution. After separation of the phases, the organic phase is
dried over MgSO.sub.4 and concentrated to dryness The crude product
thereby obtained is purified by chromatography over silica gel
(dichloromethane/methanol gradient).
[0578] LC/MS: [M+H].sup.+=791.4 vs. 791.3 calculated
Step B:
N-(4-Hydroxyphenyl)-3-[6-[(3R)-3-methyl-3,4-dihydro-1H-isoquinolin-
e-2-carbonyl]-1,3-benzodioxol-5-yl]-N-(3-methylpyrazolo[1,5-a]pyrimidin-6--
yl)indolizine-1-carboxamide hydrochloride
[0579] The procedure is in accordance with a protocol analogous to
that described in Step D of Example 1. The product thereby obtained
is subjected to a step of conversion into a salt in the presence of
HCl in ether.
[0580] IR (ATR) cm.sup.-1: 2500 to 3000 v --OH, 1614 v >C.dbd.O
amides, 1236 v >C--O--C<, 740 .gamma.>CH--Ar
[0581] High-resolution mass spectroscopy (ESI+):
[0582] Empirical formula: C.sub.40H.sub.32N.sub.6O.sub.5
[0583] [M+H].sup.+, calculated: 677.2507
[0584] [M+H].sup.+, measured: 677.2506
Pharmacological Study
EXAMPLE A
Inhibition of Bcl-2 by the Fluorescence Polarisation Technique
[0585] The fluorescence polarisation tests were carried out on
microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2
such that Bcl-2 corresponds to the UniProtKB.RTM. primary accession
number: P10415), at a final concentration of 2.50.times.10.sup.-8
M, is mixed with a fluorescent peptide
(Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of
1.00.times.10.sup.-8M in a buffer solution (Hepes 10 mM, NaCl 150
mM, Tween20 0.05%, pH 7.4), in the presence or absence of
increasing concentrations of test compounds. After incubation for 2
hours, the fluorescence polarisation is measured.
[0586] The results are expressed in IC.sub.50 (the concentration of
compound that inhibits fluorescence polarisation by 50%) and are
presented in Table 1 below.
[0587] The results show that the compounds of the invention inhibit
interaction between the Bcl-2 protein and the fluorescent peptide
described hereinbefore.
EXAMPLE B
In Vitro Cytotoxicity
[0588] The cytotoxicity studies were carried out on the RS4;11
leukaemia tumour line.
[0589] The cells are distributed onto microplates and exposed to
the test compounds for 48 hours.
[0590] The cell viability is then quantified by a colorimetric
assay, the Microculture Tetrazolium Assay (Cancer Res., 1987, 47,
939-942).
[0591] The results are expressed in IC.sub.50 (the concentration of
compound that inhibits cell viability by 50%) and are presented in
Table 1 below.
[0592] The results show that the compounds of the invention are
cytotoxic.
TABLE-US-00003 TABLE 1 IC.sub.50 of Bcl-2 inhibition (fluorescence
polarisation test) and of cytotoxicity for RS4; 11 cells IC.sub.50
(nM) Bcl-2 FP IC.sub.50 (nM) MTT RS4; 11 Example 1 17.9 11.3
Example 2 17.0 36 Example 3 33.6 66.5 Example 4 56.4 251 Example 5
55.9 416 Example 6 60.3 161 Example 7 46.4 108 Example 8 24.5 20.5
Example 9 40.6 780 Example 10 24.7 439 Example 11 10.9 83.7 Example
12 10.4 116 Example 13 5.8 33.65 Example 14 3.7 7.6 Example 15 5.7
166 Example 16 7.5 252 Example 17 3.4 11.8 Example 18 7.5 47.7
Example 19 8.0 235 Example 20 11.1 205 Example 21 4.6 25.3 Example
22 12.9 263 Example 23 3.8 9.99 Example 24 6.2 28.4 Example 25 7.9
30 Example 26 16.6 300 Example 27 7.7 44.1 Example 28 8.8 112
Example 29 19.0 163 Example 30 10.4 52.3 Example 31 5.4 13.7
Example 32 5.0 32.7 Example 33 4.6 6.33 Example 34 5.6 27.3 Example
35 15.1 62.2 Example 36 12.6 49.7 Example 37 2.9 24.7 Example 38
4.6 9.52 Example 39 4.6 26.3 Example 40 6.0 49 Example 41 41.5 294
Example 42 5.1 57.6 Example 43 4.8 26 Example 44 2.9 8.56 Example
45 3.8 63.8 Example 46 4.1 27.9 Example 47 4.3 90.1 Example 48 3.6
24.7 Example 49 3.7 84.7 Example 50 2.2 28.2 Example 51 4.8 68.8
Example 52 7.9 20.9 Example 53 5.4 70.9 Example 54 6.6 45 Example
55 5.5 22.8 Example 56 4.7 36.7 Example 57 21.2 282 Example 58 6.4
68.5 Example 59 4.0 21.2 Example 60 5.4 60.3 Example 61 7.0 61.3
Example 62 5.6 96.6 Example 63 6.2 25.4 Example 64 7.8 282 Example
65 5.3 62.8 Example 66 4.7 42 Example 67 ND ND Example 68 8.3 82.4
Example 69 4.6 1.38 Example 70 5.2 6.17 Example 71 49 ND Example 72
90.2 1520 Example 73 83.6 1320 Example 74 68.7 1340 Example 75 67.7
1360 Example 76 77.6 1630 Example 77 25.1% @10 .mu.M 1880 Example
78 823.3 1880 Example 79 99.1 1010 Example 80 299.3 1880 Example 81
12.1 778 Example 82 42% @10 .mu.M 1880 Example 83 35.8 1500 Example
84 524.9 ND Example 85 242.7 ND Example 86 5 20.1 ND: not
determined
[0593] For partial inhibitors, the percentage fluorescence
polarisation inhibition for a given concentration of the test
compound is indicated. Accordingly, 25.1% @10 .mu.M means that
25.1% fluorescence polarisation inhibition is observed for a
concentration of test compound equal to 10 .mu.M.
EXAMPLE C
Induction of Caspase Activity In Vivo
[0594] The ability of the compounds of the invention to activate
caspase 3 is evaluated in a xenograft model of RS4;11 leukaemia
cells.
[0595] 1.times.10.sup.7 RS4;11 cells are grafted sub-cutaneously
into immunosuppressed mice (SCID strain). 25 to 30 days after the
graft, the animals are treated orally with the various compounds.
Sixteen hours after treatment, the tumour masses are recovered and
lysed, and the caspase 3 activity is measured in the tumour
lysates.
[0596] This enzymatic measurement is carried out by assaying the
appearance of a fluorigenic cleavage product (DEVDase activity,
Promega). It is expressed in the form of an activation factor
corresponding to the ratio between the two caspase activities: the
activity for the treated mice divided by the activity for the
control mice.
[0597] The results obtained show that the compounds of the
invention are capable of inducing apoptosis in RS4;11 tumour cells
in vivo.
EXAMPLE D
Quantification of the Cleaved Form of Caspase 3 In Vivo
[0598] The ability of the compounds of the invention to activate
caspase 3 is evaluated in a xenograft model of RS4;11 leukaemia
cells.
[0599] 1.times.10.sup.7 RS4;11 cells are grafted sub-cutaneously
into immunosuppressed mice (SCID strain). 25 to 30 days after the
graft, the animals are treated orally with the various compounds.
After treatment, the tumour masses are recovered (after a time
period T) and lysed, and the cleaved (activated) form of caspase 3
is quantified in the tumour lysates.
[0600] The quantification is carried out using the "Meso Scale
Discovery (MSD) ELISA platform" test, which specifically assays the
cleaved form of caspase 3. It is expressed in the form of an
activation factor corresponding to the ratio between the quantity
of cleaved caspase 3 in the treated mice divided by the quantity of
cleaved caspase 3 in the control mice.
[0601] The results show that the compounds of the invention are
capable of inducing apoptosis in RS4;11 tumour cells in vivo.
TABLE-US-00004 TABLE 2 Caspase activation factors (cleaved caspase
3 MSD test in the tumours of treated mice versus control mice) in
vivo, after treatment by the oral route (exact doses in brackets)
Compound Time period after which Activation factor .+-. tested the
tumour is removed (T) SEM (versus control) Example 2 6 hours 14.6
(50 mg/kg) Example 13 2 hours 23.1 (50 mg/kg) Example 17 2 hours
15.3 (50 mg/kg) Example 21 2 hours 24.8 .+-. 1.4 (50 mg/kg) Example
32 2 hours 54.4 .+-. 2.8 (25 mg/kg) Example 33 2 hours 31.1 .+-.
10.8 (25 mg/kg) Example 38 2 hours 27.5 .+-. 2.6 (25 mg/kg) Example
39 2 hours 34.1 .+-. 2.4 (25 mg/kg) Example 42 2 hours 77.5 .+-.
4.8 (25 mg/kg) Example 50 2 hours 45.2 .+-. 3.9 (25 mg/kg) Example
56 2 hours 10.3 .+-. 4.2 (25 mg/kg)
EXAMPLE E
Anti-Tumour Activity In Vivo
[0602] The anti-tumour activity of the compounds of the invention
is evaluated in a xenograft model of RS4;11 leukaemia cells.
[0603] 1.times.10.sup.7 RS4;11 cells are grafted sub-cutaneously
into immunosuppressed mice (SCID strain). 25 to 30 days after the
graft, when the tumour mass has reached about 150 mm.sup.3, the
mice are treated orally with the various compounds in two different
regimes (daily treatment for five days per week for two weeks, or
two treatments weekly for two weeks). The tumour mass is measured
twice weekly from the start of treatment.
[0604] The results obtained accordingly show that the compounds of
the invention are capable of inducing significant tumour regression
during the treatment period.
EXAMPLE F
Pharmaceutical Composition: Tablets
TABLE-US-00005 [0605] 1000 tablets containing a dose of 5 mg of 5 g
a compound selected from Examples 1 to 86 Wheat starch 20 g Maize
starch 20 g Lactose 30 g Magnesium stearate 2 g Silica 1 g
Hydroxypropylcellulose 2 g
* * * * *